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I INTRODUCTION 
Various species in the genus Borrelia (B.) are the etiological agents of tick-borne relapsing 
fever (TBRF) and Lyme borreliosis (LB) infections in vertebrate hosts including humans 
(SCHWAN & PIESMAN, 2002). B. persica (Bp), a recently successfully in vitro culturable 
TBRF spirochete (ZAMANI et al., 2014), is transmitted by the argasid soft (fast-feeding) 
tick Ornithodoros (O.) tholozani. This bacterium represents the most significant and 
prevalent species causing human TBRF in the Central Asian and Middle Eastern countries 
(ASSOUS & WILAMOWSKI, 2009; OSHAGHI et al., 2011). Contrariwise, species of the 
B. burgdorferi sensu lato (Bbsl) complex are vectored by Ixodes (I.) hard ticks and mainly 
cause LB, namely, Lyme disease (LD). Because of the frequent association with human 
infections, the most important genospecies of Bbsl include: B. burgdorferi sensu stricto 
(Bbss) in both North America and Europe, B. afzelii, B. garinii, and B. bavariensis in Europe 
and Asia (RIZZOLI et al., 2011; BORCHERS et al., 2015). 
Consistent with other well identified TBRF species, e.g., B. hermsii and B. turicatae that are 
primarily endemic in the United States (DWORKIN et al., 2002), Bp has also been detected 
in large quantities in the peripheral blood of infected animals (RAFINEJAD et al., 2011; 
BANETH et al., 2016). In addition, blood samples from human patients with history of fever 
attacks showed numerous Bp spirochetes (DE VERDIÈRE et al., 2011; KUTSUNA et al., 
2013). During or after the appearance of spirochetemia in the bloodstream, borrelial 
organisms can be found in the brain tissues of infected mice (ADDAMIANO & 
BABUDIERI, 1957; SCHWARZER et al., 2016). However, still no information is available 
to clearly characterize the dissemination pathway of Bp in experimental animals.  
In comparison to Bp, LB spirochetes are deposited slowly during the Ixodes tick bite. At 
early days of infection (2 - 4 weeks), cutaneous inflammatory responses (erythema migrans, 
EM) around the bite site are developed frequently (STEERE, 1989; SCHWAN & PIESMAN, 
2002). Clinically, Bbsl cells have been examined in this early stage of infection by means of 
PCR or bacteriological culture from large volumes of blood or serum samples from the Lyme 
disease patients (WORMSER et al., 1998). Without treatment or being treated insufficiently, 
Bbsl infections often result in multisystemic infectious disease such as Lyme carditis (LC), 
Lyme arthritis (LA), or acrodermatitis chronica atrophicans (ACA) (STEERE et al., 1987; 
STEERE et al., 2016). It is generally believed that mechanisms of these manifestations are 
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reliant on the route of borrelia dissemination. However, the exact dissemination pathway of 
these bacteria in vivo is still in debate and not evidently understood so far. In response to 
these questions, some authors hypothesized that LB borreliae employ a hematogenous route, 
similar to some identified TBRF Borrelia spp. such as B. hermsii and B. turicatae, which 
firstly enter vasculature near the site of the tick bite and subsequently exit from the 
vasculature to various tissues (RISTOW et al., 2015; HYDE, 2017). However, some studies 
suggested the progress of chronic LB is not due to transmission of Borrelia via the 
bloodstream, but instead due to the migration of spirochetes through various tissues 
(STRAUBINGER et al., 1997).  
Do TBRF and LB species, e.g., Bp and Bbss, have the same hematogenous dissemination 
route, or not? It is of scientific importance to define the exact dissemination pathways of the 
two biologically different pathogens in the mammalian host. In the present study, we 
developed a novel long-term murine model to examine the dissemination route of host-
adapted Bp and Bbss organisms in vivo post intradermal (ID) and strict intravenous (IV) 
inoculation in immunocompetent mice. The objectives of this investigation were to (1) 
provide an animal model with a precise and defined infection route; (2) investigate the 
population dynamics of borrelia organisms disseminated in the bloodstream of the 
immunodeficient and immunocompetent mice; (3) study whether Bp and Bbss disseminate 
into tissues of mice after ID or IV inoculation; (4) characterize the immune response against 
host-adapted borrelia organisms in immunocompetent mice.  
Based on the data obtained, it is concluded that our long-term murine infection model was 
successfully established. This newly established murine model is a reliable tool to shed more 
light on the dissemination route (via blood versus via tissue) of Bp and Bbss organisms in 
immunocompetent mice. 
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II LITERATURE REVIEW 
1 Historical background 
1.1 Tick-borne relapsing fever (TBRF) 
Tick-borne relapsing fever (TBRF) caused by the spirochete Borrelia (B.) duttonii was first 
described in humans in East Africa in 1905 with a feature of acute fever episodes separated 
by afebrile intervals (DUTTON et al., 1905; BURGDORFER, 2001). In many states of the 
USA, human cases of TBRF were reported during the first half of the 20th century 
(DWORKIN et al., 2002). In Persian of Iran, the first clinical description of TBRF, which 
was spread to humans by the soft tick Ornithodoros (O.) tholozani, was published as early 
as in 1882 (THÉODORIDÈS, 1998). Its causative agent, Spirochaeta persica, was first 
isolated from the blood of a patient in 1913 (DSCHUNKOWSKY, 1913; EUZÉBY, 1997). 
In the following decades, B. persica (Spirochaeta persica, Bp) vectored by O. tholozani was 
clearly identified as the agent causing TBRF (ADLER et al., 1937; BABUDIERI, 1957; 
SKERMAN et al., 1980). Nowadays, Bp is known to be the main cause of TBRF in Central 
Asia and Middle East areas (OSHAGHI et al., 2011). 
1.2 Lyme borreliosis (LB) 
Lyme disease (LD) was originally named as Lyme arthritis (LA) in 1975 after the town of 
Lyme in Connecticut, USA, where a bizarre cluster of arthritis cases was reported from 
adolescents (STEERE et al., 1977). A skin lesion erythema chronicum migrans (ECM) was 
a typical manifestation in the early phase of LD (STEERE & MALAWISTA, 1979). In 1982, 
the etiological agent of LD was first isolated from the midgut tissues of the hard tick 
Ixodes (I.) scapularis and was named B. burgdorferi (Bb) in honor of its original discoverer 
(BURGDORFER et al., 1982; JOHNSON et al., 1984). In Europe, individual ECM had first 
been documented in 1909 (AFZELIUS, 1910) and the tick species I. ricinus was identified 
as a vector related to this clinical sign (GELBJERG-HANSEN, 1945; THÖNE, 1968). After 
the 1980s, the species B. burgdorferi, B. afzelii and B. garinii were further determined as 
etiological agents to cause LD in Europe and Asia (BORCHERS et al., 2015). Until today, 
Lyme disease or, more precise, Lyme borreliosis (LB), is considered one of the most 
prevalent tick-borne diseases (TBDs) in Europe (VAN DEN WIJNGAARD et al., 2017) and 
in the United States (PENG et al., 2017).  
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2 Etiology and epidemiology 
2.1 Taxonomy and nomenclature of Borrelia spirochetes 
Spirochetes in the genus Borrelia belong to the family Spirochaetaceae (BURGDORFER et 
al., 1982). In addition to other three families within the order Spirochaetales, 
Spirochaetaceae belongs to the class of Spirochaetes, which is incorporated in the Phylum 
of Spirochaetes (EUZÉBY, 1997). According to genomic, genetic and phylogenetic studies 
on nucleotide and protein signatures (ADEOLU & GUPTA, 2014; OREN & GARRITY, 
2016), Borreliella (“borrelia-like”) gen. nov. was proposed to differentiate the pathogens 
that cause LB from those that cause relapsing fever (RF; maintaining the genus Borrelia 
affiliation). However, the splitting of genus Borrelia into two taxonomical genera groups 
has not been accepted due to some criticism and inadequate evidence (MARGOS et al., 
2017). Nevertheless, 42 Borrelia species have nowadays been recognized and divided into 
two groups responsible for RF and LB (EUZÉBY, 2012). Except for B. recurrentis, which 
is transmitted by the body louse Pediculus humanus and causes epidemic louse-borne 
relapsing fever (LBRF) in humans, all other known RF-related Borrelia species are tick 
vectored and therefore named tick-borne relapsing fever (TBRF) (Figure 1) (BARBOUR & 
HAYES, 1986; MARGOS et al., 2017). Generally, TBRF and LB Borrelia spirochetes are 
transmitted by soft ticks of the genus Ornithodoros and hard ticks of the genus Ixodes, 
respectively. However, a TBRF inducing species, B. miyamotoi, shares the same Ixodes 
vector as LB species (TAKANO et al., 2014). Thus, TBRF can be divided into soft tick-
borne relapsing fever (STBRF) and hard tick-borne relapsing fever (HTBRF) (Figure 1) 
(TALAGRAND-REBOUL et al., 2018). 
The classification of Borrelia is as follows: 
Order: Spirochaetales 
Family: Brachyspiraceae  
Family: Brevinemataceae  
Family: Leptospiraceae 
Family: Spirochaetaceae 
Genus: Borrelia 
Species: Borrelia spp. associated with LB 
Borrelia spp. associated with RF (louse- and tick-borne) 
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Figure 1: Phylodendrogram of average nucleotide identity values among relapsing 
fever borrelia genomes 
LB borrelia genomes are shown as an outgroup.  
Cited from the reference (TALAGRAND-REBOUL et al., 2018) 
 
Among the Borrelia species Bp is one of the most important and prevalent pathogens of 
TBRF in humans (ASSOUS & WILAMOWSKI, 2009). Based on the flagellin B gene (flaB) 
and 16S ribosomal ribonucleic acid (rRNA) gene (rrs) sequencing of Bp isolated from 
O. tholozani ticks and TBRF human blood samples, a separate cluster has been formed from 
the other African (Old World) RF Borrelia in the phylogenetic tree (Figure 1) (ASSOUS et 
al., 2006; SAFDIE et al., 2010; TALAGRAND-REBOUL et al., 2018). On the other hand, 
various LB species have been classified in the B. burgdorferi sensu lato (Bbsl) complex and 
divided into 21 validated genotypes on the basis of deoxyribonucleic acid (DNA) relatedness 
(LOHR et al., 2018). Of them, the closely related species that induce most human LB cases 
have been classified as distinct genospecies such as B. burgdorferi sensu stricto (Bbss), 
B. afzelii, B. garinii (Figure 1) by DNA-DNA hybridization and 16S rRNA sequencing 
(JOHNSON et al., 1984; BARANTON et al., 1992). Also, multilocus sequence typing 
(MLST) which conducts targeted gene amplification and sequence analysis of several 
defined housekeeping genes has been used to distinguish both Bp and Bbsl species 
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(MARGOS et al., 2011; SCHWARZER et al., 2015). For example, strains of B. garinii 
OspA1 serotype 4 (a rodent-associated ecotype) have been newly designated B. bavariensis 
species by MLST in humans and ticks in Europe and Asia (MARGOS et al., 2013). In 
particular, lack of the glycerophosphodiester-phosphodiesterase gene (GlpQ) differentiates 
LB from TBRF Borrelia spp. that possess this gene (PETTERSSON et al., 2007). 
2.2 Pathogenic TBRF and LB Borrelia species 
2.2.1 TBRF Borrelia species throughout the world  
TBRF is an important global infection disease that is caused by several Borrelia species 
(Figure 1). The Ornithodoros spp. ticks, the transmitting vectors of TBRF, are present 
worldwide and are closely associated with their animal hosts (Figure 1). Naturally occurring 
infections with TBRF spirochetes have been observed in a diversity of mammals including 
squirrel monkeys, opossums, and armadillos, calves, horses and humans (LOPEZ et al., 
2016). However, the impact of TBRF on the health of domestic and wild animals is mostly 
understudied (SCHWAN et al., 2005). Nevertheless, only few cases of infection in dogs, cats, 
domestic pigs and horses from some limited parts in the world have been reported with 
veterinary importance. In comparison, clinical TBRF cases in humans have been clearly 
documented in most areas of the world and remain a noticeable public health concern 
(ELELU, 2018).  
Among pathogenic TBRF spp., B. hermsii and B. turicatae are the primary entities in the 
United States. Associated with the geographical distribution of their transmission vectors, 
O. hermsii and O. turicata, respectively, this disease is endemic in moderate to high-
elevation and coniferous forests of the United States (DWORKIN et al., 2002). B. parkeri, 
another TBRF spirochete that was recovered from O. parkeri, shares similar geographic 
distribution to B. hermsii and can also pose risks to both animals and humans (THOMPSON 
et al., 1969; BARBOUR & CAMPEAU MILLER, 2014). Of the reported TBRF cases 
(n=504) in humans from 1990 to 2011 in the USA, most are caused by B. hermsii and approx. 
70% cluster in California, Washington, and Colorado (FORRESTER et al., 2015). In Africa, 
the main circulating species are B. crocidurae in Western and Northern Africa and B. duttonii 
in Eastern, Central and Southern Africa (VIAL et al., 2006; TRAPE et al., 2013). 
B. hispanica is found in some Mediterranean countries such as Spain, Portugal, Cyprus, 
 
1 OspA: outer surface protein A 
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Greece, and North Africa (REBAUDET & PAROLA, 2006; VIAL et al., 2006; TRAPE et 
al., 2013). In certain areas of Asia, Europe and USA, B. miyamotoi has been reported 
(TALAGRAND-REBOUL et al., 2018).  
Through the Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan) 
and Middle East (Iran, Iraq, Syria, Jordan, Turkey, Israel, Egypt) region, clinical human 
cases of TBRF are confirmed and associated with Bp (PAROLA & RAOULT, 2001; 
ASSOUS et al., 2006). Especially in Israel, Iran and Jordan, Bp infection in persons have 
been detected frequently (DE VERDIERE et al., 2011). Although other species of 
B. caucasica, B. latyschewii, B. microti and B. baltazardi have been described, they are not 
prevalent in these areas (KARIMI et al., 1979; GOUBAU, 1984; AGHIGHI et al., 2007). In 
some epidemiological studies in Iran, cases of TBRF caused by Bp were mostly found in 
rural areas, especially correlated with young people (e.g., students and children) (ARSHI et 
al., 2002; ASL et al., 2009; RAFINEJAD et al., 2012; KASSIRI et al., 2014). Provinces of 
Ardabil, Hamadan, Zanjan and Kurdistan are highly endemic regions (MASOUMI ASL et 
al., 2009). In Israel and Jordan, Bp infection is often found in hikers who enter the tick 
infested habitats but normally without necessary precautions. In summer and autumn during 
the year, TBRF occurs frequently, because of human outdoor activities exposed to tick 
vectors (ASSOUS & WILAMOWSKI, 2009; KASSIRI et al., 2014). Especially in Israel, 30% 
- 60% of caves were found to be infested by ticks of O. tholozani. Therefore, TBRF in this 
country has traditionally been called cave fever (SIDI et al., 2005). 
2.2.2 LB Borrelia genospecies in the Northern Hemisphere  
Of the Lyme Borrelia spp., Bbss (also referred to Bb) predominates in the United States and 
less extensively in Europe, whereas B. afzelii and B. garinii are more endemic than 
B. spielmanii in Europe; B. bavariensis is widely distributed in Europe and Asia. All of these 
five genospecies are particularly human pathogenic agents of LB (Table 1) (MARGOS et al., 
2013; SCHOTTHOEFER & FROST, 2015; STEERE et al., 2016). Additionally, Bbss 
species in the USA has been solely detected to be pathogenic in dogs, whereas only DNA of 
B. afzelii and B. garinii was found in naturally infected dogs in Europe and Asia (HOVIUS 
et al., 1999; SPECK et al., 2001). The other species, such as B. lusitaniae, are only 
occasionally associated with human disease while the pathogenicity of other tick-isolated 
species (e.g., B. valaisiana, B. americana, B. californiensis, and B. caroliniensis) in persons 
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or animals has not been demonstrated so far (COLLARES-PEREIRA et al., 2004; DIZA et 
al., 2004; KRUPKA & STRAUBINGER, 2010).  
In humans, different genospecies seem to be variably associated with the particular clinical 
manifestations in some organs (skin, nervous system, joint) of the LB patients, although they 
share some common clinical signs such as EM and an influenza-like illness. In Europe, the 
most common disseminated symptom is Lyme neuroborreliosis (LNB) attributed to 
B. garinii (mostly) and B. bavariensis. B. afzelii is principally involved in cutaneous 
manifestations such as EM and ACA. Bbss, however, is most frequently the etiological agent 
for LA of patients (STANEK et al., 2012; VEINOVIĆ et al., 2013; COIPAN et al., 2016). 
The heterogeneity of the Bbsl strains, which are transmitted by different species of Ixodes 
ticks, is possibly the main factor accounting for the variances in the clinical symptoms of 
human LB from/in different geographical regions (MARGOS et al., 2011). A study involving 
at least 26 European countries revealed that Bbsl infection occurred from Italy to Iceland 
and from Portugal to Russia. The proportion of the population showing positive for 
B. burgdorferi antibodies differs in various countries (approx. 5 - 25%) (HABÁLEK & 
HALOUZKA, 1997). There is no obvious sex bias of LB while age distribution is generally 
bimodal, with the highest occurrence rates seen in children 5 - 9 years of age and in adults 
aged over 50 years in both the USA and Europe (BORCHERS et al., 2015). Annually, more 
than 85,000 cases are widespread in Europe, typically in Central (Germany, Austria and 
Switzerland) and Eastern Europe (LINDGREN et al., 2006). During 2005 - 2010, averagely 
106.6 LB cases per 100,000 individuals per year in the USA have been reported by the 
Centers for Disease Control and Prevention (CDC) (NELSON et al., 2015). However, recent 
modeling investigations based on claims data suggest significant under-reporting and predict 
much higher quantities of LB cases annually in the USA (>300,000) and Germany (>200,000) 
(MULLER et al., 2012; NELSON et al., 2015).  
As one of the significant infectious TBDs in the Northern Hemisphere, LB has been 
described in more than 80 countries (KUGELER et al., 2015; STEERE et al., 2016). Globally, 
it seems to be on the rise because of climate changes, land use as well as recreational 
behavior of humans which impact the ticks and thus disease prevalence (LINDGREN et al., 
2006). For example, the number of confirmed cases of LB increased approx. eight times 
between 2004 and 2012 in Canada (OGDEN et al., 2014) and from 27,444 (2007) to 29,513 
(2017) in the USA (CDC, 2017).  
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Table 1: Members of Bbsl complex of confirmed or possible human pathogenic significance of Lyme borreliosis 
causative 
agents 
typical vectors geographical 
distribution 
main reservoirs pathogenicity 
for humans 
clinical signsa 
Bbss I. scapularis, 
I. pacificus, 
I. ricinus, 
I. persulcatus (?) 
North America, 
Europe 
mammals, birds + + +  time of onset of clinical signs after exposure: 
early stage generally 3 - 30 days;  
influenza-like (e.g., mild fever, malaise, 
myalgia/arthralgia; Bbss); 
erythema migrans (Bbss, B. afzelii) 
time of onset of clinical signs after exposure:  
late stage generally > 30 days; 
arthritis; 
acrodermatitis chronica atrophicans 
(B. afzelii);  
neurological (Lyme neuroborreliosis, e.g., 
numbness, Bell’s palsy, stiffness of neck, 
declining memory, sleep disorders; 
Bbss, B. bavariensis) 
B. afzelii I. ricinus, 
I. persulcatus 
Europe, Asia small mammals + + + 
B. garinii I. ricinus, 
I. persulcatus 
Europe, Asia birds  + + + 
B. bavariensis I. ricinus, 
I. persulcatus 
Europe, Asia small mammals, 
birds 
+ + +  
B. spielmanii I. ricinus, 
I. persulcatus 
Europe garden dormouse + + + 
B. mayonii I. scapularis, 
I. pacificus 
North America mammals + +  
B. lusitaniae I. ricinus Europe lizards (+)  
B. bissettiae I. pacificus, 
I. spinipalpis, 
I. ricinus 
Europe,  
North America 
Neotoma fuscipes 
(wood rat) 
(+)  
B. valaisiana I. ricinus, 
I. granulatus, 
I. columnae 
Europe, Japan, 
Taiwan (China), 
Korea 
birds ?  
  
a Clinical signs of LB are based on the confirmed human pathogens of Bbss, B. afzelii, B. garinii, B. bavariensis, and B. spielmanii. 
Data modified from references (STONE & BRISSETTE, 2017; LOHR et al., 2018) 
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2.2.3 Cell morphology and outer membrane proteins 
Spirochetes in the genus Borrelia are gram-negative, regularly wavy, slenderly helical, 
flagellated bacteria (Figure 2). Their length and diameter may range from 8 - 30 µm and 
from 0.2 – 0.5 µm, respectively. They share the morphological properties but differ within 
the number of periplasmic flagella and the number and regularity (length, diameter, 
uniformity and tightness) of the spiral coils (BARBOUR & HAYES, 1986). For example, 
the number of flagella inserted between inner and outer membranes of the cell is 15 - 30 for 
RF spirochete (25 - 30 for Bp) and only 7 - 11 for Bbsl isolate (KARIMI et al., 1979; 
CHARON et al., 2012). The cytoplasmic membrane of Bp is followed by an outer membrane 
in which the lipoproteins were anchored with their lipid content (BARBOUR & RESTREPO, 
2000). In comparison to other TBRF borrelia (e.g., B. hermsii), which have been featured of 
spontaneous antigenic variations on their outer membrane proteins (variable-major-proteins, 
Vmps) (BARBOUR et al., 1982), Bp has been poorly understood in this item. On the other 
hand, LB spirochetes are irregularly coiled, bound by an inner cytoplasmic membrane and 
an outer membrane (Figure 2) (BARBOUR & HAYES, 1986; BORCHERS et al., 2015). 
Particularly, the outer membrane does not contain lipopolysaccharide (LPS) but instead is 
covered by several outer surface proteins (Osps) (STÜBS et al., 2009). To date, six Osps 
from OspA to OspF and various other diagnostically-relevant immunodominant protein 
components of Bbsl have been described. Of them, OspA, OspB, and OspC are most 
significant because their expression is changed to adapt to and to survive in different 
arthropod and mammalian milieus (DE SILVA & FIKRIG, 1997). The variable major 
protein-like sequence expression (VlsE) in mammals has been described and characterized 
with a special serodiagnostic relevance (INDEST et al., 2001; EICKEN et al., 2002). 
Moreover, LB spirochete harbors a small but unique linear chromosome and a variety of 
linear (12) and circular (9) plasmids in which relevant Osps are encoded (BRISSON et al., 
2012). In 1997, the complete genome size of type strain Bbss B31 was first sequenced with 
1,521,419 base pairs (bp) (FRASER et al., 1997), whereas that of Bp with 1,784,979 bp 
(1.7 Mb) was first published in 2014 partly due to the difficulty of in vitro cultivation of this 
bacteria (ELBIR et al., 2014). 
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Figure 2: Structure and morphology of B. burgdorferi 
(a) Scanning (left) and transmission (right) electron micrographs of B. burgdorferi. The helical 
shape of Borrelia (left) is imparted by the periplasmic flagella, which can be seen in the cross-
sectional view of the spirochete in the transmission electron micrograph. (b) Diagram of the 
spirochete. Flagellar insertion points are located near the termini of the spirochete. Bundles of 
flagella wind around the flexible, rod-shaped protoplasmic cylinder of Borrelia and overlap in the 
middle. The outer membrane constrains the flagellar bundles within the periplasm. (c) Detailed 
diagram of flagella. Each flagellum is inserted into the cytoplasmic membrane and extends through 
the cell wall into the periplasm. Flagella are multi-component, complex structures. Spirochetal 
motility results from coordinated rotation of the flagella. 
Cited from Rosa et al. (ROSA et al., 2005) 
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2.3 The enzootic cycle of TBRF and LB Borrelia 
2.3.1 Transmission vectors 
Ticks are the transmission vectors of TBRF and LB Borrelia (PAROLA & RAOULT, 2001). 
Until 2012, 896 tick species are defined and three families are recognized: two major 
families of the Argasidae (193 species) and the Ixodidae (702 species) and a third one, the 
Nuttalliellidae (1 species) (YAKHCHALI et al., 2012). As shown in Figure 3, the Argasidae 
ticks are characterized with flexible cuticle (soft bodied) while species of the Ixodidae family 
possess a sclerotized dorsal shield or scutum (hard bodied). Among Argasidae family, the 
genus Ornithodoros comprises the largest number of species (n=112) (GUGLIELMONE et 
al., 2010). Of them, O. tholozani (Figure 3A) serves as the principal vector for Bp with a 
large distribution of regions overlapped by TBRF cases in Middle East, Central Asia, and 
India and Kashmir. However, the occurrence of O. tholozani varies in these areas (ASSOUS 
& WILAMOWSKI, 2009; MANZANO-ROMÁN et al., 2012). The genus Ixodes (243 
species) in the Ixodidae family is most vital of vectors that transmit zoonotic pathogens with 
significant impact on human and veterinary health (GUGLIELMONE et al., 2006; 
YAKHCHALI et al., 2012). Four predominant species of Ixodes ticks (Table 1) have been 
revealed as competent vectors for LB organisms. In North America, Bbss was transmitted 
by I. scapularis (the deer tick) in the northeastern and upper midwestern USA and in Canada, 
whereas I. pacificus predominately presents in western USA along the Pacific coast. 
I. ricinus (the castor bean tick, Figure 3B) transmits LB agents in Europe and Asia while 
I. persulcatus is endemic in Asia (PIESMAN & GERN, 2004; STANEK et al., 2012).  
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Figure 3: Soft and hard bodied ticks 
(a) Soft tick of species O. tholozani, left: ventral view; right: dorsal view. (b) Three stages of unfed 
hard tick I. ricinus, left to right: adult (female), adult (male), nymph, and larva (bar, 1 cm). Scutum 
(arrow) covers entire dorsal surface in male, whereas it is confined to anterior part of body in other 
stages. Note the three pairs of walking legs in larva.  
Cited from references (PAROLA & RAOULT, 2001; ASSOUS et al., 2006) 
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Both soft and hard ticks take blood meals to reproduce, develop, and to complete their life 
cycle that comprises three stages: larva, nymph, and adult (male and female) (PAROLA & 
RAOULT, 2001). Before molting to adult, soft ticks may pass through several nymph stages 
(2 to 5 depending on the tick species; Figure 4). The nymphs feed briefly (minutes to hours) 
and repeatedly (may up to 6 times) on the same or multiple hosts (BASU & CHARLES, 
2017). Differing from soft ticks, the long/slow feeding (2 - 4 days) ixodid ticks have a unique 
nymphal stage, which means that these vectors feed only once at each stage on various hosts 
(Figure 5) (RANDOLPH, 1993). After each blood meal, soft ticks drop to molt and hide in 
their habitats such as the cracks and crevices of the houses, animal burrows, or just below 
the soil surface. Usually, they emerge at night to feed upon the host while asleep (PAROLA 
& RAOULT, 2001; BOGITSH et al., 2013). Interestingly, many hard ticks are highly 
susceptible to drying conditions. Hence, they prefer to locate on or near the soil surface with 
vegetation with a relative humidity of minimum 80% (RANDOLPH, 1993; CORTINAS et 
al., 2002; STANEK et al., 2012). Most hard ticks spend more than 95% of their lives on or 
just below the ground surface digesting the blood meal, molting, in diapause or seeking a 
host (RANDOLPH, 1993; PIESMAN & GERN, 2004). The life span of hard ticks is 
generally 2 - 3 years through a life cycle (Figure 5), because adult female ticks feed and lay 
clutches of eggs only once and die. However, like nymphs, adult females of soft ticks are 
also capable of taking blood meal for several times. Moreover, soft female ticks lay 
numerous batches of eggs multiple times during their lifetime (TYSON & J., 2009b). In 
particular, soft adult ticks can survive 5 - 10 years even with prolonged periods of starvation 
(DWORKIN et al., 2008; LOPEZ et al., 2016). 
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Figure 4: General soft tick life cycle 
The example is tick of O. moubata species transmitting B. duttonii in Africa and Asia. Nymphal 
instars vary with species.  
Cited from WHO (WHO, 1997) 
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2.3.2 Life cycle of TBRF and LB organisms 
TBRF and LB spirochetes cycle through their mammalian reservoirs and tick vectors. The 
opportunities of transmitting spirochetes vary between soft and hard species because of their 
contrasting feeding performances (KADA et al., 2017). Characteristically, uninfected larvae 
acquire borreliae through blood meal from infected rodents or other small mammals. By the 
 
2 Namely, species of Bbss in North America 
Figure 5: Transmission cycle responsible for maintaining B. burgdorferi2 in tick 
populations and allowing infection of humans and dogs 
Briefly, larvae emerge from eggs laid by female adult in spring, take blood meal upon the first 
hosts of small vertebrate mammals which may be already infected with borreliae and transfer the 
bacteria to the fed larvae. Larvae molt in spring of the following year into nymphs that are 
responsible for spreading the majority of infections via saliva to the second reservoir hosts, humans 
included. Nymphal ticks are endemic during spring and summer, with a peak activity occurring in 
late summer. Later, nymphal ticks develop into adults which feed upon the third hosts, including 
dogs, and reproduce in fall or even in winter.  
Cited from Little et al. (LITTLE et al., 2010) 
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time the larvae molt to the nymphs, borreliae are transmitted from infected nymph to 
uninfected animals during blood meal. Infected animals serve as new reservoirs for 
continuing the Borrelia transmission cycle (Figure 5). After molting to the adults, adult ticks 
are able to spread borreliae and/or acquire borreliae through blood meal between infected 
and uninfected animals. Generally, transmission frequency of LB borreliae is influenced by 
seasonal and environmental conditions (e.g., temperature, relative humidity, and the 
photoperiod), which can decide the activities of ixodid ticks. The soft ticks, however, have 
no seasonal preference (PAROLA & RAOULT, 2001). Therefore, the prevalence of TBRF 
Borrelia infection arises more often in summer due to increased human outdoor activities in 
tick-infested areas (TALAGRAND-REBOUL et al., 2018).  
TBRF organisms are mostly horizontally transmitted between Ornithodoros ticks and 
different animals. Also, a transovarial transmission (TOT) of TBRF borreliae exist via the 
adult’s eggs to the offspring. TOT of LB spirochetes, however, is rare or non-existent. 
Regularly, LB organisms are maintained in the transstadial transmission during molting 
progress of Ixodes spp. ticks: from infected larva to nymph and/or from infected nymph to 
adult (MAGNARELLI et al., 1987b; RICHTER et al., 2012; ROLLEND et al., 2013). Upon 
hard tick attachment to susceptible animals, various secretions from the salivary glands 
facilitate and support the spirochete transmission. There salivary secretions include cement, 
enzymes, vasodilators, and anti-inflammatory, antihemostatic, and immunosuppressive 
substances (PAROLA & RAOULT, 2001). Transmission of Borrelia spirochetes by soft ticks 
is faster than hard ticks and mainly through the saliva secretion at nymphal stages or via the 
coxal fluids from coxal organs of adult ticks throughout the short feeding time (SCHWAN 
& PIESMAN, 2002). 
2.3.3 Reservoirs and hosts 
In general, soft ticks are believed to serve as the natural vertebrate reservoirs of TBRF 
organisms (HOOGSTRAAL, 1985; PAROLA & RAOULT, 2001). O. tholozani, is able to 
transmit Bp and have a wide range of mammalian hosts including humans, sheep, goats, 
camels, cattle, porcupines, hedgehogs, foxes, jackals and rodents (HOOGSTRAAL, 1985). 
Besides soft ticks, other animals have been also implicated as reservoirs of Bp. These animals 
include bats in Jordan and Central Asia, and rock hyraxes (Procavia capensis) in Israel and 
the West Bank (DE ZULUETA et al., 1971; VASIL'EVA et al., 1990; KLEINERMAN et al., 
2018). Recently, reports of natural Bp infection in cats and dogs (including a young puppy) 
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from Israel and Iran suggested that domestic animals are possibly transient reservoir hosts 
of this bacterium (BANETH et al., 2016; SHIRANI et al., 2016). Soft ticks have no host 
tropism possibly due to their inhabiting environment and an adaption of natural selection 
(TALAGRAND-REBOUL et al., 2018). Also, an animal reservoir may not be necessary to 
complete Bp life cycle because of the presence of transovarial transmission 
(BURGDORFER & VARMA, 1967). Furthermore, an infected O. tholozani tick is able to 
survive impressively long for 10 years or even more without feeding. This long time lasting 
may have two important roles: as the vector and as the original natural reservoir (GOUBAU, 
1984; ASSOUS & WILAMOWSKI, 2009; BANETH et al., 2016). In a result, animals or 
humans in the life cycle of this tick may only be the source of a blood supply (BANETH et 
al., 2016).  
Ixodid ticks at different life stages may feed on a wide diversity of mammals, birds and 
reptiles (Table 1) that differ dependening on the geographical distributions. In Europe, 
I. ricinus is the main tick biting various vertebrates with over 300 species. However, only a 
few of them, such as certain strains of mice, voles, rats and shrews have been detected as 
reservoirs for Bbsl (ANDERSON, 1991; GERN et al., 1998). Garden dormice 
(Eliomys quercinus) in France and edible dormice (Glis glis) in Germany were observed 
parasitized with Ixodes spp. ticks and showed their possible roles as borrelial reservoirs 
(MATUSCHKA et al., 1994; MATUSCHKA et al., 1999). Some rodents like grey squirrels, 
sheep in the UK and red squirrels in Switzerland are associated with Bbsl (CRAINE et al., 
1997; OGDEN et al., 1997; HUMAIR & GERN, 1998). In North America, the contribution 
of the white-footed mouse (Peromyscus leucopus) is chiefly substantial as the primary 
reservoir for Bbss (LANE et al., 1991; ORLOSKI et al., 2000). White-tailed deer, other 
various species of deer (e.g., elks), and lizards apparently serve as hosts for I. scapularis and 
I. pacificus ticks. Particularly, adult Ixodes spp. ticks mate on the deer but these animals do 
not actually act as reservoirs for spirochetal transmission (PIESMAN & GERN, 2004). Some 
passerine birds (canary finches) may migrate Ixodes spp. ticks to new locations and may also 
act as reservoirs for circulating B. garinii and B. valaisiana in Europe and Bbss in the USA 
(OLSEN et al., 1996; PIESMAN & GERN, 2004). In the aspect of veterinaty health, canine 
infection with Bbsl is often associated with infestion of adult ixodid ticks (Figure 5) 
(KRUPKA & STRAUBINGER, 2010). Humans are considered as accidental hosts for both 
TBRF and LB organisms (LOPEZ et al., 2016). 
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3 Pathogenesis of TBRF and LB organisms in mammalian host 
3.1 Tick-assisted immune evasion 
A successful infection relies on blood meal by infected ticks and a succeptible host. The first 
step in the infection cascade is the tick crawling to the host skin seeking a safe attachment 
site (VERHAEGH et al., 2017). Mechanically, the infected vector cuts a hole in host’s skin, 
enabling the rapid (soft tick) or slow (hard tick) delivery of borrelial organisms into the 
mammal/bird/reptile (BOYLE et al., 2014; STEERE et al., 2016). Biochemically, 
multifunctional tick saliva or coxal fluids provide adaptive advances in tick feeding and 
transmission of spirochetes. These vasodilatory molecules secreted by the feeding tick, 
although most of them are different between soft and hard ticks, can inhibit blood-
coagulation and platelet aggregation pathways. These mechnisms allow more blood 
circulation at the cutaneous bite site and make contribution to the infectivity of the bacteria 
(KAZIMÍROVÁ & STIBRANIOVA, 2013). Some proteins derived from ixodid tick saliva 
such as tick salivary protein 20 (Salp20), Salp15, Salp25D are more directed to inactivate 
the host’s innate and adaptive immune pathways including the complement system, CD4+ 
T cell activation (DAS et al., 2001; ANGUITA et al., 2002; HOURCADE et al., 2016). A 
large family of Ixodes scapularis anticomplement (Isac) proteins and Isac-like family of 
proteins such as Ixodes ricinus anticomplement (Irac) I, Irac II, and IxAC-B1 through 5 have 
the function to inhibit the host's alternative complement pathway (VALENZUELA et al., 
2000; DAIX et al., 2007; COUVREUR et al., 2008). Furthermore, saliva of the hard tick 
inhibits the Toll-like receptors (TLRs)-induced cytokine responses in keratinocytes as well 
as on dendritic cells (DCs) (VERHAEGH et al., 2017). Regarding to argasid vectors, 
however, only O. moubata complement inhibitor (OmCI) has been recognized to date. The 
salivary lipocalins expressed by the tick of O. moubata directly bind C5, by which OmCI 
can inhibite the classical and alternative complement pathways (TYSON & J., 2009a; 
STONE & BRISSETTE, 2017). Nevertheless, all these mechanisms in turn facilitate the 
spirochetes to establish the infection in a new host milieu (PAL & FIKRIG, 2003; 
VERHAEGH et al., 2017). 
3.2 Adaptation of borreliae during transmission 
Soft ticks of Ornithodoros spp. take blood meals as fast as within a few seconds or minutes. 
For example, ticks of O. tholozani and O. hermsii attach 10 - 20 min and 15 - 90 min, 
respectively, for repletion after encountering their hosts. During the short feeding time, 
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pathogenic TBRF spirochetes can be efficiently transmitted from a tick vector to the new 
host (SCHWAN & PIESMAN, 2002; ASSOUS & WILAMOWSKI, 2009). Recent studies 
have described that deposition of B. turicatae into the bite site is a rapid event within 15 s of 
tick attachment during the blood meal. Particularly, their findings suggested that spirochetes 
disseminate into the host blood during the short time required for tick engorgement (BOYLE 
et al., 2014). Thus, it is proposed that a preadaptation of TBRF borreliae is likely established 
in the tick salivary glands. During the preadaptation period, pathogens can express some 
proteins against innate immunity in order to enter the vertebrate host by a rapid transmission, 
e.g., variable tick protein (Vtp) synthesized by B. hermsii (SCHWAN & PIESMAN, 2002; 
RAFFEL et al., 2014; LOPEZ et al., 2016).  
Lyme spirochetes are well-identified pathogens that alters the expression of Osps (Figure 6) 
over the course of its life cycle between the tick vector and mammalian host. Various Osps 
are crucial antigens in cellular physiology and act directly in pathogenesis in mammals 
(FRASER et al., 1997; SINGH & GIRSCHICK, 2004). OspA is expressed as LB spirochetes 
enter the tick vector during the uptake of an infected blood meal. This protein remains a key 
surface antigen during bacterial colonization in the midgut of unfed ticks (BATTISTI et al., 
2008). During the slow engorgement process of infectious tick feeding (2 - 4 days of the 
complete 5- to 8-day attachment period), spirochetes that undergo ambient temperature and 
pH changes (from 23 °C, high pH to 37 °C, low pH) migrate from the midgut to the salivary 
grands (TEMPLETON, 2004). Concurrently, these bacteria multiply to increase their 
quantity and downregulate the expression of OspA (particularly) and OspB (DE SILVA & 
FIKRIG, 1995; ANGUITA et al., 2003). Another surface protein, OspC, is highly 
upregulated and plays a pivotal part in spirochetal dissemination from tick midgut to the host 
dermis (GILMORE & PIESMAN, 2000; TILLY et al., 2008). Since spirochetes with OspC 
are able to invade the tick’s salivary glands and bind Salp15, prevention of complement- or 
phagocytosis-mediated killing and further recognition by antibodies (especially 
immunoglobulins M, IgM) is beneficial for LB organisms to survive at early stage of 
mammalian infection (SCHUIJT et al., 2008; CARRASCO et al., 2015). Studies reviewed 
by Verhaegh et al. show that deleting or overexpressing OspC results in quick clearance of 
borrelial organisms from the host (VERHAEGH et al., 2017). However, OspC production is 
not required for spirochete persistence in the host once the infection is established (TILLY 
et al., 2006). Nevertheless, these Osps, especially OspA and OspC as identified, are able to 
bind vector or host molecules. This mechanism protects the LB organisms against the innate 
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immune response during the initial stage of host colonization/invasion (RUDENKO et al., 
2016).  
 
 
3.3 Establishment of early infection 
Although the precise number of delivered TBRF spirochetes through the tick saliva remains 
unknown, one can speculate that it is low due to the very short (seconds to minutes) feeding 
course of Ornithodoros spp. ticks. Successful infections have been established in laboratory 
animals (ticks included) under different settings with variable infection doses and 
inoculation types. A single spirochete of B. recurrentis var. turicatae, B. duttoni, and 
B. hermsii is sufficient to produce an effective infection in rats (IP inoculation), soft ticks of 
O. moubata (capillary tube), and mice (IP inoculation), respectively (SCHUHARDT & 
WILKERSON, 1951; GEIGY & SARASIN, 1958; STOENNER et al., 1982). Motile 
Figure 6: Overview of the LB spirochete and its Osps ordered according to their 
(predicted) function  
Cited from Verhaegh et al. (VERHAEGH et al., 2017) 
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spirochetes appear in the blood of white mouse as soon as 1 h after IP injection of “a large 
inoculum” of a RF species “Borrelia erratici” (EIDMANN et al., 1959; BARBOUR & 
HAYES, 1986). Kinetic studies on the spirochete populations have confirmed mild to high-
level bacteremia in the blood of immunocompetent animals one day after tick attachment, 
ID, and IP inoculation of B. turicatae, B. persica, and B. hermsii, respectively (BOLZ et al., 
2006; LOPEZ et al., 2014; SCHWARZER et al., 2016). Therefore, TBRF spirochetes occupy 
a feature that they can pass rapidly from the tick bite site to the blood of the vertebrate host. 
Consequently, as early as the first 3 to 5 days after inoculation, TBRF pathogens that have 
survived in and adapted to the bloodstream can multiply and produce severe spirochetemia 
at a density of approx. 106 - 108 organisms per ml blood (SOUTHERN & SANFORD, 1969; 
BARBOUR & GUO, 2010; LOPEZ et al., 2016).  
In contrast to TBRF, even low-level spirochetemia is rarely seen in humans or animals with 
LB borreliae infections (BARBOUR & HAYES, 1986). In fact, the LB spirochetes remain 
locally in the mammal’s dermis for few days before their colonization in different tissues, 
including the distant skin sites or such organs as joint and heart where they can induce 
inflammatory responses (SHIH et al., 1992; ANGUITA et al., 2003; GRILLON et al., 2017). 
In the natural reservoir hosts, infections with LB organisms generally do not induce obvious 
disease manifestations, because spirochetes have co-evoluted immune evasion strategies 
with the mammals (TRACY & BAUMGARTH, 2017). The majority (95%) of the exposed 
dogs in the USA develop no clinical signs and if they become ill, arthritis, fever, anorexia, 
and lymphadenopathy are most common symptoms (LITTLE et al., 2010). Although humans 
are believed as occasional hosts and do not contribute to spreading pathogens to another host, 
they are susceptible to Bbsl infection and would experience severe disease complications in 
some cases (RADOLF et al., 2012). The earliest and most common clinical manifestation of 
LB in humans is characterized with EM, a red skin rash at the tick bite site (Figure 7), 
occurring in approx. 80% and 90% of patients in the USA and Central Europe, respectively 
(STEERE & SIKAND, 2003; STANEK & STRLE, 2018). If left untreated, EM may persist 
and expand over weeks to months, their diameter ranging from a few centimeters (≥ 5 cm) 
to more than a meter (Figure 7) (STANEK & STRLE, 2018). Multiple EM are described 
with the presence of a secondary or more lesions similar in morphology to the initial solitary 
lesion but smaller in the size criteria (STANEK & STRLE, 2018). As mentioned in an 
investigation, the expanding EM seems to represent the advancing front of a wave of the 
spirochetal organisms “dermatogenously” migrating outward from the deposition site in the 
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skin of the human host (SHIH et al., 1992). Pathogenically, the inoculated spirochetes 
initially sense the pattern recognition receptors (PRRs) such as TLRs and NOD 3 -like 
receptors (NLRs) on DCs and sentinel macrophages in the cutaneous bite site of the 
vertebrate host. Accordingly, certain pro-inflammatory molecules including type 1 
interferons (IFNs) and inflammatory chemokines and cytokines are released by the host 
immune cells with the engagement of TLRs. Also, infiltration of immune cells such as T cells 
(CD8+ and CD4+ cells), macrophages, plasmacytoid, monocytoid DCs, and neutrophils have 
been identified in biopsies of human EM skin lesions (RADOLF et al., 2012). Therefore, 
EM by LB patients is thought to be induced by both innate and adaptive immune response 
to the live and spreading spirochetes (BORCHERS et al., 2015). 
 
3 NOD: nucleotide-binding oligomerization domain 
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Figure 7: Erythema migrans (EM) skin lesions 
(a) EM shoulder, (b) EM knee pit, (c) EM lower leg, a day after onset of treatment, (d-f) EM∼9 
weeks after onset; tick bite in the axilla, (g) EM started at the breast 6 months before 
Cited from Stanek and Strle (STANEK & STRLE, 2018) 
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3.4 Susceptibility to host complement system  
Complement represents a central component of innate immunity. It functions as a well-
organized network comprising the classical, alternative, and the lectin pathway (STONE & 
BRISSETTE, 2017). The alternative pathway is triggered independently of antibodies and 
therefore serves as a primary host defense against borrelia infection before any involvement 
of humoral immune response. Particularly, a key regulatory factor H (FH; 150-kDa protein) 
is involved in the alternative pathway of complement activation (PAL & FIKRIG, 2003; 
WOODMAN et al., 2009). However, various native proteins expressed by Borrelia spp. 
organisms are able to inhibit/regulate complement activation. According to their mechanisms, 
these native proteins are collectively termed as factor H binding proteins (FHBPs) or 
complement regulator-acquiring surface proteins (CRASPs) (KRAICZY & STEVENSON, 
2013). TBRF borreliae have successfully established various sophisticated mechanisms to 
overcome innate immunity, mostly complement system (RÖTTGERDING et al., 2017). At 
least for B. hermsii resistance to complement mediated killing activity has been 
demonstrated (BHIDE et al., 2009). B. miyamotoi was described with persistence in the 
human serum, indicating that this bacterium grasps determinants to evade killing by 
complement (TEEGLER et al., 2014; WAGEMAKERS et al., 2014). More recently, 
complement binding and inhibitory protein A (CbiA) has been identified and found to 
directly inhibit both the initiation of classical pathway of complement and the assembly of 
the terminal complement complex (RÖTTGERDING et al., 2017). Taken together, TBRF 
spirochetes probably have evolved strategies to resist (successfully) the complement 
activation for their survival in the host (MERI et al., 2006; ROSSMANN et al., 2007). In 
addition, resistance to complement strengthens the transmission, survival, and dissemination 
of the Borrelia spp. in mammalian and rodent reservoir hosts (KURTENBACH et al., 2002).  
Regarding to LB organisms different OspE/F-related proteins (Erp) (Figure 6), which are 
known collectively as CRASPs, are synthesized to inhibit host complement during early 
infection phase (PAL & FIKRIG, 2003). Especially the OspE protein has been demonstrated 
to bind the host FH protein (HELLWAGE et al., 2001). However, different isolates and 
genospecies of LB vary in their susceptibility to normal human serum and are therefore 
classified as complement-resistant (most isolates of B. afzelii), complement-sensitive (most 
B. garinii isolates), and intermediate complement-sensitive (Bbss isolates) (KRAICZY et al., 
2001; DE TAEYE et al., 2013). There is evidence that these three pathogenic genospecies 
are related to diverse clinical manifestations in humans: LA with Bbss, LNB with B. garinii, 
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and ACA with B. afzelii (COIPAN et al., 2016). Differences in the complement susceptibility 
may play a part in the pathogenesis of the disease; whether or not complement resistance is 
a virulence factor of LB spirochetes needs to be confirmed. Nonetheless, one must consider 
that B. afzelii has the capacity of persistence in LB patients with ACA over the years. This 
may suggest a higher pathogenicity of complement-resistant B. afzelii isolates to the skin 
(KRAICZY et al., 2001). 
3.5 Immune evasion by borrelial antigenic variations 
Borrelial spirochetes experience an important change in environment when they are 
transmitted by a tick vector, which has no antibody-based immune system, to the vertebrate 
hosts, of which many are warm-blooded and have the capacity of responding uniquely to 
many different types of foreign substances and cells (BARBOUR, 1990). To face the 
vertebrate’s adaptive immune responses, Borrelia spirochetes achieve persistence through 
multiphasic antigenic variation (BARBOUR, 1990). 
3.5.1 Variable major proteins of TBRF Borrelia 
Human infection by TBRF Borrelia is characterized with recurring episodes of fever, which 
is consistent with the high-level spirochetemia in the blood (Figure 8) (DWORKIN et al., 
2008). Immunity of the infected mammals is therefore stimulated to generate borreliae-
specific antibodies of IgM. Once the density of antibodies is high enough, the initial 
spirochetal wave is rapidly eliminated from the bloodstream (Figure 8). Borrelial cells are 
not detectable in the blood resulting in afebrile period (BARBOUR, 1990; STONE & 
BRISSETTE, 2017). However, the lower number of spirochetes (10 to 1,000 cells/ml) in the 
blood switches to produce another antigenic serotype that is not recognized by the host 
immune response. As a result, a new population of bacteria emerges in the blood (MEIER et 
al., 1985; BARBOUR & HAYES, 1986; DAI et al., 2006). Accordingly, old populations are 
being replaced by new serotypes that have been formed in the meantime (Figure 8). The 
serotype-specific antigens are surface lipoproteins of the spirochete outer membrane and 
have been referred to as variable-major-proteins (Vmps). The existing two different classes 
of Vmps are the variable large proteins (Vlps) and the variable small proteins (Vsps) of 
about 38 kDa and 23 kDa, respectively (BARBOUR, 1990; CADAVID et al., 1997; 
CADAVID et al., 2001). Up to now, the mechanism of antigenic variation has been described 
in the following species: B. hermsii (PLASTERK et al., 1985), B. turicatae (RAS et al., 
2000), and more recently in B. miyamotoi (WAGEMAKERS et al., 2016). Regarding to Bp, 
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knowledge of its genetic mechanisms at the level of Vmps is still limited, although Vmp 
sequences have been identified (e.g., Vlp18 under NCBI accession number: WP_024653159) 
(SCHWARZER et al., 2016). Nevertheless, immune evasion of TBRF spirochetes due to the 
multiphasic antigenic variance allows a longer lasting and repeated spirochetemia (Figure 8). 
This strategy gives the chance of increasing the horizontal transmission of TBRF borreliae 
in nature, because recurrent presence of these organisms in the blood increases the likelihood 
of an infection of ticks that suck blood in short time (minutes) (PLASTERK et al., 1985; 
SCHWAN & PIESMAN, 2002). 
 
  
Figure 8: TBRF increases its persistence in blood by shifting the surface protein Vmp 
When antibodies are induced against the first serotype (red), all borreliae expressing this serotype 
are killed by Vmp-specific antibodies. Only those that have shifted to a second serotype (yellow) 
survive and proliferate to cause the first relapse. This combat continues until the host dies or the 
borrelial organisms are eradicated from the blood. Antigenic variation is the mechanism initiating 
the recurring fever, which gave the disease its name. Relapses rarely involve one, single serotype. 
Cited from Talagrand-Reboul et al. (TALAGRAND-REBOUL et al., 2018) 
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3.5.2 Variable major protein-like sequence of LB Borrelia 
After the establishment of Bbsl infection, the evasion of bactericidal antibodies becomes 
crucial for borrelial survival. For this purpose, the spirochetes again alter rapidly and 
continually the surface antigen epitopes by downregulation of OspC and simultaneous 
upregulation of VlsE protein, i.e., Vmp-like sequences (Vls) system (NORRIS, 2006; TILLY 
et al., 2008; STEERE et al., 2016). As each Osp is present as a single-copy locus, genetic 
variation is seen at the population level. Therefore, a single spirochete cannot produce 
various OspC types in situ (STONE & BRISSETTE, 2017). In contrast, VlsE encoded by 
vls gene can undergo extensive antigenic recombination. This is a significant variation 
system to help LB organisms evade the killing by host antibodies and maintain persistent 
infection in mammals (ZHANG et al., 1997). The Vls system (Figure A1) comprises around 
16 vls cassettes (the precise number differs by strain) and one expression locus, vlsE. All 
known vls cassettes are sited on the same linear plasmid (lp28-1) in close proximity to but 
in the opposite orientation of vlsE (ZHANG et al., 1997). Transcription of vlsE occurs 
through the random recombination of different segments of vls cassettes rather than 
recombination of an entire, single vls cassette. Thus, in contrast to TBRF borreliae that 
harbor a predominant serotype, recombination steps occurring to LB spirochete may 
generate thousands of sole VlsE variants but with a similar protein size (~ 36 kDa) after 
translation (STONE & BRISSETTE, 2017). Accordingly, shifted epitopes and confounding 
efforts by humoral immune response (antibodies IgG) to keep up with the sequence variation 
can be harbored in the infected mammals (MCDOWELL et al., 2002; NORRIS, 2006). As 
early as 4 days after Bbsl infection in mice, the recombination events have been identified 
and seem to occur continuously during infection (MCDOWELL et al., 2002). Interestingly, 
mutants that express non-variable VlsE are unable to re-infect animals that have been 
previously infected with Bbsl, whereas spirochetes that express variable VlsE can 
(ROGOVSKYY & BANKHEAD, 2013). However, unlike TBRF, recurring spirochetemia 
corresponding to recurrent episodes of high fever are not seen during LB organism infections.  
3.6 Persistence of Borrelia infection in mammalian host tissues 
3.6.1 Residual brain infection of TBRF spirochetes  
Antigenic variation facilitates the Borrelia infection in the mammals. When TBRF 
spirochetes are no longer measurable in the blood circulation, they may still be found in 
distant organs such as spleen, liver, kidneys, bone marrow, eyes, and the central nervous 
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system (CNS) of infected mammals. In particular, brain tissue harbors consistently persistent 
infections (BARBOUR & HAYES, 1986; CADAVID & BARBOUR, 1998; DWORKIN et 
al., 2008). Borreliae have also been recovered from the cerebrospinal fluid (CSF) of humans 
with RF (CHUNG, 1938; ANDERSON & ZIMMERMAN, 1955). Recently, Bp was found 
to be persistent in the brain tissues of infected immunocompetent mice while at the same 
time the spirochetes were not detectable in blood samples from the same animals 
(SCHWARZER et al., 2016). Residual brain infection has been found in different 
experimental animals or animals in nature (DIATTA et al., 1994; CADAVID & BARBOUR, 
1998). In some cases, brain infection has been found to remain for up to 3 years after 
spirochete inoculation. This indicates that these borreliae maintain a population large enough 
to perpetuate the infection in the brain, yet small enough to avoid host immune responses 
and noticeable tissue damage. Additionally, borreliae recovered from residual brain infection 
were susceptible to the serum of the animal and could not reenter the blood of that animal. 
These phenomena also proposed that the immune response was not effectively reaching the 
organisms in the brain (CADAVID & BARBOUR, 1998). However, immunosuppression 
could reactivate the infection, inducing bacteremia comparable to that of initial densities in 
the blood (LARSSON et al., 2006).  
3.6.2 Invasion of LB spirochetes in host tissues  
Clinically, spirochetemia at the early stage of LB organism infection was often silent in both 
American and European patients with erythema migrans. Blood culturing for Bbsl 
spirochetes have been conducted with great efforts but the yield was low in early or 
occasionally later course during disease progression (WORMSER et al., 1998; MARASPIN 
et al., 2001; LIVERIS et al., 2011; MARASPIN et al., 2011). Instead, following successful 
host colonization, LB spirochetes have a tendency to reside in host tissues. There the 
borrelial organisms evade the developing adaptive immunity of the host. Typically, skin and 
joint, where the host extracellular matrix protein decorin is found, are the immune-privileged 
sites for LB bacteria (TILLY et al., 2008; BORCHERS et al., 2015). Also, the skin but not 
the blood of the vertebrate reservoir host is indicated to play a critical part in receiving, 
hosting, and transmitting the LB pathogens (GRILLON et al., 2017). A large number of 
genes are selectively expressed on outer membranes of Bbsl, which likely contribute to 
spirochete migration and colonization in target tissues (PAL & FIKRIG, 2003). Among them, 
decorin-binding proteins (Dbps) such as DbpA and DbpB and fibronectin binding protein 
BBK32 have been identified with critical roles in LB organism infection within the 
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mammalian environment (Figure 6) (GUO et al., 1995; GUO et al., 1998; PROBERT & 
JOHNSON, 1998). The pore protein P66, another Bbsl surface antigen, has been reported to 
have adhesive properties and bind human ß3-chain integrins that are synthesized in a wide 
range of host location (COBURN et al., 1999). Therefore, multiple adhesin mechanisms 
through widespread host receptors such as decorin, fibronectin or integrins contribute to the 
virulence of the LB spirochete and aid the pathogen to establish chronic infection in multiple 
tissues (PAL & FIKRIG, 2003).  
The most significant clinical sign of LB is acute or chronic arthritis (LA) occurring to ~ 10% 
of all LB patients in the United States. However, the isolation rate of borrelial spirochetes 
from joint fluid and synovial is very low (STANEK & STRLE, 2018). In Europe, 
acrodermatitis chronica atrophicans (ACA) remains a slowly progressive lesion that is 
located primarily on the extensor (acral) surfaces of the extremities. Approximately 20% of 
LB patients with ACA have a history that is consistent with a preceding spontaneously healed 
EM lesion. Usually, ACA lesion develops 6 months to 8 years later on this healed EM 
extremity. Unfortunately, ACA does not resolve spontaneously. Bbsl spirochetes have been 
isolated more than 10 years post onset of this skin lesion from untreated patients with early 
disease manifestations (EM or early LNB) (ASBRINK & HOVMARK, 1985; STEERE et 
al., 2016). 
3.7 Patterns of Borrelia dissemination in mammalian host 
3.7.1 Hematogenous dissemination of TBRF borrelia 
TBRF spirochetes translocate rapidly into the bloodstream from the tick bite site, multiply 
and produce cyclic high-level spirochetemia (BOYLE et al., 2014; LOPEZ et al., 2016). In 
the absence of antibiotic treatment, the cyclic nature of bacteremia in the blood and its 
correlated clinical sign, recurring fever, can continue even for months (SOUTHERN & 
SANFORD, 1969). B. duttonii, B. crocidurae, B. hispanica and Bp frequently bind or rosette 
blood erythrocytes, and thus cause erythrocytes to aggregate. This phenomenon can prevent 
the interaction of spirochetes with host immune cells and thus may enhance persistence of 
these organisms within the bloodstream (BURMAN et al., 1998; SHAMAEI-TOUSI et al., 
1999; TALAGRAND-REBOUL et al., 2018). Along the infection time, motile organisms in 
terms of B. hermsii, B. turicatae, B. crocidurae and Bp spp. have been isolated from the 
animal brain tissue, although spirochetes are not detectable in the bloodstream (CADAVID 
et al., 2001; NORDSTRAND et al., 2001; MEHRA et al., 2009; SCHWARZER et al., 2016). 
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Undoubtedly, these TBRF borrelia, as well as the LBRF species B. recurrentis, have an 
excellent ability to cross the microvessels and tight barriers, such as blood-brain-barrier 
(BBB) and the dura mater-arachnoid barrier (CADAVID et al., 2001). Moreover, blood 
transfusion-transmitted infections (TTI) of B. recurrentis and B. duttonii in humans have 
been reported (WANG & LEE, 1936; HIRA & HUSEIN, 1979; NADELMAN et al., 1990), 
indicating that these accidentally injected borrelial organisms are capable of surviving in the 
bloodstream of the adopter. After IV inoculation in experimental immunocompetent animals, 
B. hermsii and B. miyamotoi induced a mild to high-level spirochetemia (BENOIT et al., 
2010; POLICASTRO et al., 2013; DICKINSON et al., 2014; KRAUSE et al., 2015). 
Therefore, these TBRF spirochetes are considered to have predominantly a 
hematogenous/blood-borne dissemination route. In this way, borreliae enter and leave the 
bloodstream by invading through the endothelium, followed by a massive spirochetemia and 
further infection in distant tissues (e.g., brain) (MERI et al., 2006).  
3.7.2 Controversial dissemination pathways of LB borrelia 
Once transmitted into the dermis of the mammalian host, Bbsl spirochetes were shown to 
disseminate to a variety of remote sites. The pathogens have been detected in skin, blood, 
CSF, and synovial fluids in humans (BENACH et al., 1983; STEERE et al., 1983; 
JOHNSTON et al., 1985) as well as in skin, blood, and urinary bladder in rabbits and natural 
reservoir hosts (P. leucopus) (KORNBLATT et al., 1984; SCHWAN et al., 1988). According 
to some experimental studies on LB spirochete infection, some systematic manifestations 
especially in skin tissue, joints, nervous system, or heart were induced (STEERE et al., 2016). 
However, the relationship between the dissemination of spirochetes and the subsequent 
severity of disease is a complex question. Generally, dissemination through the bloodstream 
has long been hypothesized as the main route of spreading the borrelia organisms 
(GOODMAN et al., 1995; WORMSER et al., 1999; OJAIMI et al., 2005). Reports of 
B. burgdorferi-positive blood cultures from LB patients or of blood samples tested positive 
by polymerase chain reaction (PCR) in early stages of the illness seem to support the view 
of a blood-borne bacterial spread (BENACH et al., 1983; GOODMAN et al., 1995). 
However, these reports, which were based on large sample volume of 9 - 18 ml plasma or 
blood, yielded a very low rate of spirochete-positive culture (≤ 5%) (WORMSER et al., 1998; 
WORMSER, 2006). Results of such culturing were consistent with an estimate of 0.1 
cultivable spirochete per ml blood (WORMSER, 2006). Therefore, the bacterial burden in 
blood is actually extremely low. Additionally, an in vitro investigation on B. recurrentis, 
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B. duttonii, and Bbss provided evidence that LB pathogens are less immune serum-resistant 
than the RF spirochetes (MERI et al., 2006), indicating that LB spirochetes are less able to 
survive in the blood than the RF species.  
On the other hand, some authors hold the view that LB borreliae disseminate from the tick 
bite site through perhaps blood or tissue planes to other distant locations (STANEK et al., 
2012). Other authors also stated a “dermatogenous” migration of spirochetes from the 
deposition site outward to further tissues causing EM skin lesions of the human host (SHIH 
et al., 1992). Experimental data on the development of persistent LB in dogs clarified that 
live spirochetes are found more frequently in tissues of the somatic quadrant closest to the 
tick bite than in tissues further from the site of infection (STRAUBINGER et al., 1997). If 
the LB borreliae had spread to the joint space through the bloodstream, a random distribution 
of infection of different joints would have been anticipated. Therefore, this interesting study 
suggested that the progress of chronic LB is not due to proliferation of borrelia in the 
bloodstream, but especially due to the migration of spirochetes through various tissues 
(STRAUBINGER et al., 1997). Additionally, in a separate investigation of humans with 
LNB, the presence of skin lesion EM on an extremity was also topographically related with 
motor paresis of that specific extremity (HANSEN & LEBECH, 1992). This finding has also 
suggested that the spirochetes disseminate through soft tissues. Notably, up to now there is 
no reported cases of transfusion-transmitted infections by Bbsl via donated blood from LB 
patients, although other transfusion-associated bacteria such as Babesia microti and 
Anaplasma phagocytophilum, which are transmitted by the same Ixodes spp. ticks, have been 
documented (LEIBY, 2004; BIHL et al., 2007).  
The differences of TBRF and LB species (Table 2) still remain to be further determined, but 
probably affect the pathogenetic properties of the organisms (BUNIKIS et al., 2004). 
Mechanisms of dissemination and invasion are important not only for the pathogenesis but 
also for the development of spirochete persistence in hosts. 
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Table 2: Comparison of TBRF, LBRF and LB species associated with their pathogenicity 
characteristic TBRF LBRF LB 
agent several species B. recurrentis Bbsla 
vector Ornithodoros spp. (soft ticks) P. humanus  
(human body louse) 
Ixodes spp. (hard ticks) 
fever (temperature of ≥ 39 °C) common common  rareb 
fever relapses multiple  few  no 
local skin rash no  no  common (EMc) 
arthritis  no  no  commond  
spirochetes in blood smear yes  yes  no  
spirochetemia (cells/ml blood) from 105 to >106  from 105 to >106 occasionally but low level 
neurological involvement  commone rare  commonf  
tissue tropism brain  brain  skin, joint  
serological assay specificity fair to poorg fair to poorg good to excellent 
dissemination pathway hematogenoush  hematogenoush hematogenous or tissue migrationi 
blood transfusion-mediated infection human and mouse model casesj humans casesk no 
a typically: Bbss, B. afzelii, B. garinii 
b Fever is rarely one of the constitutional symptoms accompanied with the development of erythema migrans at early stage of LB (BORCHERS et al., 2015). 
c erythema migrans 
d Arthritis is the most common manifestation of late LB, occurring weeks to months after the initial infection (MURRAY & SHAPIRO, 2010). 
e common in ≥ 10% of patients with disseminated disease 
f Lyme neuroborreliosis (LNB) may be associated with early disseminated stage of LB spirochete infection (BORCHERS et al., 2015). 
g Variable major proteins (Vmps) of RF borreliae during infection may not be produced by the in vitro cultured spirochete that is utilized as a whole-cell 
lysate antigen in the serologic testing; this may reduce the reactivity of a sample in the IFA and ELISA falsely. 
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h supported by references summarized in chapter 3.7.1 
i supported by references summarized in chapter 3.7.2 
j supported by references (HIRA & HUSEIN, 1979; NADELMAN et al., 1990; BENOIT et al., 2010; POLICASTRO et al., 2013; DICKINSON et al., 2014) 
k supported by references (WANG & LEE, 1936; NADELMAN et al., 1990) 
Data summarized and modified from references (BARBOUR & HAYES, 1986; CADAVID & BARBOUR, 1998; DWORKIN et al., 2008) 
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III STUDY HYPOTHESIS AND OBJECTIVE 
Prior studies have reported rapid and high-level spirochetemia of Bp in the bloodstream of 
laboratory mice (SCHWARZER et al., 2016). After deposition by ixodid ticks, LB 
spirochetes multipy locally in the skin during the first few days of infection and subsequently 
disseminate to remote sites, thus causing clinical manifestations (GRILLON et al., 2017). 
To the best of our knowledge, we hypothesize that 1) Bp spirochetes probably rely on a 
hematogenous dissemination, like the other well-studied RF species (e.g., B. recurrentis, 
B. hermsii, B. duttonii, and B. turicatae) (MERI et al., 2006; BOYLE et al., 2014; LOPEZ 
et al., 2016); 2) (most) motile LB spirochetes at the deposition site migrate actively through 
tissues to further distant tissues and accidentally (only some few of the deposited borreliae) 
may penetrate the blood vessel into bloodstream. To test these hypotheses, we established a 
murine anmial model. In this study model, host-adapted Bp and Bbss organisms were 
intradermally (ID) or strictly intravenously (IV) inoculated into immunocompetent animals. 
If the IV injected spirochetes are capable of multiplying in the bloodstream and 
transmigrating through the blood vessels, further infection should be established in distant 
tissues of the immunocompetent animal. Moreover, the immune system should recognize 
and respond to the multiplying bacteria. Only based on positive results from IV inoculated 
animals can it be undoubtedly believed that Bp and Bbss borreliae disseminate 
hematogenously. 
The objectives of our murine infection model were to: 
i) establish an animal model with a specific infection route; 
ii) investigate the population kinetics of borrelia organisms in the bloodstream of the 
immunodeficient and immunocompetent mice;  
iii) study whether host-adapted, ID or IV inoculated Bp and Bbss disseminate into tissues 
of immunocompetent mice; 
iv) compare the tissue tropism of Bp and Bbss in immunodeficient and immunocompetent 
mice; 
v) characterize the immune response against host-adapted borrelia organisms in 
immunocompetent animals; 
vi) illustrate the possibility and risk of the blood transfusion-transmitted infection by Bp 
and Bbss spirochetes.   
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IV ANIMALS, MATERIALS AND METHODS 
1 Experimental design 
This study was performed with the following two parts: 
i) generation of host-adapted borrelia organisms in immunodeficient mice after ID 
inoculation of culture-derived motile borrelia spirochetes;  
ii) after ID or IV inoculation of the host-adapted spirochetes, observation of the 
spirochete population dynamics in the immunocompetent mice.  
2 Animals 
The experimental project was based on murine model and received approval by the 
government of Upper Bavaria in accordance with § 8 of the German Animal Welfare Act 
(TierSchG, version of 18 May 2006) (Registration number: AZ 55.2-1-54-2532-144-2015). 
Mouse strains of immunodeficient NOD-SCID and immunocompetent C3H/HeOuJ 
(Figure 9) were used for the in vivo experiments of the present dissertation.  
 
Figure 9: Mouse strains used in this study 
(a) NOD-SCID mouse; photo from Janvier Labs (Saint Berthevin Cedex, France), (b) C3H/HeOuJ 
mouse; photo from The Jackson Laboratory (Maine, USA) 
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2.1 Immunodeficient NOD-SCID mouse 
In this murine model, immunocompromised mice were firstly used to generate host-adapted 
borrelia organisms, in order to avoid the interference of any antigen derived from in vitro 
cultivation. For example, expression of OspA of LB spirochete derived from in vitro cultures 
differs profoundly from that in arthropod vector and mammalian milieu (DE SILVA & 
FIKRIG, 1997; CROWLEY & HUBER, 2003). A critical advantage of using the 
immunodeficient mice is that persistent spirochetemia can be induced, because the lack of 
immunity allows high bacterial load in the bloodstream compared to that affected by immune 
responses in immunocompetent animals (HODZIC et al., 2003; LIU et al., 2004; RISTOW 
et al., 2015). Therefore, host-adapted borreliae can be easily harvested by sampling blood at 
scheduled time points. The viability and number of spirochetes can be examined under dark 
field microscope and by PCR method, respectively. 
In this study, 35 NOD-SCID (Non Obese Diabetic-Severe Combined Immune Deficiency) 
mice (Figure 9A), which do not contain mature T and B cells and complement, were 
purchased at the age of week 6 (~ 15 g body weight) from Janvier Labs at various schedule 
time. Compared to regular SCID mice, NOD-SCID mice have reduced macrophages and 
natural kill (NK) cell function (MILSOM et al., 2013). 
2.2 Immunocompetent C3H/HeOuJ mouse 
Immunocompetent mice develop a well-detectable antibody response in the course of 
borrelia infection as long as the inoculated spirochetes are infectious. Given that C3H mice 
may develop severe Lyme arthritis and possess a higher bacterial burden in tissues compared 
to the resistant strain of BALB/c mice (ZEIDNER et al., 1997; WOOTEN & WEIS, 2001), 
the immunocompetent C3H/HeOuJ mice (Figure 9B) were used in our study. This mouse 
strain is easily treatable and tolerated with blood sampling and anaesthesia. At the age of 
week 8 (~ 20 g body weight), 38 C3H/HeOuJ mice were obtained from Charles River 
(Sulzfeld, Germany) at different time points based on the experiment scheme. 
2.3 Mouse hygiene and handling management 
The specific-pathogen-free (SPF) female mice were obtained at different time points based 
on the work schedule. One to two weeks prior to the experiment mice were introduced into 
the animal facility of the Institute of Infectious Diseases and Zoonoses, Ludwig-
Maximilians-Universität (LMU, Munich) in order to ensure adequate acclimation to the new 
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environment. According to guidelines and principles of Gesellschaft für 
Versuchstierkunde/Society of Laboratory Animal Science (GV-SOLAS), maintenance and 
handling of these mice were conducted in the laminar flow systems to sustain SPF conditions. 
Three to five mice were kept in an individually ventilated cage (IVC, ISOcage N System; 
Tecniplast Deutschland GmbH, Hohenpeißenberg, Germany) at controlled room 
temperature (20 - 24 °C) and humidity (45%). The animals received standard feed for 
laboratory rodents (housing food V 1536) ad libitum; autoclaved water is indefinitely 
available to the mice from drinking bottles.  
Three days prior to the experiment, blood samples were obtained from naïve mice for 
baseline controls. Collection of blood specimens in small volume (2 - 4 drops ≈ 10 - 30 µl) 
was carried out from the facial vein of the mouse without anaesthesia. Puncture in the skin 
was performed with a 4-mm Goldenrod Animal Lancet (Braintree Scientific, Bio-Medical 
Instruments, Zöllnitz, Germany), which is a rapid and simple method for submandibular 
bleeding of mice (Figure 10) (GOLDE et al., 2005). The dropping blood from the facial vein 
was maintained in the Microvette 100 K3E (preparation K3EDTA; Sarstedt AG & Co., 
Nümbrecht, Germany). At the end of the experiment, a large final blood volume was 
harvested aseptically into the S-Monovette 2.7 ml K3E (Sarstedt AG & Co.) by intracardiac 
puncture. Mice were anaesthetized by IP administration of medetomidine and midazolam 
(Table 3) (DHEIN et al., 2005; XU, 2006). ID and IV inoculation were conducted on the 
shaven dorsal back and via the right jugular vein, respectively (procedures in detail will be 
described in the following sections). Specific antagonists (Table 3) were used to neutralize 
the anaesthetics. Fentanyl and naloxone provided adequate sedation and analgesia, 
respectively. Recovery of mice after each challenge were observed closely. The surgical 
instruments were autoclaved. Standardized aseptic techniques were employed during all 
procedures. After each experiment based on the scheduled course of period, anaesthetized 
mice were sacrificed by cervical dislocation. 
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Table 3: Anaesthetics and antagonists used in mice 
 drug dosage 
(mg/kg)a 
product  
unit (mg/ml) 
source 
a
n
a
e
s
th
e
ti
c
s
 
Medetomidine 
hydrochlorideb 
0.5 1 Dechra Veterinary 
Products Deutschland GmbH,
Aulendorf, Germany 
Midazolam 5 5 Hexal AG, 
Holzkirchen, Germany 
Fentanyl 0.05 0.05 B. Braun Melsungen AG, 
Melsungen, Germany 
a
n
ta
g
o
n
is
ts
 
Atipamezole 2.5 5 Dechra Veterinary 
Products Deutschland GmbH 
Flumazenil 0.5 0.1 Hexal AG 
Naloxone 1.2 0.4 B. Braun Melsungen AG 
 
  
Figure 10: Facial vein bleeding from mouse 
(a) positioning and poking the cheek with the lancet; photo from Golde et al. (GOLDE et al., 
2005), (b) collecting blood from the cheek; photo from Braintree scientific, Inc. (Braintree, USA) 
a All three substances used as anaesthetics or antagonists were diluted in sterile physiological saline 
(isotonic saline; B. Braun Melsungen AG); the combined solution was dosed at 10 µl per g body 
weight of the mouse. 
b Sedator® 1.0 mg/ml solution 
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3 Borrelial strains and cultivation 
3.1 Bp LMU-01 and Bbss N40 
In this study, borrelia spirochetes of the following two strains were used to infect the animals: 
Bp LMU-01 strain was originally isolated from a heparinized blood specimen of an ill cat 
in Jerusalem (Israel) (SCHWARZER et al., 2015). After cultivation in filtered human serum, 
passage 2 of this strain was used with 6.9 x 105 Bp spirochetes per ml of serum. Aliquots of 
100-µl serum were frozen at -80 °C until used. The minimal infectious dose of this borrelia 
strain in immunocompetent mice has been reported between 4 and 100 organisms per animal 
(in vitro cultured, passage 3) (SCHWARZER et al., 2016).  
Bbss N40 strain was isolated from a skin biopsy of an experimentally infected dog (APPEL 
et al., 1993). Its passage 3 was used in a prior study, indicating the infectivity of 1.0 x 106 
cultured cells in immunocompetent mice (RAFINEJAD et al., 2011). In vitro culture 
(passage 4) was frozen in the presence of 15% sterile glycerol, containing 1.1 x 106 
spirochetes in each 100-µl aliquot.  
3.2 Preparation of spirochetes for initial inoculation using in vitro culture 
Spirochetes used to infect immunodeficient mice were prepared by in vitro cultivation. A list 
of necessary materials and devices used in this step is given in Table 4. Briefly, a 5-ml 
polypropylene tube was filled with 3 ml in-house prepared Pettenkofer/LMU Bp medium 
(SCHWARZER et al., 2015). An aliquot of frozen passage 2 stock (100µl, Bp LMU-01 strain) 
was maintained in this medium at 37 °C with a humidified 5% CO2 air atmosphere. For 
cultivation of Bbss spirochetes (at 33 °C), the frozen passage 4 stock (100 µl, Bbss N40 
strain) was applied to 6 ml Barbour-Stoenner-Kelly H (BSK-H) complete medium in a 12-
ml screw top tube. This medium was additionally supplemented with 6% heat-inactivated 
(at 56 °C) rabbit serum (POLLACK et al., 1993). The mobility and morphology of the 
organisms (passage 3 and 5 of Bp and Bbss, respectively) were inspected by dark-field 
microscope. Spirochete counts were achieved in a Petroff-Hausser counting chamber. Viable 
spirochetes were grown to day 7 and day 6 at the mid-log phase, reaching densities of 2.0 x 
106 Bp and 1.0 x 107 Bbss per ml medium, respectively. By adjusting the medium volume to 
50 µl and 100 µl, an inoculum dose of 1.0 x 105 Bp or 1.0 x 106 Bbss of motile spirochetes 
was prepared in the 1.5-ml safe-lock centrifuge tubes for further use. Another inoculation 
dose of 1.0 x 108 viable Bbss organisms was harvested as follows:  
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i) cultivation of frozen passage 4 stocks of Bbss in 20 of the 12-ml screw top tubes for 6 
days to the concentration of ~ 1.0 x 107 cells/ml as described above;  
ii) centrifugation of 120 ml culture in 3 of the 45-ml centrifuge tubes (each 40 ml) at 
15,000 × g for 10 min at 23 °C;  
iii) washing the three pellets with 1 ml sterile phosphate-buffered saline (PBS, pH 7.3);  
iv) transfer of 3 ml PBS into a 5-ml sterile safe-lock centrifuge tube;  
v) centrifugation of 5-ml tube at 15,000 × g for 10 min at 23 °C;  
vi) resuspension of the pellet in 1 ml fresh BSK-H medium;  
vii) dilution of 10-µl re-suspended solution (1:100) and count for the concentration of live 
spirochetes (1.0 x 109 cells/ml);  
viii) adjustment with appropriate medium volume (100 µl) for further use. 
 
Table 4: Materials used for in vitro cultivation and preparation of inoculum dose 
instrument, ingredient comment source 
BSK-H complete medium  Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
centrifuge  
5430R and 5810R 
 Eppendorf Vertrieb Deutschland GmbH, 
Wesseling-Berzdorf, Germany 
centrifuge tube 45-ml Sarstedt AG & Co. 
dark-field microscope  Leica Microsystems GmbH,  
Wetzlar, Germany 
Galaxy 170S CO2 incubator  Eppendorf Vertrieb Deutschland GmbH 
Petroff-Hausser counting 
chamber 
 Hausser Scientific, 
Horsham, PA, USA 
polypropylene tube 5-ml Sarstedt AG & Co. 
rabbit serum  activated  Sigma-Aldrich Chemie GmbH 
safe-lock centrifuge tube 1.5-ml, 5-ml Eppendorf Vertrieb Deutschland GmbH 
screw top tube  
(centrifuge tube 12) 
12-ml, TPP Faust Lab Science GmbH,  
Klettgau, Germany 
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4 Experimental procedures 
4.1 Negative control group 
Before the experiments that animals were exposed to spirochetes, a negative group (NG) 
was performed as control (Table 5). Briefly, anticoagulated whole blood (free of borrelia 
organisms) were collected from two non-infected NOD-SCID mice. One hundred microliter 
blood was IV injected into five immunocompetent C3H/HeOuJ mice under anaesthesia. The 
challenged mice were monitored for five weeks; blood was collected once a week. Once 
ensured that there was no inflammation on the surgical area (Figure 11) and no microsurgery-
induced specific antibody levels, the experimental test with borrelia organisms was then performed.  
Table 5: Mice used for negative control 
mouse strain subgroup procedure number of animals 
negative 
group (NG) 
NOD-SCID N-NG Harvesting of blood 2 
C3H/HeOuJ C-NG IV inoculation 5 
 
 
Figure 11: Recovery of C3H/HeOuJ mouse after microsurgery via the jugular vein 
(a) recovery of sutured wound on day 2 after microsurgery, (b) recovery of sutured wound on 
day 6 after microsurgery 
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4.2 Generation of host-adapted borreliae in NOD-SCID mice 
4.2.1 Intradermal inoculation of culture-derived spirochetes 
As described above, the inoculum dose of 1.0 x 105 Bp or 1.0 x 106 (or 1.0 x 108) Bbss 
spirochetes was freshly prepared before use. Each of six NOD-SCID mice was ID injected 
with the borrelial organisms (Bp or Bbss) into the shaven back (Figure 12). The time point 
was named day 0. The injection volume was divided into small portions (5 x 10 µl of Bp, 10 
x 10 µl of Bbss), placed closely to each other into the dermis (~ 4 cm2 area). Thereafter, six 
mice were randomly separated into two subgroups (3 mice of each) (Table 6). 
 
Table 6: NOD-SCID mice used to detect populations of host-adapted borreliae 
borrelial species injection route inoculum dose  subgroup number 
Bp (passage 3) ID 1.0 x 105 
N-A 3 
N-B 3 
Bbss (passage 5) ID 
1.0 x 106 
N-C 3 
N-D 3 
1.0 x 108 
N-E 3 
N-F 3 
Figure 12: Intradermal injection of culture-derived spirochetes into the shave back 
of NOD-SCID mouse under anesthesia 
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4.2.2 Dynamic detection of host-adapted borreliae in blood 
In order to obtain data for each single day of the scheduled 17-day interval, mice in different 
subgroups were bled via facial vein puncture according to the alternating scheme. Briefly, 
blood specimens (~ 10 - 30 µl) from each single mouse in subgroup N-A, N-C, and N-E 
were collected at odd days (day 1, 3…17) and subgroup N-B, N-D, and N-F at even days 
(day 2, 4…16) (Figure 13). Puncture alternated between the right and left facial vein at each 
sampling day to produce less impact on the mice as possible. Blood aliquots (5 µl each) from 
each single mouse at each time point were separated in individual 1.5-ml safe-lock tubes and 
stored at -30 °C. By DNA extraction and PCR examination, the population kinetics of the 
hematogenous spirochete load from six NOD-SCID mice that received the same inoculum 
dose was monitored between day 0 and 17. The term “the anticipated day”, namely the time 
point to reach the largest bacteria load in the blood was determined during this step. 
Additionally, 30-µl blood from three mice in each individual subgroup was diluted and 
mixed with 500 µl medium for Bp or Bbss cultivation, followed by an examination for motile 
spirochetes using dark-field microscope. Once no viable spirochete was observed, the 
solution above was transferred to 5 ml corresponding medium for further growth and 
inspection of potential Bp or Bbss spirochetes. The ~ 5.5-ml culture medium used here 
contained antibiotics (Table 7).  
 
Figure 13: Blood sampling from NOD-SCID mice based on alternative schedule 
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Table 7: Antibiotics used in medium for spirochete isolation from blood samples 
antibiotic product No. concentration source 
Kanamycina K0129 8 µg/ml Sigma-Aldrich Chemie GmbH 
Rifampicinb R3501 50 µg/ml 
 
4.2.3 Harvesting of host-adapted borreliae in blood 
Based on the obtained population kinetics of spirochetes circulating in the bloodstream, a 
second separate group consisting of five NOD-SCID mice was performed using ID 
inoculation of the in-medium cultured 1.0 x 105 Bp or 1.0 x 106 Bbss spirochetes (Table 8). 
Blood samples at a time point before the anticipated day were collected to determine if these 
mice were infected with borreliae. At the anticipated day with the highest spirochete load, 
anticoagulated peripheral blood was collected aseptically by intracardiac puncture under 
anaesthesia. A S-Monovette 2.7 ml K3E was connected with a 23-gauge needle for puncture 
into the heart and utilized for the maintenance of the anticoagulated blood (~ 0.8 - 1.2 ml) 
from each individual mouse (Figure 14). Thirty microliter blood from each single mouse 
were diluted in 500 µl fresh medium and motile spirochetes were visualized with a dark-
field microscope. All blood samples containing Bp or Bbss spirochetes were pooled in one 
S-Monovette 2.7 ml K3E and checked again for bacterial viability with the dark-field 
microscope. Aliquots (5 µl) from pooled blood were prepared and stored at -30 °C for 
borrelial density determination.  
Table 8: NOD-SCID mice used for generation of host-adapted borrelia organisms 
borrelial species injection 
route 
inoculum  
dose  
subgroup number mouse  
no. 
Bp (passage 3) ID 1.0 x 105 N-G 5 N1-5  
Bbss (passage 5) ID 1.0 x 106 
N-H 5 N6-10 
N-I 5 N11-15 
 
 
 
 
a 20 ml solution, 10 mg kanamycin per ml 0.9% sterile NaCl 
b 250 mg powder stock, dissolved in 5 ml DMSO (dimethyl sulfoxide, Sigma-Aldrich Chemie GmbH) 
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4.2.4 Collection of tissue samples for cultivation and PCR testing 
Besides blood, other tissues including ear, skin (injection areal), tibiotarsal joint, spleen, 
urinary bladder, heart, and brain were removed from the sacrificed NOD-SCID mice 
(subgroup N-G and N-H) at the anticipated day (protocol seen in the following section). 
Each collected tissue sample was divided into approx. equal two parts. Half of each tissue 
sample was transferred to medium for bacterial culture and the other half was kept at -80 °C 
for DNA extraction and further PCR testing. 
4.3 Inoculation of host-adapted borreliae into C3H/HeOuJ mice 
4.3.1 Intradermal inoculation of host-adapted borreliae 
Anaesthetized immunocompetent C3H/HeOuJ mice (n=16; Table 9) were intradermally 
inoculated with 100 µl freshly pooled blood containing the NOD-SCID-adapted borrelia 
organisms (Bp or Bbss) in the shaven dorsal back (the same ID injection technique as used 
for NOD-SCID mice). 
Figure 14: Blood collection by intracardiac puncture  
(a) technique model of blood collection by intracardiac puncture; photo from Howard University 
(HOWARD UNIVERSITY), (b) collected anticoagulated blood in S-Monovette 2.7 ml K3E 
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Table 9: Subgroups of C3H/HeOuJ mice used for ID and IV inoculation 
borrelial 
speciesa 
NOD-SCID C3H/HeOuJ  
subgroup subgroup injection route number mouse no. 
Bp N-G 
C-A ID 5 C1-5 
C-B IV 6 C6-11 
Bbss 
N-H 
C-C ID 5 C21-25 
C-D IV 5 C26-30 
N-I 
C-E ID 6 C31-36 
C-F IV 6 C37-42 
 
4.3.2 Strict intravenous inoculation of host-adapted borreliae 
C3H/HeOuJ mice (n=17) were strictly IV inoculated with the same pooled blood as used in 
each subgroup of ID injection (Table 9). Each mouse was transferred into the open space of 
the SPF-conditioned animal handling room (Figure 15). The IV inoculation was carried out 
via the right jugular vein (Figure 16) and instruments used in this procedure are listed in 
Table 10. Briefly, C3H/HeOuJ mouse was deeply anaesthetized for the surgical procedure. 
The warming pad was used to maintain the body temperature at ~ 37 °C. Hair under the chin 
was shaved and this area was disinfected with 70% ethanol. On the position slightly right to 
the body midline under the chin, a ~ 1 cm long incision was made into the skin. Using the 
stereo microscope equipped with Leica MC170 HD camera and two goose lights (Figure 15), 
the right jugular vein was carefully separated from the connective tissue and fat without any 
bleeding. Splinter forceps and eye forceps were utilized during this procedure. The exposed 
vein and removed tissue were immersed in sterile physiological saline. By holding the 
jugular vein with bulb-headed probe, two loop ligations were made around the vein with 
SURGICRYL® PGA Polyglycolic acid suture. The up-ligation was completely closed and 
the down-ligation was a loose knot fixed with Student Halsted-Mosquito Hemostats. The 
jugular vein was held well with two bulb-headed probes to avoid bleeding when a 45°-angle 
hole on the up side of the vein was cut by the Vannas-style spring scissors. The micro hook 
assisted greatly to open and grab the wall of the vessel for inserting the catheter. When 
~ 9 mm of the Alzet Mouse Jugular Catheter (filled with ~ 13 µl sterile isotonic saline) tip 
was introduced parallel into the jugular vein, the down-ligation was closed and secured that 
a Borrelial organisms were host-adapted and present in pooled blood from NOD-SCID mice in 
each subgroup. 
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the catheter would not slip out from the vein. The down-put bulb-headed probe was removed 
from the jugular vein for adequate space and fluent injection. After connecting the Terumo 
Agani needle (attached to the 1-ml syringe filled with 140 µl pooled blood) with the exposed 
end of the catheter, 100 µl blood were injected very slowly (~ 10 µl/min) into the vein. 
Thereafter, the needle was removed from the catheter and a second 23-gauge needle 
connected with a 1-ml syringe (filled with sterile saline) was subsequently attached to the 
catheter. Then, the catheter was flushed slowly with 50 µl sterile saline. Without withdrawing 
the needle and syringe the catheter tip was carefully pulled back. Simultaneously and 
immediately, the down-ligation was fastened entirely without any bleeding into the 
surrounded tissue. After the injection, the incision site was sutured intracutaneously (4 - 5 
single sutures) with Monosyn® Easyslide. Then, antagonists were injected intraperitoneally 
for recovery. The procedure, from making the incision on the chin until closing the skin, took 
approx. 60 minutes per mouse. During the IV inoculation, movie (available on the CD-ROM) 
was taken through 10x/1.6 objectives on the stereo microscope. 
 
Figure 15: Working condition and anaesthetized mouse before IV inoculation 
mouse kept on a warming pad 
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Figure 16: Strict IV injection via the jugular vein monitored with a stereo microscope 
(a) a 1-cm long incision in the skin under the chin, (b) right jugular vein separated from connective 
tissue and fat, (c) up-ligation (fixed) and down-ligation (a loose knot), (d) injection of pooled 
blood containing host-adapted borreliae into right jugular vein, (e) two ligations around the right 
jugular vein after injection, (f) closed skin after injection 
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Table 10: Materials used for microsurgery via the jugular vein 
instrument comment source 
Alzet Mouse Jugular  
Catheter 
No. 0007700 Durect Corporation,  
California, USA 
bulb-headed probe No. 310335 Henry Schein VET GmbH, 
Hamburg, Germany 
camera Leica MC170 HD Leica Microsystems GmbH 
eye forceps No. 310174 Henry Schein VET GmbH 
goose light Leica LED3000 SLI Leica Microsystems GmbH 
micro hook No. 10062-12; blunt Fine Science Tools GmbH, 
Heidelberg, Germany 
Monosyn® Easyslide suture DS16 (5/0) B. Braun Surgical SA, 
Barcelona, Spain 
single use syringe 1-ml Dispomed Witt oHG,  
Gelnhausen, Germany 
splinter forceps No. 310645 Henry Schein VET GmbH 
stereo microscope Leica M60 Leica Microsystems GmbH 
Student Halsted-mosquito  
hemostats 
No. 91309-12 Fine Science Tools GmbH 
 
SURGICRYL® PGA  
Polyglycolic acid suture 
 SMI AG, St. Vith, Belgium 
Terumo Agani needle 23-gauge Shanghai international Holding 
Corporation GmbH (Europe),  
Hamburg, Germany 
Vannas-style spring scissors No. 15000-03 Fine Science Tools GmbH 
warming pad Model #39DP Braintree scientific, Inc., 
Braintree, USA 
 
4.3.3 Blood collection, plasma and serum samples 
After the ID and IV injection, blood samples were collected via facial vein bleeding from 
C3H/HeOuJ mice at indicated intervals (Figure 17). Considering the recovery time of the 
surgical skin of the IV inoculated mice (Figure 11), the first blood samples were collected 
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on day 6 after surgery and subsequently every three days until day 30 post inoculation (p.i.). 
Afterwards, bleeding was performed on day 37, day 44, and day 49/50 (ID challenged mice 
on day 49, IV mice on day 50). Aliquots of blood (5 µl) were prepared from each single 
mouse at each time point. Plasma was obtained from pooled blood from each ID or IV 
subgroup by soft centrifugation at 350 × g for 10 min at 23 °C. On day 49/50, final blood 
samples via intracardiac puncture were collected with a 23-gauge needle connected with a 
2-ml sterile single use syringe (Henry Schein VET GmbH). Non-coagulated blood was kept 
in a micro tube (1.1 ml Z-Gel; Sarstedt AG & Co.) and serum sample was harvested by 
centrifugation as describe above. All samples were stored in the 1.5-ml safe-lock tubes at -
30 °C for subsequent tests. 
 
 
4.3.4 Culture of spirochetes from blood and tissue samples 
Thirty microliter pooled blood from C3H/HeOuJ mice of ID or IV challenged subgroup were 
diluted and mixed with 500 µl culture medium (for Bp or Bbss cultivation). Detection of 
motile spirochetes was performed using dark-field microscope. Once no viable spirochetes 
were observed, the solution above was transferred to 5 ml medium for culture of Bp or Bbss 
spirochetes. The ~ 5.5-ml culture medium used was supplemented with kanamycin and 
rifampicin (Table 7) to supress undesirable contaminating bacterial growth.  
On day 49/50 p.i., various tissue samples from the ear, skin (injection areal; ~ 6 mm 
diameter), tibiotarsal joint, spleen, urinary bladder, heart, and brain were collected from each 
Figure 17: Blood sampling from C3H/HeOuJ mice  
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euthanatized C3H/HeOuJ mouse. Tissues were immersed in 70% ethanol for 1 min and then 
washed with sterile PBS (pH 7.3) for 30 seconds. Ear and skin tissues were immersed in 70% 
ethanol for 2 min. After washing, tissues were cut into approx. equal two parts. Half of each 
sample was put in a 1.5-ml microcentrifuge tube and stored at -30 °C for DNA extraction 
and further PCR testing. For spirochete cultivation the other half part was transferred into a 
sterile Stomacher closure bag (Seward Laboratory, London, UK), which contained 2 ml 
Pettenkofer/LMU Bp medium (for Bp) or 2 ml BSK-H complete medium (for Bbss) devoid 
of any antimicrobials. Once tissue samples from all mice in ID and IV subgroups were 
obtained, the Stomacher bags were processed at normal speed for 60 seconds with a 
Stomacher® 80 microBiomaster (Seward Laboratory). The pressed tissue sample and 
medium was subsequently transferred into the 12-ml screw top tube prefilled with 8 ml of 
the same medium. All cultures were kept at 37 °C (Bp) or 33 °C (Bbss) for six weeks and 
inspected once a week using a dark-field microscope. 
4.4 Detection and quantification of borrelial DNA in blood and tissue samples 
4.4.1 DNA extraction 
All blood and tissue samples from the NOD-SCID and C3H/HeOuJ mice were subjected to 
DNA extraction using AS3000 Maxwell 16 MDx Instrument and the Maxwell 16 LEV Blood 
DNA Kit. Reagents and materials used in this experiment are listed in Table 11. The 
protocols, which were successfully applied in a previous study (SCHWARZER et al., 2016), 
are depicted in Figure 18. The extracted DNA was eluted in 50 µl elution buffer and frozen 
in the 1.5-ml safe-lock tube at -30 °C until used.  
Table 11: Materials and reagents used for DNA extraction 
name source 
1.5-ml safe-lock tube Eppendorf Vertrieb Deutschland GmbH 
AS3000 Maxwell 16 MDx Instrument Promega GmbH, Mannheim, Germany 
incubation buffer Promega GmbH 
Maxwell 16 LEV Blood DNA Kita Promega GmbH 
micro pestle Faust Lab Science GmbH 
PBS in-house made, sterile, pH 7.3 
ThermoMixer comfort 5355 V 2.0 Eppendorf Vertrieb Deutschland GmbH 
 
a containing lysis buffer, proteinase K, and elution buffer 
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4.4.2 PCR testing 
Borrelia-specific DNA was detected and quantified using the QuantStudio 5 real-time 
quantitative PCR (qPCR) system (Applied Biosystems, ThermoFisher Scientific GmbH, 
Ulm, Germany). The target sequence of flaB (Bp) and ospA (Bbss) genes (Table 12) have 
been described in the prior studies (STRAUBINGER, 2000; SCHWARZER et al., 2016). 
Oligonucleotide primers and probes of the genes were synthesized by Eurofins Genomics 
(Ebersberg, Germany). Each qPCR reaction was set up in a 20 µl final volume (Table 13). 
The qPCR running program consisted of (i) heating at 95 °C for 2 min for polymerase 
activation and DNA denaturation, (ii) amplification for 40 cycles with denaturation at 95 °C 
for 5 s and extension and annealing at 60 °C for 25 s, (iii) a final step at 25 °C for 2 min.  
Table 12: Primers and probes used in this study 
Figure 18: Borrelial DNA extraction from blood (a) and tissue samples (b) 
primer name sequence 
Bp_flaB_fw 5’-GAGGGTGCTCAACAAGCAA-3’ 
Bp_flaB_re 5’-CAACAGCAGTTGTAACATTAACTGG-3’ 
Bp_flaB_probe 5’-FAM-AAATCAGGAAGGAGTACAACCAGCAGCA-3’-TAM 
BbssN40-ospA 17 fw 5’-AATGTTAGCAGCCTTGACGAGAA-3’ 
BbssN40-ospA 119 re 5’-GATCGTACTTGCCGTCTTTGTTT-3’ 
BbssN40-ospA-41T 5’-FAM-AACAGCGTTTCAGTAGATTTGCCTGGTGA-3’-TAM 
(a) 
(b) 
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Table 13: PCR reaction used in this study 
PCR Bp (flaB) Bbss (ospA) 
working 
concentration 
reaction 
volume (µl) 
working 
concentration 
reaction 
volume (µl) 
master mixa 1x 10 1x 10 
forward primer 600 nM 1.2 900 nM 0.64 
reverse primer 600 nM 1.2 900 nM 0.64 
probe 200 nM 0.8 100 nM 0.97 
reference dyeb  0.1 - - 
nuclease-free water  4.2  5.25 
template DNA  2.5  2.5 
 
In order to quantify spirochetes in the DNA samples extracted from blood or tissue samples, 
a PCR-based standard curve was established. Briefly, double stranded DNA (dsDNA) 
targeting the sequence of flaB (Bp) or ospA (Bbss) genes with known quantities (0.5 nmol) 
was synthesized by Metabion International AG (Planegg, Germany). The dry dsDNA stock 
was diluted in 5 µl nuclease-free water (0.1 nmol/µl). Considering that 1.0 mol is 
6.022 x 1023 molecules, concentration of the target gene copy numbers in this dsDNA 
solution was 6.022 x 1013 molecules/µl. Ten-fold serial dilutions were prepared with 
nuclease-free water. Dilutions ranging from 6.022 x 107 to 6.022 x 100 molecules/µl were 
used to run a qPCR procedure as described above. After analysis using the QuantStudio 
Design & Analysis Software (Applied Biosystems), the standard curve was established, 
which was determined by the threshold cycles (Ct) of the dsDNA copy numbers at each 
dilution. Ten-microliter aliquots of dsDNA solution at concentration of 6.022 x 105 and 6.022 
x 103 molecules/µl, were prepared and stored at -30 °C before use.  
In each run of the qPCR system a no-template-control (NTC, 2.5 µl nuclease-free water) and 
two positive controls of dsDNA (6.022 x 105 and 6.022 x 103 molecules/µl as prepared above) 
were included in the 96 Multiply PCR plate natural (Sarstedt AG & Co.). Both standard 
template dsDNA and sample DNA from blood and tissue samples were amplified in triplicate. 
Spirochete number per ml blood or per mg tissue were obtained with the QuantStudio Design 
& Analysis Software (Applied Biosystems) considering Ct-values for each sample analysed. 
a QuantiNova Probe PCR Master Mix (Qiagen GmbH, Hilden, Germany) 
b QN ROX reference dye (Qiagen GmbH) 
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4.5 Serological analysis  
4.5.1 ELISA  
Antigen production was prepared from cultured spirochetes of Bp and Bbss. The purified 
borrelial cell lysate was used to detect mouse antibodies by ELISA test. Spirochetes of the 
frozen stocks of Bp LMU-01 (passage 2) and Bbss N40 (passage 4) were grown in medium 
as described in section IV.3 (borrelial strains and cultivation). When reaching the desired 
concentration of 107 to 108 spirochetes/ml, the 6-ml bacteria suspensions of Bp or Bbss were 
transferred to a sterile airtight screw cap glass bottle containing 1.0 l of the corresponding 
medium. The cultures were further incubated for 7 to 9 days to stationary phase. According 
to the protocols described by earlier studies (TÖPFER, 2005; TÖPFER & STRAUBINGER, 
2007), one liter of the culture was separated into 250- ml tubes and centrifuged at 10,000 × g 
at 20 °C for 15 min. After discarding the supernatants, the pellets were re-suspended in 
sterile PBS. The suspensions were centrifuged at 10,000 × g at 4 °C for 15 min. This step 
was repeated twice. After the last centrifugation, the spirochetes were re-suspended in 5 ml 
sterile PBS and placed on ice. Ultrasound disruption of these borrelia organisms was done 
on ice at 35 W for 3 to 5 s, repeating the procedure for 3 times (Bandelin Sonoplus UW2070, 
Berlin, Germany). After controlling the bacteria disintegration applying dark-field 
microscope, the solution of disrupted cells was centrifuged at 10,000 × g at 4 °C for 10 min. 
The supernatant of the whole-cell lysate was collected and stored at -30 °C until used. 
Protein concentration of the Bp or Bbss cell lysate was measured using the bicinchoninic 
acid (BCA) protocol (BCA Protein Assay Kits; Pierce Biotechnology Inc., Rockford, USA). 
The quality of the antigen preparation was determined using SDS-PAGE gels stained with 
silver nitrate salt (SilverQuest Silver Staining Kit; Invitrogen GmbH, Karlsruhe, Germany). 
ELISA plates were prepared by coating the whole-cell antigen lysate of Bp and Bbss in the 
microdilution plates (Nunc-Immuno Microwell Maxisorp C96; Thermo Scientific, VWR 
International GmbH, Ismaning, Germany). According to the published protocol (BARTH et 
al., 2014; SCHWARZER et al., 2016), a solution of carbonate coating buffer (CO3, 0.1M), 
CO3/ME/SDS, and borrelia antigen was prepared. Preparation of CO3 and CO3/ME/SDS 
were described by Töpfer (TÖPFER, 2005). The final concentration of Bp or Bbss antigen 
proteins was 0.2 µg (Bp) or 0.18 µg (Bbss) per 100 µl of each well, respectively. For the 
Bbss-ELISA plate, pure recombinant OspA (1 ml/1 dose, Rekombitek Lyme; Merial, Duluth, 
GA, USA) was also applied in the solution at a concentration of 0.32 µl per well (100 µl). 
Half of the wells received 100 µl aliquots of the prepared antigen solution and the remaining 
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wells were coated with only 100 µl of CO3, serving as negative control values. Coated plates 
were covered and incubated at 4 °C overnight. Then, the plates were stored at -30 °C over a 
24-hour period until used.  
A computerized kinetic ELISA (KELA) test was carried out to detect the specific 
antibodies against Bp or Bbss. Before use, the coated 96-well ELISA plates and the collected 
plasma and serum samples from inoculated C3H/HeOuJ mice were thawed to room 
temperature. Each test included three negative and three positive controls. Negative plasma 
samples derived from borrelia-free C3H/HeOuJ mice (in the negative control group see 
section IV.4.1) and positive serum samples were from previously Bp or Bbss infected mice. 
All plasma and serum samples were tested in duplicate and mean values are reported. The 
washing process for the 96-well plate was done with an AquaMax® microplate washer 
(Molecular Devices, Sunnyvale, USA). All subsequent washes were performed with 
washing buffer of PBS containing 0.05% Tween 20 (AppliChem GmbH, Darmstadt, 
Germany). Samples of plasma and serum were diluted at 1:100 with sample buffer PBS 
containing 0.05% of Tween 20 and 2% non-fat dry milk (Merck KGaA, Darmstadt, 
Germany). After one wash with washing buffer, 100 µl of the diluted samples were added to 
each well (in duplicate each with lysate antigen and carbonate buffer control) and incubated 
for 1 h at 37 °C. After a second wash, 100 µl of 1:4000 (for Bp) or 1:3000 (for Bbss) diluted 
secondary peroxidase-conjugated goat anti-mouse immunoglobulins (IgG, IgA, IgM; MP 
Biomedicals, LLC, Heidelberg, Germany) were added to each well and incubated for 30 min 
at room temperature. After a final wash, 100 µl of the substrate (TMB Microwell Peroxidase 
Substrate Kit; KPL, medac GmbH, Wedel, Germany) were immediately added to each well 
(within 1 min 45 s). The extinction of each well was immediately read 5 times at 650 nm in 
35-s intervals in a SpectraMax Plus 384 Microplate Reader (Molecular Devices, Wokingham, 
UK). Results were analyzed with the SoftMax Pro software 5.3 (Molecular Devices). To 
standardize the sample assessment and compare the plates of every run, all results of the 
tested specimens in antibody units were adjusted to the evaluated values of the control 
samples. Note that the same control samples were performed for each ELISA test in the same 
Bp or Bbss experiments. 
4.5.2 LIA  
Serum samples collected from C3H/HeOuJ mice on day 49/50 p.i. with Bbss were analysed 
with a specific line immunoblot assay (LIA), in order to visualize specific antibodies against 
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this agent. Briefly, the commercially available IgG immunoblotting strips (Sekisui Virotech 
GmbH, Rüsselsheim, Germany) were used according to the manufacturer’s instructions. The 
recombinant protein fractions of VlsE mix, OspA mix, DbpA mix, OspC mix, BmpA, p58, 
and p83/100 antigens (Table 14) are considered to be specific for LB infection in humans 
and animals (BRUCKBAUER et al., 1992; ZÖLLER et al., 1993). Serum was 1:100 diluted 
in the ready to use IgG immunoblot dilution-/wash buffer (Sekisui Virotech GmbH). At a 
dilution of 1:1,000, secondary peroxidase-conjugated goat anti-mouse immunoglobulins 
(IgG, IgA, IgM; MP Biomedicals) were incubated with the strips for 30 min at room 
temperature. After three washing steps with dilution-/wash buffer and one time with distilled 
water, the colour reaction was initiated by adding substrate solution (Opti-4CN Substrate Kit; 
Bio-Rad Laboratories GmbH) and stopped by washing the strips 3 times with distilled water. 
Table 14: Name and molecular weight of Bbss antigens used for LIA test 
name molecular 
weight (kDa) 
origin/function reference 
DbpA 17-18 Osp, immunodominant, 
chronic infection 
JAURIS-HEIPKE et al., 1999 
OspC 22-24 Osp, early infection  
(see section II.3.2) 
PAL et al., 2004 
OspA 31-33 Osp, early and late infection 
(see section II.3.2) 
WILSKE et al., 1993 
BmpA 39 Osp, immunodominant,  
role in biology of borrelia 
SHIN et al., 2004 
p58  58 Osp, immunodominant HAUSER et al., 1997 
VlsE 66 in vivo-expressed protein, 
plasmid encoded, persistent 
infection (see section II.3.5.2) 
BYKOWSKI et al., 2006 
p83/100  83-100 protein from protoplasmic 
cylinder, highly specific for 
chronic infection 
BRUCKBAUER et al., 1992 
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4.6 Statistics and data analysis 
Bacteria-free blood and tissue samples, which were collected from mice before borreliae 
exposure, served as negative controls. All data for graphs in this study were prepared with 
the OriginPro 2017 Software (Additive GmbH, Friedrichsdorf, Germany). Data obtained 
from each single mouse in the same subgroup are presented as mean and standard deviation 
(SD).  
The students unpaired, two-tailed t test was utilized to determine if there is a significant 
difference between mouse subgroups after ID or IV inoculation of Bbss spirochetes. 
Difference was considered statistically significant when this test resulted in p values that 
were lower than 0.05. 
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V RESULTS 
1 Population kinetics of host-adapted borreliae in the blood of 
immunodeficient NOD-SCID mice 
Six immunodeficient NOD-SCID mice were ID challenged with an inoculum dose of in vitro 
cultured 1.0 x 105 Bp or 1.0 x 106 (or 1.0 x 108) Bbss spirochetes. During a 17-day infection 
course, viable borrelia organisms and their numbers in the bloodstream were recorded.  
1.1 Kinetics of host-adapted Bp spirochetes  
On day 1 after ID inoculation, Bp DNA targeting flaB gene (1.3 ± 0.2 x 105 copies/ml) was 
detectable in the blood samples from six mice in subgroup N-A and N-B by qPCR testing 
(Figure 19). Viable spirochetes were also observed in the blood samples after dilution (30 µl 
blood in 500 µl medium). Borrelial counts increased the following days after inoculation. 
Although, minor drop-offs occurred on day 4 (2.2 ± 1.7 x 105 cells/ml), day 7 (1.8 ± 0.5 x 
106 cells/ml), and day 11 (3.6 ± 2.0 x 106 cells/ml) (Figure 19). Considering the number and 
viability of Bp occurring between day 1 and day 17 (8.8 ± 1.2 x 106 cells/ml) in the 
bloodstream, day 12 (5.6 ± 1.2 x 106 cells/ml blood) was determined as the anticipated time 
point to obtain the blood samples for further experiments. Subsequently, each of the other 
five NOD-SCID mice (subgroup N-G) were ID inoculated with cultured 1.0 x 105 Bp 
organisms. On day 6 p.i., each microliter blood was detected with 1.5 ± 0.1 x 106 spirochetes. 
On day 12, 7.2 x 106 Bp organisms were detected in one millilitre of the pooled blood from 
these five mice (Figure 19).  
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Figure 19: Kinetics of host-adapted Bp organisms in the blood of immunodeficient 
NOD-SCID mice  
Kinetics of host-adapted Bp organisms in the blood of NOD-SCID mice (subgroup N-A and N-B) 
are shown with symbol ● during a 17-day infection period. Standard deviations between 
individual mice are indicated with the error bars. On day 12 p.i., 7.2 x 106 Bp spirochetes were 
detected per ml pooled blood (◆) from five mice in subgroup N-G. 
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1.2 Kinetics of host-adapted Bbss spirochetes 
After ID injection with cultured 1.0 x 106 (subgroup N-C and N-D) or 1.0 x 108 (subgroup 
N-E and N-F) Bbss organisms, six NOD-SCID mice were monitored for motile spirochetes 
in the blood samples collected between day 3 and day 17. As shown in Figure 20, Bbss 
organisms in the bloodstream was firstly detectable by qPCR (targeting ospA gene) on day 
2 p.i. In the case of the inoculum dose of 1.0 x 106 Bbss, the borrelial counts rose from 8.5 
± 1.4 x 103 cells/ml blood on day 2 up to 4.9 ± 3.3 x 104 cells/ml blood on day 7, followed 
by a small decrease on day 8 (2.6 ± 1.2 x 104 spirochetes/ml). On day 10, a second peak of 
spirochemia occurred with 3.9 ± 1.3 x 104 viable organisms per ml blood. Subsequently, 
borrelial concentration plateaued at ~ 3.0 x 104 cells/ml until day 17 (Figure 20). After ID 
injection of the higher inoculum dose of 108 Bbss spirochetes, the first bacteraemia was noted 
on day 5 (7.2 ± 0.8 x 104 organisms/ml blood). On day 7 and day 11, 6.9 ± 2.1 x 104 and 
4.9 ± 1.0 x 104 organisms circulated in each millilitre blood, respectively. At the other days, 
however, lower spirochete density was detected, which plateaued at ~ 4.0 x 104 (ranging 
from 2.3 x 104 to 3.9 x 104) per ml blood (Figure 20). According to statistical analyse, the 
highest spirochete densities in the blood caused by 106 and 108 Bbss inoculum showed no 
significant difference (p = 0.1958). Considering the difficulty of centrifugation for higher 
Bbss counts and the viability of spirochetes in the suspended medium, the inoculum dose of 
106 was used for further experiments. Day 10 (3.9 x 104 cells/ml blood) was considered as 
the expected day with host-adapted and relatively peaking number of borreliae. As shown in 
Figure 20, 3.5 x 104 (subgroup N-H) and 2.8 x 104 (subgroup N-I) Bbss organisms per ml 
were recorded in pooled blood of each five NOD-SCID mice on day 10 post injection. 
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Figure 20: Kinetics of host-adapted Bbss organisms in the blood of NOD-SCID mice  
During a 17-day infection period, kinetics of host-adapted Bbss organisms in the blood of NOD-
SCID mice are shown with symbol ▼ (subgroup N-C and N-D with 1.0 x 106 Bbss inoculum dose) 
and ▲ (subgroup N-E and N-F with 1.0 x 108 Bbss inoculum dose). The standard deviations 
between individual mice are shown with the error bars. On day 10 p.i., 3.5 x 104 (●) and 2.8 x 104 
(◆) Bbss organisms per ml pooled blood from five mice in subgroup N-H and N-I were detected, 
respectively. 
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2 Distribution of borreliae in tissues of NOD-SCID mice 
On day 12 and day 10 after injection of culture-derived 1.0 x 105 Bp and 1.0 x 106 Bbss, 
respectively, in most of the collected tissue samples from NOD-SCID mice (subgroup N-G 
and N-H) the flaB (Bp) and the ospA (Bbss) gene were detected by qPCR. Motile spirochetes 
were also identified by cultivation (Table 15). Briefly, Bp DNA was detected in all skin 
(infection areal) (5/5), tibiotarsal joint (5/5), spleen (5/5), urinary bladder (5/5), heart (5/5), 
and brain tissue (5/5) samples, but not in either of the five ear tissue samples (0/5). In 
subgroup N-H, each collected tissue sample (ear, skin, joint, spleen, bladder, heart, and brain) 
was positive for Bbss DNA. Although contamination occurred to some tissue samples as 
shown in Table 15, motile spirochetes were demonstrated in cultures with following tissue 
samples: joint (1/5 with Bp; 4/5 with Bbss), spleen (2/5 Bp; 3/5 Bbss), bladder (3/5 Bp; 5/5 
Bbss), heart (2/5 Bp; 4/5 Bbss), and brain (3/5 Bp; 5/5 Bbss).  
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Table 15: Distribution of Bp and Bbss in tissues of NOD-SCID mice 
inoculum*  mouse 
no.  
spirochetes in tissue samples detected by culture/qPCR (organisms/mg) 
   ear skin joint spleen bladder heart brain 
Bp 
1.0 x 105 
ID 
s
u
b
g
ro
u
p
 N
-G
 
n
=
5
 
N1 # / 0 # /       17 # /     199 + /   873 + /     74518 + / 14017 + /   3702 
N2 # / 0 # / 47690 # /     117 # /     19 # /       1743 # / 46102 # / 10721 
N3 # / 0 # / 11529 + /     262 - /  3381 + /     83700 + / 23582 + / 11929 
N4 # / 0 # /   1171 # /     574 + / 1050 + /     26254 # / 28797 + /   2639 
N5 # / 0 # /     311 # /       24 # /   144 # /   131872 # /   6168 # /   1896 
positive rate 3 / 5  0 / 0 0 / 5 1 / 5 2 / 5 3 / 5 2 / 5 3 / 5 
Bbss 
1.0 x 106 
ID 
s
u
b
g
ro
u
p
 N
-H
 
n
=
5
 
N6 # /       48 # / 41467 + / 20395 + /     22 + /   266594 + /     360 + /       11 
N7 # /     522 # / 18795 + / 37393 + /   537 + /   217600 # /     333 + /       12 
N8 # /   3082 # / 16655 # /   2113 # /     14 + / 2110835 + /     357 + /       15 
N9 # / 10372 # / 18435 + / 40571 # /       3 + / 1141583 + /   1122 + /       47 
N10 # /   4987 # / 15288 + / 17693 + /   992 + /   384204 + /   2057 + /       12 
positive rate 5 / 5  0 / 5 0 / 5 4 / 5 3 / 5 5 / 5 4 / 5 5 / 5 
 
 
 
 
*, culture-derived borreliae 
#, contaminated culture 
+, positive with motile spirochetes in culture 
-, negative with spirochetes in culture 
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3 Population kinetics of borreliae in the blood of immunocompetent 
C3H/HeOuJ mice 
One hundred microliter pooled blood that contained host-adapted Bp or Bbss organisms were 
injected ID or strictly IV into C3H/HeOuJ mice. Thereafter, blood samples were collected 
at defined time points throughout a 49/50-day study period. Spirochete numbers in the 
bloodstream were detected by qPCR testing. 
3.1 Population kinetics of Bp spirochetes in blood 
As described above, 7.2 x 105 host-adapted Bp spirochetes in 100 µl pooled blood were 
inoculated into mice of subgroup C-A (ID injection) and C-B (IV injection). Blood samples 
from all ID and IV challenged animals were screened for the flaB gene applying the qPCR 
method until day 15 p.i. (Figure 21). Correspondingly, viable spirochetes were cultured and 
observed applying dark-field microscope. In ID inoculated mice, spirochete concentration 
was 8.3 ± 1.9 x 105 and 9.4 ± 15.8 x 105 Bp cells/ml blood on day 6 and day 9, respectively. 
A second peak of spirochetemia occurred on day 12 with 1.9 ± 1.7 x 106 organisms/ml. On 
day 18, however, only one single mouse (no. C4) was detected to be positive for Bp with 
7.4 x 104 organisms/ml blood. Similarly, the IV injected mice in subgroup C-B demonstrated 
two peaks of Bp populations: 3.7 ± 2.4 x 106 organisms per ml blood on day 6 
and 4.1 ± 6.8 x 106 organisms per ml blood on day 12. Interestingly, one single mouse (no. 
C10) contained 2.8 x 105 and 3.8 x 105 Bp cells/ml blood on day 21 day 24, respectively 
(Figure 21). Between day 27 and day 49/50, however, all of the ID and IV inoculated mice 
were negative for borrelial DNA and no motile spirochetes were re-cultured in medium.  
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Figure 21: Kinetics of Bp spirochetemia in the blood of immunocompetent 
C3H/HeOuJ mice 
 
3.2 Population kinetics of Bbss spirochetes in blood 
One hundred microliter pooled blood from NOD-SCID mice in subgroup N-H and N-I 
contained 3.5 x 103 and 2.8 x 103 Bbss organisms, respectively. All blood samples from ID 
(subgroup C-C and C-E) or IV (subgroup C-D and C-F) injected mice produced no positive 
results for Bbss-specific DNA. Spirochetes were not visible when dark-field microscope was 
applied. Cultivation of 30-µl blood from single mice or pooled blood from either ID or IV 
subgroup showed no growth of Bbss spirochetes in 5 ml BSK-H medium. 
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4 Distribution of borreliae in tissues of C3H/HeOuJ mice 
Tissue samples including ear, skin (inoculation areal), tibiotarsal joint, spleen, urinary 
bladder, heart, and brain were aseptically obtained from C3H/HeOuJ mice and separately 
cultivated in 10 ml of Pettenkofer/LMU Bp medium (for Bp at 37°C) or BSK-H medium (for 
Bbss at 33°C) without any antibiotics. By qPCR testing and 6 weeks’ cultivation, results 
were obtained.  
4.1 Bp in tissues  
Tissue samples were collected at the end of the observation period 49/50 days after 
spirochete inoculation. Bp organisms were detected in all brain tissue samples (100%) 
removed from C3H/HeOuJ mice that had received the bacteria either ID or IV. The other 
tissue samples (ear, skin, tibiotarsal joint, spleen, urinary bladder, and heart), however, 
produced neither viable spirochetes in the culture medium nor flaB gene signals in the qPCR 
tests. Bacterial contamination and overgrowth occurred in cultures with ear (10/11) and skin 
tissue samples (8/11; Table 16). 
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Table 16: Distribution of Bp in tissues of C3H/HeOuJ mice 
inoculum*  mouse
no. 
spirochetes in tissue samples by  
culture/qPCR (organisms/mg) 
   ear skin joint spleen bladder heart brain 
Bp 
7.2 x 105 
ID 
s
u
b
g
ro
u
p
 C
-A
 
n
=
5
 
C1 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 + /   39 
C2 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 + /   31 
C3 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 + /   89 
C4 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 + /   59 
C5 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 + / 136 
positive rate 5 / 5  0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 5 / 5 
Bp 
7.2 x 105 
IV 
s
u
b
g
ro
u
p
 C
-B
 
n
=
6
 
C6 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 + /   30 
C7 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 + /   34 
C8 - / 0 - / 0 - / 0 - / 0 - / 0 - / 0 + /   75 
C9 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 + / 216 
C10 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 + /   63 
C11 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 + /   74 
positive rate 6 / 6  0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 6 / 6 
4.2 Bbss in tissues 
On day 49/50 after ID inoculation of host-adapted spirochetes, 100% of the exposed mice 
(5/5, subgroup C-C; 6/6, subgroup C-E) were positive for Bbss as shown by cultivation and 
qPCR testing of tissue samples (Table 17). Motile spirochete organisms were visualized in 
cultures containing tissue specimens from ears (4/11), skin samples (10/11), joints (11/11), 
spleen samples (4/11), bladders (11/11), hearts (11/11), and brains (2/11), except for the 
contaminated and negative cultures. Interestingly, Bbss-specific DNA was detected only in 
urinary bladders (11/11) and heart tissue samples (7/11) of these Bbss-ID inoculated animals 
(Table 17). Again, all 11 Bbss-IV inoculated mice (subgroup C-D and C-F) tested completely 
negative for borrelial DNA and for motile Bbss organisms in each tissue sample (Table 17). 
  
*, host-adapted borreliae 
#, contaminated culture 
+, positive with motile spirochetes in culture 
-, negative with spirochetes in culture 
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Table 17: Distribution of Bbss in tissues of C3H/HeOuJ mice 
inoculum*  mouse
no. 
spirochetes in tissue samples by  
culture/qPCR (organisms/mg) 
   ear skin joint spleen bladder heart brain 
Bbss  
3.5 x 103 
ID 
s
u
b
g
ro
u
p
 C
-C
 
n
=
5
 
C21 # / 0 + / 0 + / 0 # / 0 + /   875 + / 0 - / 0 
C22 # / 0 + / 0 + / 0 + / 0 + /   676 + / 0 + / 0 
C23 + / 0 + / 0 + / 0 + / 0 + / 1041 + / 409 - / 0 
C24 # / 0 + / 0 + / 0 + / 0 + / 1867 + / 0 + / 0 
C25 # / 0 # / 0 + / 0 + / 0 + / 1482 + / 0 - / 0 
positive rate 5 / 5  1 / 0 4 / 0 5 / 0 4 / 0 5 / 5 5 / 1 2 / 0 
Bbss  
3.5 x 103 
IV 
s
u
b
g
ro
u
p
 C
-D
 
n
=
5
 
C26 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C27 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C28 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C29 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C30 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
positive rate 0 / 0  0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 
Bbss  
2.8 x 103 
ID 
s
u
b
g
ro
u
p
 C
-E
 
n
=
6
 
C31 + / 0 + / 0 + / 0 - / 0 +/   2420 + / 893 - / 0 
C32 + / 0 + / 0 + / 0 - / 0 +/ 10295 + / 501 - / 0 
C33 + / 0 + / 0 + / 0 - / 0 +/   1383 + / 788 - / 0 
C34 # / 0 + / 0 + / 0 - / 0 +/   2741 + / 817 - / 0 
C35 # / 0 + / 0 + / 0 - / 0 +/     906 + / 109 - / 0 
C36 # / 0 + / 0 + / 0 - / 0 +/   3487 + / 607 - / 0 
positive rate 6/6  3 / 0 6 / 0 6 / 0 0 / 0 6 / 6 6 / 6 0 / 0 
Bbss  
2.8 x 103 
IV 
s
u
b
g
ro
u
p
 C
-F
 
n
=
6
 
C37 - / 0 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C38 - / 0 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C39 - / 0 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C40 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C41 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
C42 # / 0 # / 0 - / 0 - / 0 - / 0 - / 0 - / 0 
positive rate 0 / 0  0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 0 / 0 
  
*, host-adapted borreliae 
#, contaminated culture 
+, positive with motile spirochetes in culture 
-, negative with spirochetes in culture 
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5 Specific antibodies against Bp and Bbss in C3H/HeOuJ mice 
Plasma and serum samples were obtained from the blood samples of C3H/HeOuJ mice post 
ID or IV inoculation. Serological testing (ELISA or/and LIA) was applied to characterize 
the kinetics of antibody levels and the quality of the specific antibody response induced by 
borrelial spirochetes.  
5.1 Kinetics of specific antibody response against Bp  
As shown in Figure 22, ID and IV inoculation of host-adapted Bp organisms into 
C3H/HeOuJ mice elicited positive antibody responses. Clearly, Bp-ID mice generated 
similar antibody levels to that of the Bp-IV counterparts. In subgroup C-A and C-B, antibody 
levels rose to 267.5 and 166.1 KELA units on day 21 and decreased to 214.1 and 104.9 
KELA units on day 24, respectively. Afterwards, antibody responses increased steadily and 
reached 300.1 (ID) and 264.5 (IV) KELA units on day 49/50 (end of this study). Serum 
samples obtained on the final day of the experiment were tested individually for each mouse. 
Calculated mean values were 296.6 ± 103.1 KELA units for Bp-ID and 208.7 ± 42.5 KELA 
units for Bp-IV.  
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Figure 22: Kinetics of specific antibody response against Bp in C3H/HeOuJ mice 
 
5.2 Kinetics of specific antibody response against Bbss 
Mice that had been injected intradermally with host-adapted Bbss organisms (Bbss-ID) 
developed specific antibodies with a steady increase (Figure 23). In subgroup C-C and C-E, 
the antibody levels increased similarly up to 493.7 and 526.9 KELA units, respectively, on 
day 49/50 p.i. In contrast, none of IV-injected mice (subgroup C-D and C-F) produced 
specific antibodies against Bbss. Only approx. 30 KELA units were recorded, ranging from 
13.7 to 59,8. Serum samples from individual mice clearly showed specific IgG and IgM 
antibody responses: 478.9 ± 54.9 KELA units (Bbss-ID-1, subgroup C-C), and 492.7 ± 68.8 
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KELA units (Bbss-ID-2, subgroup C-E), 31.3 ± 25.5 KELA units (Bbss-IV-1, subgroup C-
D) and 28.6 ± 17.1 KELA units (Bbss-IV-2, subgroup C-F). 
No data are available from mouse no. C23 in subgroup C-C, because the final blood 
collection via intracardiac puncture failed.  
 
Figure 23: Kinetics of specific antibody response against Bbss in C3H/HeOuJ mice 
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5.3 Visualization of specific antibodies against Bbss 
As shown in Figure 24, individual serum samples obtained from 11 mice inoculated 
intravenously with Bbss (5 in subgroup C-D and 6 in subgroup C-F) produced no specific 
signals on the line immunoblot (lanes 4 to 14). In contrast, serum samples collected from ten 
animals inoculated intradermally with Bbss (4 in subgroup C-C, because no serum was from 
mouse no. C23; and 6 in subgroup C-E) reacted with following antigens (lanes 15 to 24): 
strong signals with VlsE mix (10/10); strong/moderate signals with OspC mix (8/10), BmpA 
(7/10) and p58 (58 kDa; 5/10); weak signals with DbpA mix (10/10) and p83 (83 kDa; 8/10). 
 
Figure 24: Representative IgG line immunoblots of individual serum samples from 
Bbss inoculated C3H/HeOuJ mice 
Lanes belong to the individual serum samples in the following groups: NG (lanes 1-3) to plasma 
samples from three of five mice in subgroup C-NG; IV-1 (subgroup C-D) to lanes 4-8; IV-2 
(subgroup C-F) to lanes 9-14; ID-1 (subgroup C-C, except for one mouse no. C23) to lane 15-18; 
ID-2 (subgroup C-E) to lanes 19-24. 
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VI DISCUSSION 
Tick-borne relapsing fever (TBRF), although recognized for ages, remains one of the 
neglected diseases with only a few studies clarifying the interactions between host, tick and 
pathogens (TALAGRAND-REBOUL et al., 2018). Among its pathogens, Bp can cause acute 
infection and make TBRF a widespread disease in the large areas of Middle East and Central 
Asia. This bacterium poses a noteworthy health threat not only to the local residents and the 
military but also to the tourists who may carry the infection back to non-endemic countries 
on their return journey (SIDI et al., 2005; DE VERDIERE et al., 2011; KUTSUNA et al., 
2013). However, to the best of our knowledge, data on the pathogenesis of Bp in the 
vertebrate host are still limited, though previous studies have developed animal models with 
Bp infection via ID or IP inoculation (ASSOUS et al., 2006; SCHWARZER et al., 2016). 
On the other hand, Lyme borreliosis (LB) is the most common tick-borne disease in the 
northern hemisphere, but continuously needs to be extensively investigated because of its 
long-lasting infections in humans (STONE & BRISSETTE, 2017; SPRONG et al., 2018). 
Bbss, the endemic species causing LB in the USA and Europe, has been the focus of 
scientific research in the last years. However, some authors still hold different views on its 
dissemination route in the vertebrate host. In the context of the characterization of the exact 
dissemination pathway of both TBRF and LB borreliae in mammals, there is to date no 
suitable animal model available in which specific organisms are injected into the venous 
system for long-term infection. With the intention of further insights into pathogenic 
strategies of Borrelia, research in the underlying dissemination is of great importance. 
Therefore, we established the present murine model using ID and strict IV inoculation of 
host-adapted Bp and Bbss organisms into immunocompetent mice. Evident clarifications 
from our study are as follows. Firstly, Bp causes persistent infection in the 
immunocompetent mice regardless of the ID or IV inoculation route. This indicates its 
excellent adaptation to the circulation environment and its robust capability of surviving in 
the bloodstream. During the course of the infection, Bp spirochetes disseminate 
hematogenously to distant organs (especially brain), causing persistent infection. Secondly, 
Bbss, in comparison to Bp, cannot lead to a systemic infection via IV inoculation, because 
these spirochetes in the bloodstream are probably unable to cross the blood vessel and 
thereafter translocate to distal tissues. However, LB spirochetes are able to migrate to distant 
tissues primarily via non-hematogenous pathways (i.e., tissue migration shown after ID 
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inoculation) and establish systemic infections in tissues such as ear, skin, joint, bladder and 
heart. The distribution of Bbss organisms in our ID-inoculated mice also resembles the 
scenario that was observed in human tissue specimens with LB infection (DURAY & 
STEERE, 1988; DURAY, 1989). Finally, our murine model could be a valuable research 
tool in understanding the pathogenesis of TBRF and LB borreliae during human and animal 
infections. Nevertheless, our data provide insight into potential risk factors that come with 
blood transfusions in clinical practice. Transfusion of Bp contaminated blood is highly 
problematic, because of its potential to cause spirochetemia and persistent brain infection in 
recipients. On the contrary, the risk of receiving Bbss infection via blood transfusion is low 
or should be considered to be non-existent. 
1 Host-adapted Bp and Bbss organisms 
In our study, immunodeficient NOD-SCID mice were used to generate host-adapted borrelia 
organisms. After ID injection of 1.0 x 105 in vitro cultured Bp spirochetes, hematogenous 
organisms were first detected on day 1 (the first sampling time point p.i.) with 1.3 ± 0.2 x 
105 cells per ml blood. Along the infection time, Bp burden kept rising up to 8.8 ± 1.2 x 106 
cells/ml blood (on day 17-end time point), except for some slight decrease on day 4, 7 and 
11 (see Figure 19). By contrast, Bbss organisms were first detectable on day 2 with 8.5 ± 1.4 
x 103 and 2.5 ± 0.1 x 104 cells per ml blood of NOD-SCID mouse after ID inoculation of 1.0 
x 106 and 1.0 x 108 cultured spirochetes, respectively (see Figure 20). The highest density 
recorded was 7.2 ± 0.8 x 104 Bbss per ml blood, although a high inoculum dose (1.0 x 108) 
was used. Given that Bp organisms (1.0 x 105) were injected in a 10- and 103-fold lower dose 
than Bbss, it seems that Bp adapts more rapidly to the circulation than Bbss and proliferates 
efficiently in the bloodstream of immunodeficient animals.  
On day 12 and day 10 post injection of cultured Bp (1.0 x 105 cells) and Bbss (1.0 x 106 
cells), respectively, most sampled tissue samples collected from the ears, skin (site of 
inoculation), tibiotarsal joints, spleens, urinary bladders, hearts, and brains from NOD-SCID 
mice presented with spirochetes by in vitro cultivation and qPCR (see Table 15). Therefore, 
spirochetes of both Bp and Bbss can disseminate to various distant tissues of 
immunodeficient animals. For the first time, our study reported the population dynamics of 
Bp in the bloodstream and its distribution in different tissues of immunodeficient mice, 
which complete data from a prior study (SCHWARZER et al., 2016) and also results we 
obtained with immunocompetent mice (see Figure 21 and Table 16).  
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As described above, on day 12 and day 10, 7.2 x 106 Bp and 3.5 x 104 or 2.8 x 104 Bbss 
organisms per ml blood were harvested from NOD-SCID mice, respectively. After ID 
inoculation of 100 µl pooled blood that contained these host-adapted Bp (7.2 x 105) or Bbss 
(3.5 x 103 or 2.8 x 103) organisms, persistent infection was induced in all immunocompetent 
mice as confirmed by the detection of viable spirochetes in various tissue samples collected 
at the end of the observation periods (see Tables 16 and 17) and the induction of consistently 
rising Borrelia-specific antibody levels (see Figures 22 and 23). These evidences are 
substantial to prove that host-adapted borrelia organisms are invasive and pathogenic to the 
immunocompetent host even though a low inoculum dose of Bbss was used. However, this 
relatively low number of borreliae may reflect more faithfully the actual pathophysiological 
conditions in terms of a low spirochete load (~ 103 to 105 or less) being transmitted from the 
tick to the host or from the infectious host to the naïve tick (BURKOT et al., 1993; GOLDE 
et al., 1994; DE SILVA & FIKRIG, 1995; KERN et al., 2011; GRILLON et al., 2017). It is 
also reasonable to explain why many studies dealing with TBRF and LB borreliae widely 
utilize an injection dose of approx. 103 - 106 spirochetes. According to clinical case studies, 
Bbss was positively re-isolated from large quantity of plasma or blood sample volume (9 - 
18 ml) from patients at early stage of LB infection (WORMSER et al., 1998; MARASPIN 
et al., 2001; WORMSER, 2006; LIVERIS et al., 2011). This indicates that the actual 
spirochete number in blood of the LB patients is extremely low, which was estimated to be 
0.1 cultivable cell/ml in whole blood (WORMSER, 2006). Compared to LB infection, 
numerous Bp organisms were found in blood of naturally infected animals and humans (DE 
VERDIÈRE et al., 2011; RAFINEJAD et al., 2011; KUTSUNA et al., 2013; BANETH et al., 
2016). Consequently, the injection doses used for host-adapted Bp and Bbss spirochetes in 
this project can be considered as practical and optimal for further experiment as scheduled 
in this study. Furthermore, experimental results based on the host-adapted bacteria appear to 
be more reliable and reproducible compared to those using in vitro cultured bacteria as stated 
by Woodman et al. (WOODMAN et al., 2009).  
2 Intravenous inoculation via jugular vein but not tail vein 
According to the published data, the lateral tail vein of the rat or mouse was preferentially 
utilized for IV inoculation with the help of a suitable restrainer (Figure 25) (STEEL et al., 
2008). However, this method is considered challenging and often unsuccessful (YARDENI 
et al., 2011). Firstly, it is technically difficult to visualize the vessel. The fragile tail vein 
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shows a poor visibleness through the dark brown skin of the C3H/HeOuJ mouse used in our 
study. Injection errors may occur. For example, the needle may accidentally punch through 
the vessel walls due to a small size of the tail vein. Secondly, a low number of bacteria 
adhering to the tip of the needle might be unavoidably carried off into the surrounding tissue 
or skin during the process of removing the apparatus from the mouse’s tail. Unpublished 
data from an earlier experiment, which was independently carried out of the present study, 
showed an overall successful rate of 93.1% (67 of 72 C3H mice) on IV injection via tail vein. 
 
Therefore, an alternate route of IV injection was considered. The jugular vein, in comparison 
to other vessels such as femoral vein and retro-orbital plexus, is easier to be separated from 
the connective tissue and exposed clearly for further procedures carried out under the 
constant surveillance with a stereo microscope (Figure 16). Many investigators use catheters 
into jugular vein for intravenous administration or chronic/acute implantation (BARR et al., 
1979), although it is necessary to ligate the vein to avoid bleeding while puncturing it with 
a needle (POPOVIC & POPOVIC, 1960).  
In our experiment, the right jugular vein was ligated. This procedure does not affect the 
blood-brain-barrier or the blood circulation in mice as previously described (SAKATA et al., 
1999; ATKINSON et al., 2012). Special sterile instruments/materials such as Vannas-style 
 
Figure 25: Demonstration for mouse lateral tail vein injection 
(a) mouse restrainer and tail vein injection technique, (b) axial section of mouse tail anatomy,  
(c) sagittal cross section of mouse lateral tail with needle in position 
Cited from Brown et al. (BROWN et al., 2018) 
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spring scissors, blunt micro hook and Alzet mouse jugular catheter made great contributions 
to the strict IV inoculation without producing severe damage to the vessel wall. Flushing 
with 50 µl sterile isotonic saline avoided dead space in the catheter to ensure that the 
complete blood volume and spirochete dose was applied. Above all, the visual observation 
of the whole procedure during injecting, flushing, and removing was clearly visible using 
stereo microscopy with optimal magnification. The success rate of the injection into the 
jugular vein was 100% (6/6 for Bp, 11/11 for Bbss) without any bleeding of blood into 
surrounding tissues. On day 49/50 after intravenous inoculation of host-adapted borreliae 
into the immunocompetent C3H/HeOuJ mice, Bp organisms induced noticeable antibody 
levels and brain infections were detected consistently (see Figure 22 and Table 16) whereas 
neither Bbss-specific-antibody levels nor motile Bbss spirochetes were detectable (see 
Figure 23 and Table 17). Thus, Bbss organisms, although host-adapted and invasive as 
demonstrated by the ID inoculation, are unlikely to cross the blood vessels for further 
infection of distant sites in C3H/HeOuJ mice. The clear results of Bp and Bbss infection via 
IV inoculation are strong evidence for our successful microvasculature surgery without any 
blood/borreliae leakage.  
However, previous studies claim that hematogenous dissemination of Bbss is still the 
spreading route used by this organism. The careful reading of the publication reveals that 
mice were exposed to Bbss by an intraperitoneal injection due to unsuccessful IV technique 
(GABITZSCH et al., 2006). Obviously, the results obtained by an IP but not IV inoculation 
may lead to a misinterpretation of the data, but do not clarify how Bbss disseminates from 
the injection site to the distant tissues. Other studies used huge doses (4 x 108 organisms per 
animal) and culture-derived Bbss for IV inoculation (MORIARTY et al., 2008; NORMAN 
et al., 2008). Even though they indicated the hematogenous spread based on few interactions 
of spirochetes and the blood vessels under shear force condition, only a small area was 
visualized within a short time period (5 - 45 min). The puzzling results of these studies with 
the large inoculum dose were also argued by some authors (HYDE et al., 2011). It should be 
mentioned that under optimal conditions Borrelia spirochetes reach cell densities of ∼ 108 
to 109 per ml in culture medium (AGUERO-ROSENFELD et al., 2005; PAPPAS et al., 
2011). However, only few spirochetes are naturally deposited in the dermis of the mammals 
after tick attachment as described above. Hence, both the strict IV inoculation and a 
reasonable inoculum dose play the most crucial roles to establish a reliable murine model 
and to draw a realistic conclusion. 
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3 Spirochetemia and brain infection of Bp in C3H/HeOuJ mice 
A hematogenous dissemination of some TBRF Borrelia spp. (e.g., B. hermsii, B. duttonii, 
and B. turicatae) from the bloodstream to distant tissue sites in the mammals has been 
described (CADAVID & BARBOUR, 1998; DWORKIN et al., 2008). Previous studies on 
the infection dynamics have all described spirochetemia regardless of the TBRF spirochete 
or inoculation route: Bp (ID and IP), B. hermsii (ID, IP, IV, and SB4), B. turicatae (ID), and 
B. miyamotoi (blood transfusion) (HOVIS et al., 2006; BENOIT et al., 2010; RAFINEJAD 
et al., 2011; BOYLE et al., 2014; DICKINSON et al., 2014; KRAUSE et al., 2015; 
SCHWARZER et al., 2016). In our study, numerous Bp organisms in blood of C3H/HeOuJ 
mouse were detectable until day 24 after either ID or IV inoculation with 7.2 x 105 host-
adapted organisms (see Figure 21). Fluctuations of spirochetemia during the infection period 
in our ID infected mice, which are consistent with previous data (SCHWARZER et al., 2016), 
were similarly observed in our IV challenged animals (see Figure 21). For example, higher-
level spirochetemia was detected at day 6 and day 12 followed by a small decrease until 
day 9 and day 15, respectively. Our first bleeding time point at day 6 showed 8.3 ± 1.9 x 105 
Bp cells/ml blood after ID injection while 3.7 ± 2.4 x 106 were seen after IV injection. 
Taking into account that ~ 1.5 x 105 (at day 1 p.i.) and ~ 4 x 106 (at day 6 p.i.) Bp 
organisms/ml blood was reported in the prior study (SCHWARZER et al., 2016), this 
suggests that Bp’s entry from the inoculation sites into the circulation is a rapid event, 
followed by a rapid proliferation in the bloodstream of immunocompetent animals. This 
suggestion has been supported by other researchers, who found that transmission and 
dissemination of B. turicatae, another TBRF Borrelia, occurred during the short time 
required for tick engorgement (BOYLE et al., 2014).  
Correlated with the fluctuations of spirochetemia, Bp-specific antibodies appeared in both 
ID and IV inoculated mice and the antibody level increased steadily until day 21 followed 
by a slight decline until day 24. Although no spirochetes were detected by qPCR or in vitro 
cultivation from day 24 until days 49/50 p.i., the antibody level in both ID and IV infected 
mice rose again during this period (see Figure 22). A reasonable explanation might be that 
the immune response is permanently triggered by antigen provided by a persistent infection. 
All cerebral tissue samples collected on day 49/50 p.i. were positive for Bp (see Table 16). 
However, antibodies even at a high level were not able to eliminate Bp organisms present in 
 
4 SB: subcutaneous inoculation 
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brain tissue – probably an immune-privileged site. Bp spirochetes seem to sustain a persistent 
infection in the brain while at the same time they induce no tissue damage or clinical signs 
(SCHWARZER et al., 2016).  
4 Bbss' lack of spirochetemia in C3H/HeOuJ mice 
In our study, neither Bbss DNA detection nor re-cultivation of vital spirochetes was possible 
in any blood specimen of C3H/HeOuJ mice regardless of ID or IV inoculation of host-
adapted Bbss organisms (3.5 x 103 or 2.8 x 103). Similarly, some murine studies have found 
that LB spirochetes can only occasionally or even not at all be reisolated from peripheral 
blood of experimental immunocompetent animals, though a persisten infection was 
established by high (108; SB), or low (103, 104; ID) inoculum doses of Bbsl organisms 
(SIMON et al., 1991; HODZIC et al., 2003; LIU et al., 2004). Although previous data 
reported low yield of Bbsl borreliae by culturing blood/plasma from some LB patients at the 
early infection stage (WORMSER et al., 1998; MARASPIN et al., 2001; WORMSER, 2006; 
LIVERIS et al., 2011), no scientific data so far have shown whether these low number of 
blood-borne spirochetes travel to distal tissues and cause persistent infection there. 
According to our hypothesis, strict IV inoculated Bbss spirochetes mimic closely the LB 
organisms in infected mammalian hosts, including humans. However, neither Bbss 
spirochetes in blood or tissues (see Table 17) nor Bbss-specific antibodies (see Figure 23 
and 24) were detected in IV challenged C3H/HeOuJ mice. Consequently, Bbss organisms 
cannot survive in the bloodstream or disseminate further to other tissues. Possibly the 
spirochetes are cleared by the complement system, which plays a critical role in controlling 
early infection before the specific humoral immune response is induced (STEERE et al., 
2016). This can also explain why no specific antibodies against these host-adapted Bbss cells 
were detected during the entire infection period of our study. It should be questioned, 
whether the low density of blood-carrying LB borreliae in human patients should be 
considered the same as the high-level spirochetemia of TBRF organisms, which can 
disseminate from the bloodstream to distant sites in the body (e.g., brain). On the contrary, 
our intradermally injected animals produced Bbss-induced specific antibodies during the 
infection period (see Figure 23 and 24). On day 49/50 (the end of the observation period), 
motile spirochetes were also isolated from most tissue samples such as ear, skin (inoculation 
site), urinary bladder and tibiotarsal joint (see Table 17). Interestingly, some tissue samples 
showed positive spirochetes in the culture but no Bbss DNA was detectable in the same 
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tissue. Reasons might be: 1) no Bbss DNA was extracted from the tissue (weight ≤ 50 mg); 2) 
Bbss-specific DNA presented in the extracted DNA sample was present at a very low 
concentration that was below the detection limit of the applied qPCR. This phenomena could 
be explained by the finding that even one single viable spirochete may be recovered by 
culture but it is not possible to detect DNA from one single cell by PCR (BARBOUR, 1984). 
Unlike Bp, our infectious Bbss spirochetes appear to only infrequently target the brain tissue 
but prefer to persist in tissues such as skin, bladder, joint, and heart of the immunocompetent 
mice, consistent with prior publications dealing with LB infection in humans and animals 
(SHIH et al., 1992; DIVAN et al., 2018).  
Infection with LB spirochetes initially begins after the deposition of the bacteria into the 
dermis by the vector tick (Ixodes spp.). Presumably, infection may remain locally at this site 
until it is cleared by antibiotic treatment or by strong immunological responses in the 
mammalian hosts. Alternatively, the borrelial organisms may disseminate to other cutaneous 
sites and/or more significantly to extracutaneous sites, such as the joints, nervous system, or 
heart (STEERE et al., 1987; GRILLON et al., 2017). During this dissemination, only few 
spirochetes may accidentally disseminate into the bloodstream. However, as indicated by 
our results based on IV inoculation, these blood-borne borreliae are not capable of leaving 
the bloodstream for further tissue infection. On the contrary, the spirochetes injected in the 
dermis caused persistent infection in various tissues. Therefore, the blood circulation is not 
significantly involved during the dissemination. Instead, skin and connective soft tissues 
probably serve as critical intermediate media for spirochete spread and spirochete tissue 
migration. This view is further supported by the fact that immunosuppression with 
dermocorticoid clobetasol reactivated borrelia in the skin tissue while the blood still 
remained spirochete-negative (GRILLON et al., 2017). In contrast, high-level spirochetemia 
was achieved during TBRF infection and brain tissue colonization by inducing 
immunosuppression (LARSSON et al., 2006). Moreover, early studies have determined 
some Bbsl proteins, e.g., DbpA, DbpB, and BBK32, which may contribute to spirochete 
migration and colonization through mediating tissue adherence (GUO et al., 1995; GUO et 
al., 1998; PROBERT & JOHNSON, 1998). As clarified by other studies, extracellular matrix 
and connective tissues, which are especially rich in collagen, provide a protective niche for 
migration and persistence of Lyme disease spirochetes (CABELLO et al., 2007).  
In summary, infectious Bbss spirochetes, which induced persistent infection via ID but not 
via IV inoculation, probably disseminates via a non-hematogenous route, i.e., via tissue 
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migration. In fact, certain observational and experimental data from a couple of other studies 
support the idea of tissue migration used by Bbss organism (HANSEN & LEBECH, 1992; 
BERGLUND et al., 1995; STRAUBINGER et al., 1997; MOTAMENI et al., 2005; 
CABELLO et al., 2007; TUNEV et al., 2011). 
5 Diagnosis and treatment of TBRF and LB infection 
As indicated from our results and other studies as mentioned above, blood samples from 
TBRF borrelia infected patients can be used for diagnostic test, especially those 
characterized with high fever attacks and a history of tick exposure (DWORKIN et al., 2008). 
The dark field or fluorescence microscope can be useful tools to observe spirochetes in the 
blood. Molecular methods, especially PCR, identifies most Borrelia spp. by amplification 
and analysis of species-specific markers in their genomic DNA (FUKUNAGA et al., 1996; 
SAFDIE et al., 2010). However, spirochetes with a low density in the blood, especially 
during afebrile periods of TBRF infection in patients, can be missed by microscope and 
limited to PCR tests. Therefore, serologic confirmation of TBRF infections is further 
performed, most frequently by ELISA and western blot tests as used in our and prior studies 
(DWORKIN et al., 2008; SCHWARZER et al., 2016). However, some limitations still occur 
to the serodiagnosis of TBRF infection in patients and naturally infected animals. It is known 
that the serologic assays are based on the antigen of whole-cell lysate of the in vitro cultured 
spirochetes. Therefore, false-positive reactions may be possible in the ELISA and IFA, 
partially caused by reactive epitopes on the spirochete’s flagellin protein, which presents in 
other borrelial species as well (MAGNARELLI et al., 1984; MAGNARELLI et al., 1987a). 
Additionally, serologic test can be challenging due to antigenic variations of TBRF 
spirochetes during infection in various mammals, including humans (DWORKIN et al., 
2008). In addition, residual brain infection as shown by our and other results (SCHWARZER 
et al., 2016) ask for new diagnostic approaches, especially when no biopsy specimens are 
available. Once infected with Bp, early treatment strategies can be carried out with 
intravenous medication of antibiotics, if oral administration is not tolerated (DWORKIN et 
al., 2008). Importantly, antimicrobial medicines that can penetrate the blood-brain-barrier 
are necessary for the treatment of brain infection.  
In terms of Bbss infection, our murine model shows clearly the fact that diagnostic 
procedures based on routinely blood detection, either culture or molecular assay or both, 
produce most likely unreliable or negative results. The skin rash EM, the most common and 
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earliest clinical manifestation of LB infection in humans, is considered as the only evidence 
that enables a reliable clinical diagnosis of this disease (STRLE & STANEK, 2009). 
Spirochetes can also be culture-confirmed from this skin lesion, which expands as LB 
borreliae migrate away from the site of the tick bite (NADELMAN et al., 1996). Without 
treatment or in the course of an insufficient treatment LB spirochetes are able to establish 
chronic (month- to year-long) infections in skin tissue of mice and dogs (BARTHOLD et al., 
1993; KRUPKA & STRAUBINGER, 2010). In autopsy/biopsy specimens and human skin 
lesions even months to years after initial LB infection, small numbers of Bbsl borreliae have 
been detected. The remaining spirochetes in the skin suggest their direct role in the 
generation and perpetuation of clinical signs of LB (BARTHOLD et al., 1991). 
Investigations on B. afzelii in wild and laboratory rodents have revealed that the spirochete 
load in the skin regulates the success of host-to-tick transmission (RÅBERG, 2012; REGO 
et al., 2014; JACQUET et al., 2015). Studies from Grillon et al. also suggested that naïve 
nymphs acquire the low density of spirochetes exclusively from the local skin and not from 
the blood (GRILLON et al., 2017). Therefore, skin biopsy specimens close to the tick bite 
or even distal site (e.g., ear tissue), are most suspicious for detection of LB borrelia infection 
during early or even late stages. As shown in our study, Bbss was re-isolated from skin 
(injection areal) and even ear tissue (distal for skin) after needle inoculation. However, not 
all patients present the skin lesion EM and some patients infected or co-infected with other 
pathogens [e.g., Southern tick-associated rash illness (STARI); Masters’ disease] also show 
similarity to EM (MASTERS et al., 1998; MASTERS et al., 2008). Some patients are even 
asymptomatic during Bbsl infection. Consequently, diagnosis avoiding false-negative or 
false-positive should be carried out further based on detection of corresponding antibodies. 
Our serological results (see Figure 23 and 24) indicate obviously that a two-tiered test 
including ELISA and LIA is reliable for confirmation of a successful Bbss infection in the 
mammals (CDC, 1995; WILSKE et al., 2000). 
According to some investigations (SHIH et al., 1992; KNAUER et al., 2011), the topical 
treatment with penicillin G, amoxicillin, ceftriaxone, doxycycline, and azithromycin-
containing formulation effectively cleared Bbsl spirochetes and stopped the infection when 
these antibiotics were applied on murine skin shortly after tick exposure or needle 
inoculation. Therefore, topical treatment strategies with proper antibiotics on deposition site 
are of particular importance to discontinue the spread of LB spirochetes (KNAUER et al., 
2011). In the context of persistent infection of LB borreliae in host tissues, however, a major 
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question, whether antibiotics used are able to eliminate the spirochetes hiding in these 
immune-privileged sites, is still in need to answer. 
6 Prospect  
The in vivo model described in this dissertation provides profound insights into the 
hematogenous and tissue-bound pathways of dissemination followed by Bp and Bbss 
organisms, respectively, which play significant roles in pathogenetic mechanism in 
mammalian hosts.  
The successful initiation of persistent infections by 7.2 x 105 Bp organisms after IV 
inoculation into C3H/HeOuJ mice reveals clearly the risk of transfusion-transmitted 
infections (TTI) humans face when they receive such treatment. Injection of only 100 Bp 
organisms can induce high-level spirochetemia (~ 106 organisms/ml blood) and persistent 
brain infection (SCHWARZER et al., 2016). Based on the ability to survive and proliferate 
in the blood circulation, it is reasonable to presume that even such a low inoculum dose can 
induce infection in immunocompetent individuals when transfused in case of an emergency. 
Hence, physicians should be aware of the potential danger in blood donation and transfusion. 
On the contrary, no TTI of LB borreliae has been reported so far. And according to our data, 
the medical risk of receiving this infection by blood transfusion can be considered as non-
existent. Distinct clinical signs of LB, i.e. LA, ACA, and LNB, are thought to be associated 
with distinct genospecies of Bbss, B. afzelii, and B. garinii, respectively. Therefore, further 
attempts are necessary to explore and compare the dissemination capacities of these species 
for better understanding how LB spirochetes interact with mammalian hosts and cause 
diseases. 
Furthermore, the recent discovery of new borrelia species such as B. miyamotoi, a relapsing 
fever spirochete that is transmitted by hard-shell ticks (e.g., I. ricinus) needs to be considered 
as an additional risk factor for humans and animals. Further studies are needed to describe 
in detail the exact route this organism may take to invade distant sites in mammalian hosts. 
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VII SUMMARY 
Borrelia persica (Bp) is the most prevalent species causing tick-borne relapsing fever (TBRF) 
in Central Asia and the Middle Eastern countries whilst B. burgdorferi sensu stricto (Bbss) 
is an endemic genospecies causing Lyme borreliosis (LB) in North America and Europe. 
TBRF patients commonly suffer from recurrent fever attacks due to spirochete proliferation 
and antibody-mediated killing of these organisms in the blood, whereas during the early 
stage of infection LB patients commonly show skin lesions (erythema migrans). If left 
untreated, LB patients may develop to a chronic phase with Lyme arthritis or other tissue 
lesion due to inflammatory responses (e.g., acrodermatitis chronica atrophicans). Despite a 
severe debate over the exact dissemination pathways employed by borrelia organisms, little 
is known how Bp and Bbss disseminate in the body of mammalian hosts. Hence, a murine 
model with a novel and precise infection approach was established to explore the 
dissemination route of host-adapted Bp and Bbss organisms post intradermal (ID) and 
intravenous (IV) inoculation in immunocompetent C3H/HeOuJ mice. 
Since borreliae are able to express differentially outer surface proteins (Osps) in vitro and in 
vivo, it was necessary to generate the host-adapted bacteria from immunodeficient NOD-
SCID mice. An ID inoculation of 1.0 x 105 culture-derived Bp organisms per animal resulted 
in the peak of spirochetemia with 8.8 x 106 cells per ml blood of NOD-SCID mouse. 
However, 1.0 x 106 and 1.0 x 108 cultured Bbss caused spirochetemia with a low load 
resulting in up to 4.9 x 104 and 7.2 x 104 organisms per ml blood, respectively. Interestingly, 
hematogenous Bp spirochetes were detectable by both qPCR and cultivation at least one day 
earlier when compared to Bbss. It seems that Bp is more efficient in entering the bloodstream 
and multiplying in the circulation of the immunodeficient mice than Bbss. 
Compared to the ID injection the strict IV inoculation via the jugular vein in C3H/HeOuJ 
mice was the most critical step to clarify whether host-adapted Bp and Bbss organisms are 
capable of leaving the bloodstream for further colonization in mammalian tissues. After 
either ID or IV inoculation of 7.2 x 105 host-adapted Bp organisms, these spirochetes were 
detectable up to day 24 in C3H/HeOuJ mice. Bp counts reached up to 1.9 x 106 and 4.1 x 106 
per ml blood sampled at day 12 post ID and IV challenge, respectively. Correspondingly, 
antibody detection with collected plasma and serum samples showed that specific antibodies 
to Bp were induced. Notably, all brain tissue samples from both ID and IV inoculated 
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C3H/HeOuJ mice were positive for Bp when tested with molecular methods and cultivation. 
In contrast, neither the Bbss ospA gene nor viable spirochetes were found in the blood of any 
C3H/HeOuJ mouse inoculated either ID or IV with approx. 3 x 103 host-adapted Bbss 
spirochetes. Interestingly, on day 49/50 after ID injection, Bbss spirochetes were re-isolated 
from most tissue samples collected from the ears, skins (injection areal), tibiotarsal joints, 
urinary bladders, and hearts. Strong antibody responses against Bbss were detected in all ID 
inoculated animals. In contrast, after IV injection of host-derived Bbss organisms, neither 
borrelial DNA nor viable spirochetes were present in any tissue sample collected from these 
animals. In addition, they did not produce specific antibodies against Bbss. 
In summary, 1) Bp is excellently capable of adapting to and surviving in the bloodstream. 
The spirochete disseminates predominantly via hematogenous route to distant organs (e.g., 
brain) to establish a persistent infection; 2) Bbss is a tissue-bound spirochete that migrates 
primarily via non-hematogenous routes. Intradermal deposition will cause a successful 
persistent infection while the blood vessel system is an impasse for this bacterium. The 
animal model applied in this study mimics the natural infection conditions of tick bite as 
closely as possible. Borreliae were used in an inoculum dose expected to be deposited by 
ticks in the skin of mammal hosts or in a development phase (host-adapted) they most likely 
express in blood. The detailed characterization of the spirochetes' dissemination pathways 
provides an advanced understanding of the pathogenicity mechanism of TBRF and LB 
species, and can help to improve diagnostic approaches or therapeutic strategies. Notably, 
blood transfusion of Bp may poses a high risk of infection to recipients whereas the risk to 
become infected with Bbss is nonexistent. 
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VIII ZUSAMMENFASSUNG 
Borrelia persica (Bp) zählt zu den verbreitetsten Spirochätenarten, die Rückfallfieber (tick-
borne relapsing fever, TBRF) in Zentralasien und Ländern des Mittleren Ostens verursacht, 
während Borrelia burgdorferi sensu stricto (Bbss) als endemische Genospezies in 
Nordamerika und Europa vorkommt und die Lyme-Borreliose (LB) verursacht. TBRF-
Patienten leiden häufig unter wiederkehrenden Fiberattacken, ausgelöst durch 
Spirochätämie und die dadurch verursachte Antikörper-mediierte Bekämpfung der Erreger. 
LB-Patienten hingehen zeigen in der frühen Krankheitsphase in der Regel nur eine 
charakteristische Hautläsion (Erythema migrans). Unterbleibt die Behandlung der LB-
Patienten, kann sich die Infektion auf Grund der anhaltenden Entzündungsprozesse zur 
chronischen LB (z. B. acrodermatitis chronica atrophicans) weiterentwickeln. Obwohl eine 
angeregte Diskussion zur Verbreitung der Spirochäten, ob über den Blutkreislauf oder über 
das Gewebe, zu den verschiedenen Borrelien vorherrscht, ist wenig über deren genauen 
Verbreitungsmechanismen bekannt. Deshalb wurde in dieser Studie ein Mausmodell mit 
einem neuartigen und präzisen Injektionsmethode etabliert, um den Verbreitungsweg von 
zuvor wirtsadaptierten Bp- oder Bbss-Organismen nach intradermaler (ID) und strikter 
intravenöser (IV) Inokulation in immunkompetenten C3H/HeOuJ-Mäusen zu untersuchen. 
Da Borrelien in der Lage sind, ihre Oberflächenproteine (Osps) unter in-vitro- und in-vivo-
Bedingungen unterschiedlich zu exprimieren, war es zunächst notwendig, wirtsadaptierte 
Borrelien aus ursprünglich kulturadaptierten Bakterien mithilfe von immundefizienten 
NOD-SCID-Mäusen zu erzeugen. Dafür wurden die Tiere einerseits intradermal Bp-
Organismen (1,0 x 105) inokuliert, was zu einer Spirochätämie mit bis zu 8,8 x 106 Zellen/ml 
Blut in den Mäusen führte. Die intradermale Injektion von 1,0 x 106 bzw. 1,0 x 108 aus der 
Kultur gewonnenen Bbss-Organismen resultierte hingegen in einer Spirochätämie auf 
niedrigem Niveau (4,9 x 104 und 7,2 x 104 Zellen/ml). Zudem waren Bp-Spirochäten im Blut 
mit Hilfe der qPCR und Kultivierung mindestens einen Tag früher nachweisbar als Bbss. 
Insoweit scheint es, dass Bp im Vergleich zu Bbss besser dazu in der Lage ist, in den 
Blutkreislauf von immundefizienten Mäusen einzudringen und sich dort zu vermehren. 
Im Vergleich zur ID-Injektion war die strenge IV-Inokulation über die Jugularvene der 
C3H/HeOuJ-Maus der kritischste Schritt, um zu klären, ob wirtsadaptierte Bp- und Bbss-
Organismen in der Lage sind, den Blutkreislauf für eine Besiedlung der Gewebe im 
Säugetierwirt zu verlassen. Nach ID- oder IV-Inokulation von 7,2 x 105 Wirts-adaptierten 
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Bp-Organismen waren die Spirochäten im Blut der C3H/HeOuJ-Mäusen bis zum Tag 24 
nachweisbar. Die Zahl der Bp erreichte Höchstwerte von bis zu 1,8 x 106 und 4,1 x 106 pro 
ml Blut am Tag 12 nach der ID- und IV-Inokulation. Dementsprechend wurden spezifische 
Antikörper gegen Bp in Plasma- und Serumproben der Mäuse nachgewiesen. Mit Hilfe 
molekularer Methoden und Kultivierung konnte gezeigt werden, dass insbesondere alle 
Hirngewebeproben der C3H/HeOuJ-Mäusen sowohl nach ID- als auch nach IV-Injektion 
positiv für Bp waren. Im Gegensatz dazu wurden weder das Bbss-ospA-Gen noch lebende 
Spirochäten im Blut aller C3H/HeOuJ-Mäuse gefunden, die ca. 3 x 103 wirtsangepasste 
Bbss-Spirochäten erhalten hatten. Allerdings wurden am Tag 49/50 nach der ID-Injektion 
Bbss-Spirochäten aus den meisten Proben, die aus Ohr-, Haut (Injektionsfläche), 
Tibiotarsalgelenk-, Harnblase- und Herzgewebe entnommen wurden, isoliert. Eine robuste 
Antikörperreaktion gegen Bbss wurden in allen ID-inokulierten Mäusen nachgewiesen. Im 
Gegensatz dazu konnten in Gewebeproben der IV-inokulierten Tieren weder Borrelien-DNA 
noch lebensfähige Spirochäten detektiert werden. Eine spezifische Antikörperreaktion gegen 
Bbss blieb in diesen Tieren völlig aus. 
Zusammenfassend wurde in dieser Studie gezeigt, dass 1) Bp sich hervorragend an den 
Blutstrom der Wirte anpassen und darin überleben kann. Danach verbreitet sich das 
Bakterium vorwiegend auf hämatogenem Weg zu entfernt gelegenen Organen (z. B. Gehirn), 
um eine persistierende Infektion zu etablieren; 2) Bbss ist ein gewebegebundenes Bakterium, 
das sich hauptsächlich durch Gewebe fortbewegt und sich so im Körper des Wirtes verbreitet. 
Das intradermale Einbringen der Bbss-Organismen führt zu einer erfolgreich etablierten 
persistierenden Infektion, während die intravenöse Injektion eine Sackgasse für dieses 
Bakterium darstellt. Hervorzuheben ist insbesondere, dass das hier vorgestellte Mausmodell 
die natürlichen Infektionsbedingungen nach Zeckenbiss so gut wie möglich durch die 
Verwendung einer Injektionsdosis nachahmt, die nach Zeckenstich in der Haut eines Wirtes 
zu erwarten ist. Zudem wurden wirtsadaptierte Spirochäten verwendet, die wie in dieser 
Studie vorliegenden Entwicklungsphase so auch im Blut der Wirte vorkommen sollten.  
Die detaillierte Beschreibung der Ausbreitungswege ermöglicht ein besseres Verständnis der 
Pathogenitätsmechanismen sowohl der TBRF- als auch der LB-Spirochäten und kann dazu 
beitragen, die Diagnose- und Behandlungsstrategien für die durch diese Spirochäten 
ausgelösten Krankheiten verbessern. Insbesondere ist anzumerken, dass das Risiko sich nach 
Bluttransfusion mit Bp sich zu infizieren hoch ist, während das Risiko sich mit Bbss zu 
infizieren vernachlässigbar ist. 
Bibliography  89 
 
IX BIBLIOGRAPHY 
Addamiano L, Babudieri B. Research on spirochaetal strains isolated in Jordan. Bull World 
Health Organ 1957; 17: 483. 
Adeolu M, Gupta RS. A phylogenomic and molecular marker based proposal for the division 
of the genus Borrelia into two genera: the emended genus Borrelia containing only the 
members of the relapsing fever Borrelia, and the genus Borreliella gen. nov. containing the 
members of the Lyme disease Borrelia (Borrelia burgdorferi sensu lato complex). Antonie 
Van Leeuwenhoek 2014; 105: 1049-72. 
Adler S, Theodor O, Schieber H. Observations on Tick-Transmitted Human Spirochaetosis 
in Palestine. Annals of Tropical Medicine & Parasitology 1937; 31: 25-35. 
Afzelius A. Verhandlungen der Gesellschaft zu Stockholm on October 29, 1909. Archives 
of Dermatology and Syphilis 1910; 20: 7-17. 
Aghighi Z, Assmar M, Piazak N, Javadian E, Rashti MS, Kia E, Rassi Y, Vatandoost H. 
Distribution of soft ticks and their natural infection with Borrelia in a focus of relapsing 
fever in Iran. Journal of Arthropod-Borne Diseases 2007: 14-8. 
Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of Lyme borreliosis. 
Clinical microbiology reviews 2005; 18: 484-509. 
Anderson JF. Epizootiology of Lyme borreliosis. Scand J Infect Dis Suppl 1991; 77: 23-34. 
Anderson TR, Zimmerman LE. Relapsing Fever in Korea: A Clinicopathologic Study of 
Eleven Fatal Cases with Special Attention to Association with Salmonella Infections. The 
American Journal of Pathology 1955; 31: 1083-109. 
Anguita J, Ramamoorthi N, Hovius JW, Das S, Thomas V, Persinski R, Conze D, Askenase 
PW, Rincon M, Kantor FS, Fikrig E. Salp15, an Ixodes scapularis salivary protein, inhibits 
CD4(+) T cell activation. Immunity 2002; 16: 849-59. 
Anguita J, Hedrick MN, Fikrig E. Adaptation of Borrelia burgdorferi in the tick and the 
mammalian host. FEMS Microbiol Rev 2003; 27: 493-504. 
Bibliography  90 
 
Appel MJ, Allan S, Jacobson RH, Lauderdale TL, Chang YF, Shin SJ, Thomford JW, 
Todhunter RJ, Summers BA. Experimental Lyme disease in dogs produces arthritis and 
persistent infection. J Infect Dis 1993; 167: 651-64. 
Arshi S, Majidpoor A, Sadeghi H, Asmar M, Emdadi D, Derakhshan M. Relapsing fever in 
Ardabil, a northwestern province of Iran. 2002; 5: 141-5. 
Asbrink E, Hovmark A. Successful cultivation of spirochetes from skin lesions of patients 
with erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans. Acta 
Pathol Microbiol Immunol Scand B 1985; 93: 161-3. 
Asl HM, Goya M, Vatandoost H, Zahraei S, Mafi M, Asmar M, Piazak N, Aghighi Z. The 
epidemiology of tick-borne relapsing fever in Iran during 1997–2006. Travel Med Infect Dis 
2009; 7: 160-4. 
Assous MV, Wilamowski A, Bercovier H, Marva E. Molecular characterization of tickborne 
relapsing fever Borrelia, Israel. Emerg Infect Dis 2006; 12: 1740-3. 
Assous MV, Wilamowski A. Relapsing fever borreliosis in Eurasia--forgotten, but certainly 
not gone! Clin Microbiol Infect 2009; 15: 407-14. 
Atkinson W, Forghani R, Wojtkiewicz GR, Pulli B, Iwamoto Y, Ueno T, Waterman P, 
Truelove J, Oklu R, Chen JW. Ligation of the Jugular Veins Does Not Result in Brain 
Inflammation or Demyelination in Mice. PLoS One 2012; 7: e33671. 
Babudieri B. Relapsing fever in Jordan. Bull World Health Organ 1957; 16: 911-28. 
Baneth G, Nachum-Biala Y, Halperin T, Hershko Y, Kleinerman G, Anug Y, Abdeen Z, Lavy 
E, Aroch I, Straubinger RK. Borrelia persica infection in dogs and cats: clinical 
manifestations, clinicopathological findings and genetic characterization. Parasit Vectors 
2016; 9: 244. 
Baranton G, Postic D, Saint Girons I, Boerlin P, Piffaretti JC, Assous M, Grimont PA. 
Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 
associated with Lyme borreliosis. Int J Syst Bacteriol 1992; 42: 378-83. 
Barbour AG, Tessier SL, Stoenner HG. Variable major proteins of Borrellia hermsii. J Exp 
Med 1982; 156: 1312-24. 
Bibliography  91 
 
Barbour AG. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med 1984; 
57: 521-5. 
Barbour AG, Hayes SF. Biology of Borrelia species. Microbiol Rev 1986; 50: 381-400. 
Barbour AG. Antigenic variation of a relapsing fever Borrelia species. Annu Rev Microbiol 
1990; 44: 155-71. 
Barbour AG, Restrepo BI. Antigenic variation in vector-borne pathogens. Emerging 
Infectious Diseases 2000; 6: 449-57. 
Barbour AG, Guo BP. Pathogenesis of relapsing fever. In: Borrelia: molecular biology, host 
interaction and pathogenesis. D. Scott Samuels, Radolf JD, eds. Norwich, UK: Caister 
Academic Press 2010: 333-57. 
Barbour AG, Campeau Miller S. Genome Sequence of Borrelia parkeri, an Agent of 
Enzootic Relapsing Fever in Western North America. Genome Announcements 2014; 2: 
e00018-14. 
Barr JE, Holmes DB, Ryan LJ, Sharpless SK. Techniques for the chronic cannulation of the 
jugular vein in mice. Pharmacol Biochem Behav 1979; 11: 115-8. 
Barth C, Straubinger RK, Krupka I, Muller E, Sauter-Louis C, Hartmann K. Comparison of 
different diagnostic assays for the detection of Borrelia burgdorferi-specific antibodies in 
dogs. Vet Clin Pathol 2014; 43: 496-504. 
Barthold SW, Persing DH, Armstrong AL, Peeples RA. Kinetics of Borrelia burgdorferi 
dissemination and evolution of disease after intradermal inoculation of mice. Am J Pathol 
1991; 139: 263-73. 
Barthold SW, de Souza MS, Janotka JL, Smith AL, Persing DH. Chronic Lyme borreliosis 
in the laboratory mouse. Am J Pathol 1993; 143: 959-71. 
Basu A, Charles R. Chapter 1 - A general account of ticks. Ticks of Trinidad and Tobago - 
An overview 2017: 1-33. 
Battisti JM, Bono JL, Rosa PA, Schrumpf ME, Schwan TG, Policastro PF. Outer surface 
protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector. 
Infection and immunity 2008; 76: 5228-37. 
Bibliography  92 
 
Benach JL, Bosler EM, Hanrahan JP, Coleman JL, Habicht GS, Bast TF, Cameron DJ, 
Ziegler JL, Barbour AG, Burgdorfer W, Edelman R, Kaslow RA. Spirochetes isolated from 
the blood of two patients with Lyme disease. N Engl J Med 1983; 308: 740-2. 
Benoit VM, Petrich A, Alugupalli KR, Marty-Roix R, Moter A, Leong JM, Boyartchuk VL. 
Genetic control of the innate immune response to Borrelia hermsii influences the course of 
relapsing fever in inbred strains of mice. Infect Immun 2010; 78: 586-94. 
Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringer A, Elmrud H, Carlsson M, Runehagen 
A, Svanborg C, Norrby R. An epidemiologic study of Lyme disease in southern Sweden. N 
Engl J Med 1995; 333: 1319-27. 
Bhide MR, Escudero R, Camafeita E, Gil H, Jado I, Anda P. Complement factor H binding 
by different Lyme disease and relapsing fever Borrelia in animals and human. BMC Res 
Notes 2009; 2: 134. 
Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion-transmitted infections. 
Journal of Translational Medicine 2007; 5: 25-. 
Bogitsh BJ, Carter CE, Oeltmann TN. Chapter 18 - Arthropods as Vectors. In: Human 
Parasitology (Fourth Edition). Bogitsh BJ, Carter CE, Oeltmann TN, eds. Boston: Academic 
Press 2013: 349-79. 
Bolz DD, Sundsbak RS, Ma Y, Akira S, Weis JH, Schwan TG, Weis JJ. Dual role of MyD88 
in rapid clearance of relapsing fever Borrelia spp. Infection and immunity 2006; 74: 6750-
60. 
Borchers AT, Keen CL, Huntley AC, Gershwin ME. Lyme disease: a rigorous review of 
diagnostic criteria and treatment. J Autoimmun 2015; 57: 82-115. 
Boyle WK, Wilder HK, Lawrence AM, Lopez JE. Transmission dynamics of 
Borrelia turicatae from the arthropod vector. PLoS Negl Trop Dis 2014; 8: e2767. 
Brisson D, Drecktrah D, Eggers CH, Samuels DS. Genetics of Borrelia burgdorferi. Annu 
Rev Genet 2012; 46: 515-36. 
Brown RA, Richardson KL, Kalinowski FC, Epis MR, Horsham JL, Kabir TD, De Pinho 
MH, Beveridge DJ, Stuart LM, Wintle LC. Evaluation of MicroRNA Delivery In Vivo. In: 
MicroRNA and Cancer: Springer 2018: 155-78. 
Bibliography  93 
 
Bruckbauer H, Preac-Mursic V, Fuchs R, Wilske B. Cross-reactive proteins of 
Borrelia burgdorferi. European Journal of Clinical Microbiology and Infectious Diseases 
1992; 11: 224-32. 
Bunikis J, Tsao J, Garpmo U, Berglund J, Fish D, Barbour AG. Typing of Borrelia Relapsing 
Fever Group Strains. Emerging Infectious Diseases 2004; 10: 1661-4. 
Burgdorfer W, Varma MG. Trans-stadial and transovarial development of disease agents in 
arthropods. Annu Rev Entomol 1967; 12: 347-76. 
Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease-a 
tick-borne spirochetosis? Science 1982; 216: 1317-9. 
Burgdorfer W. Arthropod-borne spirochetoses: a historical perspective. Eur J Clin Microbiol 
Infect Dis 2001; 20: 1-5. 
Burkot TR, Wirtz RA, Luft B, Piesman J. An OspA antigen-capture enzyme-linked 
immunosorbent assay for detecting North American isolates of Borrelia burgdorferi in larval 
and nymphal Ixodes dammini. Journal of Clinical Microbiology 1993; 31: 272-8. 
Burman N, Shamaei-Tousi A, Bergstrom S. The spirochete Borrelia crocidurae causes 
erythrocyte rosetting during relapsing fever. Infect Immun 1998; 66: 815-9. 
Bykowski T, Babb K, von Lackum K, Riley SP, Norris SJ, Stevenson B. Transcriptional 
regulation of the Borrelia burgdorferi antigenically variable VlsE surface protein. J Bacteriol 
2006; 188: 4879-89. 
Cabello FC, Godfrey HP, Newman SA. Hidden in plain sight: Borrelia burgdorferi and the 
extracellular matrix. Trends Microbiol 2007; 15: 350-4. 
Cadavid D, Pennington PM, Kerentseva TA, Bergstrom S, Barbour AG. Immunologic and 
genetic analyses of VmpA of a neurotropic strain of Borrelia turicatae. Infect Immun 1997; 
65: 3352-60. 
Cadavid D, Barbour AG. Neuroborreliosis during relapsing fever: review of the clinical 
manifestations, pathology, and treatment of infections in humans and experimental animals. 
Clin Infect Dis 1998; 26: 151-64. 
Bibliography  94 
 
Cadavid D, Pachner AR, Estanislao L, Patalapati R, Barbour AG. Isogenic Serotypes of 
Borrelia turicatae Show Different Localization in the Brain and Skin of Mice. Infection and 
immunity 2001; 69: 3389-97. 
Carrasco SE, Troxell B, Yang Y, Brandt SL, Li H, Sandusky GE, Condon KW, Serezani CH, 
Yang XF. Outer surface protein OspC is an antiphagocytic factor that protects Borrelia 
burgdorferi from phagocytosis by macrophages. Infect Immun 2015; 83: 4848-60. 
CDC. Recommendations for test performance and interpretation from the Second National 
Conference on Serologic Diagnosis of Lyme Disease. MMWR Morbidity and mortality 
weekly report 1995; 44: 590-1. 
CDC. Reported cases of Lyme disease by state or locality, 2007-2017. Atlanta, GA 2017. 
Available at: https://www.cdc.gov/lyme/stats/tables.html. Accessed 28.02.2019.  
Charon NW, Cockburn A, Li C, Liu J, Miller KA, Miller MR, Motaleb MA, Wolgemuth CW. 
The unique paradigm of spirochete motility and chemotaxis. Annu Rev Microbiol 2012; 66: 
349-70. 
Chung H-L. The Cerebrospinal Fluid of Patients suffering from the Chinese Strain of 
Relapsing Fever. Transactions of the Royal Society of Tropical Medicine and Hygiene 1938; 
31. 
Coburn J, Chege W, Magoun L, Bodary SC, Leong JM. Characterization of a candidate 
Borrelia burgdorferi beta3-chain integrin ligand identified using a phage display library. Mol 
Microbiol 1999; 34: 926-40. 
Coipan EC, Jahfari S, Fonville M, Oei GA, Spanjaard L, Takumi K, Hovius JW, Sprong H. 
Imbalanced presence of Borrelia burgdorferi s.l. multilocus sequence types in clinical 
manifestations of Lyme borreliosis. Infect Genet Evol 2016; 42: 66-76. 
Collares-Pereira M, Couceiro S, Franca I, Kurtenbach K, Schäfer SM, Vitorino L, Gonçalves 
L, Baptista S, Vieira ML, Cunha C. First Isolation of Borrelia lusitaniae from a Human 
Patient. Journal of Clinical Microbiology 2004; 42: 1316-8. 
Cortinas MR, Guerra MA, Jones CJ, Kitron U. Detection, characterization, and prediction 
of tick-borne disease foci. Int J Med Microbiol 2002; 291 Suppl 33: 11-20. 
Bibliography  95 
 
Couvreur B, Beaufays J, Charon C, Lahaye K, Gensale F, Denis V, Charloteaux B, Decrem 
Y, Prevot PP, Brossard M, Vanhamme L, Godfroid E. Variability and action mechanism of a 
family of anticomplement proteins in Ixodes ricinus. PLoS One 2008; 3: e1400. 
Craine NG, Nuttall PA, Marriott AC, Randolph SE. Role of grey squirrels and pheasants in 
the transmission of Borrelia burgdorferi sensu lato, the Lyme disease spirochaete, in the U.K. 
Folia Parasitol (Praha) 1997; 44: 155-60. 
Crowley H, Huber BT. Host-adapted Borrelia burgdorferi in mice expresses OspA during 
inflammation. Infection and immunity 2003; 71: 4003-10. 
Dai Q, Restrepo BI, Porcella SF, Raffel SJ, Schwan TG, Barbour AG. Antigenic variation by 
Borrelia hermsii occurs through recombination between extragenic repetitive elements on 
linear plasmids. Mol Microbiol 2006; 60: 1329-43. 
Daix V, Schroeder H, Praet N, Georgin JP, Chiappino I, Gillet L, de Fays K, Decrem Y, 
Leboulle G, Godfroid E, Bollen A, Pastoret PP, Gern L, Sharp PM, Vanderplasschen A. 
Ixodes ticks belonging to the Ixodes ricinus complex encode a family of anticomplement 
proteins. Insect Mol Biol 2007; 16: 155-66. 
Das S, Banerjee G, DePonte K, Marcantonio N, Kantor FS, Fikrig E. Salp25D, an 
Ixodes scapularis antioxidant, is 1 of 14 immunodominant antigens in engorged tick salivary 
glands. J Infect Dis 2001; 184: 1056-64. 
De Silva AM, Fikrig E. Growth and migration of Borrelia burgdorferi in Ixodes ticks during 
blood feeding. Am J Trop Med Hyg 1995; 53: 397-404. 
De Silva AM, Fikrig E. Arthropod-and host-specific gene expression by Borrelia burgdorferi. 
J Clin Invest 1997; 99: 377-9. 
de Taeye SW, Kreuk L, van Dam AP, Hovius JW, Schuijt TJ. Complement evasion by 
Borrelia burgdorferi: it takes three to tango. Trends Parasitol 2013; 29: 119-28. 
de Verdiere NC, Hamane S, Assous M-V, Sertour N, Ferquel E, Cornet M. Tickborne 
relapsing fever caused by Borrelia persica, Uzbekistan and Tajikistan. Emerging Infectious 
Diseases 2011; 17: 1325. 
Bibliography  96 
 
de Verdière NC, Hamane S, Assous M-V, Sertour N, Ferquel E, Cornet M. Tickborne 
relapsing fever caused by Borrelia persica, Uzbekistan and Tajikistan. Emerging Infectious 
Diseases 2011; 17: 1325. 
De Zulueta J, Nasrallah S, Karam JS, Anani AR, Sweatman GK, Muir DA. Finding of tick-
borne relapsing fever in Jordan by the Malaria Eradication Service. Ann Trop Med Parasitol 
1971; 65: 491-5. 
Dhein S, Mohr FW, Delmar M. Anaesthesia of Laboratory Animals. In: Practical methods in 
cardiovascular research: Springer 2005: p. 23. 
Diatta G, Trape J-F, Legros F, Rogier C, Duplantier J-M. A comparative study of three 
methods of detection of Borrelia crocidurae in wild rodents in Senegal. Transactions of the 
Royal Society of Tropical Medicine and Hygiene 1994; 88: 423-4. 
Dickinson GS, Sun G, Bram RJ, Alugupalli KR. Efficient B Cell Responses to 
Borrelia hermsii Infection Depend on BAFF and BAFFR but Not TACI. Infection and 
immunity 2014; 82: 453-9. 
Divan A, Casselli T, Narayanan SA, Mukherjee S, Zawieja DC, Watt JA, Brissette CA, 
Newell-Rogers MK. Borrelia burgdorferi adhere to blood vessels in the dura mater and are 
associated with increased meningeal T cells during murine disseminated borreliosis. PLoS 
One 2018; 13: e0196893. 
Diza E, Papa A, Vezyri E, Tsounis S, Milonas I, Antoniadis A. Borrelia valaisiana in 
Cerebrospinal Fluid. Emerging Infectious Diseases 2004; 10: 1692-3. 
Dschunkowsky E. Das Rückfallfieber in Persien. DMW-Deutsche Medizinische 
Wochenschrift 1913; 39: 419-20. 
Duray PH, Steere AC. Clinical pathologic correlations of Lyme disease by stage. Ann N Y 
Acad Sci 1988; 539: 65-79. 
Duray PH. Histopathology of clinical phases of human Lyme disease. Rheum Dis Clin North 
Am 1989; 15: 691-710. 
Dutton JE, Todd JL, Newstead R. The Nature of Human Tick-fever in the Eastern Part of the 
Congo Free State: With Notes on the Distribution and Bionomics of the Tick. University 
Press of Liverpool, 1905. 
Bibliography  97 
 
Dworkin MS, Schwan TG, Anderson DE. Tick-borne relapsing fever in North America. 
Medical Clinics 2002; 86: 417-33. 
Dworkin MS, Schwan TG, Anderson DE, Borchardt SM. Tick-Borne Relapsing Fever. 
Infectious disease clinics of North America 2008; 22: 449-68. 
Eicken C, Sharma V, Klabunde T, Lawrenz MB, Hardham JM, Norris SJ, Sacchettini JC. 
Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferi. 
Journal of Biological Chemistry 2002; 277: 21691-6. 
Eidmann E, Lippelt H, Poespodihardjo J. Quantitative Untersuchungen über die Vermehrung 
von Borrelia erratici in der weißen Maus. Z. Tropenmed. Parasitol 1959; 10: 339. 
Elbir H, Larsson P, Normark J, Upreti M, Korenberg E, Larsson C, Bergström S. Genome 
sequence of the Asiatic species Borrelia persica. Genome Announc. 2014; 2: e01127-13. 
Elelu N. Tick-borne relapsing fever as a potential veterinary medical problem. Vet Med Sci 
2018; 4: 271-9. 
Euzéby JP. List of Bacterial Names with Standing in Nomenclature: a folder available on the 
Internet. Int J Syst Bacteriol 1997; 47: 590-2. 
Euzéby JP. List of prokaryotic names with standing in nomenclature: a folder available on 
the internet. 2012. Available at: http://www.bacterio.net/borrelia.html. Cited on 12.08.2018. 
Forrester JD, Kjemtrup AM, Fritz CL, Marsden-Haug N, Nichols JB, Tengelsen LA, 
Sowadsky R, DeBess E, Cieslak PR, Weiss J, Evert N, Ettestad P, Smelser C, Iralu J, Nett 
RJ, Mosher E, Baker JS, Van Houten C, Thorp E, Geissler AL, Kugeler K, Mead P. Tickborne 
Relapsing Fever - United States, 1990-2011. Morbidity and Mortality Weekly Report 2015; 
64: 58-60. 
Fraser CM, Casjens S, Huang WM, Sutton GG, Clayton R, Lathigra R, White O, Ketchum 
KA, Dodson R, Hickey EK, Gwinn M, Dougherty B, Tomb JF, Fleischmann RD, Richardson 
D, Peterson J, Kerlavage AR, Quackenbush J, Salzberg S, Hanson M, van Vugt R, Palmer 
N, Adams MD, Gocayne J, Weidman J, Utterback T, Watthey L, McDonald L, Artiach P, 
Bowman C, Garland S, Fuji C, Cotton MD, Horst K, Roberts K, Hatch B, Smith HO, Venter 
JC. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 1997; 
390: 580-6. 
Bibliography  98 
 
Fukunaga M, Okada K, Nakao M, Konishi T, Sato Y. Phylogenetic analysis of Borrelia 
species based on flagellin gene sequences and its application for molecular typing of Lyme 
disease borreliae. Int J Syst Bacteriol 1996; 46: 898-905. 
Gabitzsch ES, Piesman J, Dolan MC, Sykes CM, Zeidner NS. Transfer of 
Borrelia burgdorferi ss infection via blood transfusion in a murine model. Journal of 
Parasitology 2006; 92: 869-70. 
Geigy R, Sarasin G. Isolatstämme von Borrelia duttoni und ihr Immunisierungsverhalten 
gegenüber der weissen Maus. Verlag für Recht und Gesellschaft, 1958. 
Gelbjerg-Hansen G. Erythema chronicum migrans Afzelii and meningitis after a tick bite. 
Acta Derm Venereol (Stockh) 1945; 25: 458-63. 
Gern L, Estrada-Pena A, Frandsen F, Gray JS, Jaenson TG, Jongejan F, Kahl O, Korenberg 
E, Mehl R, Nuttall PA. European reservoir hosts of Borrelia burgdorferi sensu lato. Zentralbl 
Bakteriol 1998; 287: 196-204. 
Gilmore RD, Jr., Piesman J. Inhibition of Borrelia burgdorferi migration from the midgut to 
the salivary glands following feeding by ticks on OspC-immunized mice. Infect Immun 2000; 
68: 411-4. 
Golde WT, Kappel KJ, Dequesne G, Feron C, Plainchamp D, Capiau C, Lobet Y. Tick 
transmission of Borrelia burgdorferi to inbred strains of mice induces an antibody response 
to P39 but not to outer surface protein A. Infection and immunity 1994; 62: 2625-7. 
Golde WT, Gollobin P, Rodriguez LL. A rapid, simple, and humane method for 
submandibular bleeding of mice using a lancet. Lab Anim (NY) 2005; 34: 39. 
Goodman JL, Bradley JF, Ross AE, Goellner P, Lagus A, Vitale B, Berger BW, Luger S, 
Johnson RC. Bloodstream invasion in early Lyme disease: results from a prospective, 
controlled, blinded study using the polymerase chain reaction. The American journal of 
medicine 1995; 99: 6-12. 
Goubau PF. Relapsing fevers. A review. Ann Soc Belg Med Trop 1984; 64: 335-64. 
Grillon A, Westermann B, Cantero P, Jaulhac B, Voordouw MJ, Kapps D, Collin E, Barthel 
C, Ehret-Sabatier L, Boulanger N. Identification of Borrelia protein candidates in mouse 
skin for potential diagnosis of disseminated Lyme borreliosis. Sci Rep 2017; 7: 16719. 
Bibliography  99 
 
Guglielmone AA, Venzal JM, González-Acuña D, Nava S, Hinojosa A, Mangold AJ. The 
phylogenetic position of Ixodes stilesi Neumann, 1911 (Acari: Ixodidae): morphological and 
preliminary molecular evidences from 16S rDNA sequences. Systematic Parasitology 2006; 
65: 1-11. 
Guglielmone AA, Robbins RG, Apanaskevich DA, Petney TN, Estrada-Peña A, Horak IG, 
Shao R, Barker SC. The Argasidae, Ixodidae and Nuttalliellidae (Acari: Ixodida) of the world: 
a list of valid species names. Zootaxa 2010; 2528: 1-28. 
Guo BP, Norris SJ, Rosenberg LC, Höök M. Adherence of Borrelia burgdorferi to the 
proteoglycan decorin. Infection and immunity 1995; 63: 3467-72. 
Guo BP, Brown EL, Dorward DW, Rosenberg LC, Höök M. Decorin-binding adhesins from 
Borrelia burgdorferi. Mol Microbiol 1998; 30: 711-23. 
Habálek Z, Halouzka J. Distribution of Borrelia burgdorferi sensu lato genomic groups in 
Europe, a review. Eur J Epidemiol 1997; 13: 951-7. 
Hansen K, Lebech A-M. The clinical and epidemiological profile of Lyme neuroborreliosis 
in Denmark 1985–1990: a prospective study of 187 patients with Borrelia burgdorferi 
specific intrathecal antibody productionm. Brain 1992; 115: 399-423. 
Hauser U, Lehnert G, Lobentanzer R, Wilske B. Interpretation criteria for standardized 
Western blots for three European species of Borrelia burgdorferi sensu lato. Journal of 
Clinical Microbiology 1997; 35: 1433-44. 
Hellwage J, Meri T, Heikkilä T, Alitalo A, Panelius J, Lahdenne P, Seppälä IJ, Meri S. The 
complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. 
Journal of Biological Chemistry 2001; 276: 8427-35. 
Hira P, Husein S. Some transfusion-induced parasitic infections in Zambia. Journal of 
hygiene, epidemiology, microbiology, and immunology 1979; 23: 436-44. 
Hodzic E, Feng S, Freet KJ, Barthold SW. Borrelia burgdorferi population dynamics and 
prototype gene expression during infection of immunocompetent and immunodeficient mice. 
Infect Immun 2003; 71: 5042-55. 
Hoogstraal H. Argasid and Nuttalliellid Ticks as Parasites and Vectors. In: Advances in 
Parasitology. Baker JR, Muller R, eds.: Academic Press 1985: 135-238. 
Bibliography  100 
 
Hourcade DE, Akk AM, Mitchell LM, Zhou HF, Hauhart R, Pham CT. Anti-complement 
activity of the Ixodes scapularis salivary protein Salp20. Mol Immunol 2016; 69: 62-9. 
Hovis KM, Schriefer ME, Bahlani S, Marconi RT. Immunological and Molecular Analyses 
of the Borrelia hermsii Factor H and Factor H-Like Protein 1 Binding Protein, FhbA: 
Demonstration of Its Utility as a Diagnostic Marker and Epidemiological Tool for Tick-
Borne Relapsing Fever. Infection and immunity 2006; 74: 4519-29. 
Hovius KE, Stark LA, Bleumink-Pluym NM, van de Pol I, Verbeek-de Kruif N, Rijpkema 
SG, Schouls LM, Houwers DJ. Presence and distribution of Borrelia burgdorferi sensu lato 
species in internal organs and skin of naturally infected symptomatic and asymptomatic dogs, 
as detected by polymerase chain reaction. Veterinary quarterly 1999; 21: 54-8. 
Howard University. Intracardiac puncture for terminal blood collection in mice and rats. 
Work Instructions (Instruction Number: VS-WI-03). Available at: 
http://www.orrchoward.com/Working_instructions_for_IC_Puncture_Terminal_Blood_Col
lection_in_Mice_and_Rats_.pdf.  
Humair PF, Gern L. Relationship between Borrelia burgdorferi sensu lato species, red 
squirrels (Sciurus vulgaris) and Ixodes ricinus in enzootic areas in Switzerland. Acta Trop 
1998; 69: 213-27. 
Hyde JA, Weening EH, Chang M, Trzeciakowski JP, Hook M, Cirillo JD, Skare JT. 
Bioluminescent imaging of Borrelia burgdorferi in vivo demonstrates that the fibronectin-
binding protein BBK32 is required for optimal infectivity. Mol Microbiol 2011; 82: 99-113. 
Hyde JA. Borrelia burgdorferi keeps moving and carries on: a review of borrelial 
dissemination and invasion. Front Immunol 2017; 8: 114. 
Indest KJ, Howell JK, Jacobs MB, Scholl-Meeker D, Norris SJ, Philipp MT. Analysis of 
Borrelia burgdorferi vlsE gene expression and recombination in the tick vector. Infection 
and immunity 2001; 69: 7083-90. 
Jacquet M, Durand J, Rais O, Voordouw MJ. Cross-reactive acquired immunity influences 
transmission success of the Lyme disease pathogen, Borrelia afzelii. Infect Genet Evol 2015; 
36: 131-40. 
Bibliography  101 
 
Jauris-Heipke S, Rößle B, Wanner G, Habermann C, Rössler D, Fingerle V, Lehnert G, 
Lobentanzer R, Pradel I, Hillenbrand B. Osp17, a novel immunodominant outer surface 
protein of Borrelia afzelii: recombinant expression in Escherichia coli and its use as a 
diagnostic antigen for serodiagnosis of Lyme borreliosis. Medical microbiology and 
immunology 1999; 187: 213-9. 
Johnson RC, Schmid GP, Hyde FW, Steigerwalt A, Brenner DJ. Borrelia burgdorferi sp. nov.: 
etiologic agent of Lyme disease. International Journal of Systematic and Evolutionary 
Microbiology 1984; 34: 496-7. 
Johnston YE, Duray PH, Steere AC, Kashgarian M, Buza J, Malawista SE, Askenase PW. 
Lyme arthritis. Spirochetes found in synovial microangiopathic lesions. The American 
Journal of Pathology 1985; 118: 26-34. 
Kada S, McCoy KD, Boulinier T. Impact of life stage-dependent dispersal on the 
colonization dynamics of host patches by ticks and tick-borne infectious agents. Parasites & 
Vectors 2017; 10: 375. 
Karimi Y, Hovind-Hougen K, Birch-Andersen A, Asmar M. Borrelia persica and 
B. baltazardi sp. nov.: experimental pathogenicity for some animals and comparison of the 
ultrastructure. Ann Microbiol (Paris) 1979; 130(2): 157-68. 
Kassiri H, Kasiri A, Dostifar K, Lotfi M. The epidemiology of tick-borne relapsing fever in 
Bijar County, North-Western Iran. Journal of Acute Disease 2014; 3: 224-7. 
Kazimírová M, Stibraniova I. Tick salivary compounds: their role in modulation of host 
defences and pathogen transmission. Front Cell Infect Microbiol 2013; 3: 43. 
Kern A, Collin E, Barthel C, Michel C, Jaulhac B, Boulanger N. Tick saliva represses innate 
immunity and cutaneous inflammation in a murine model of Lyme disease. Vector Borne 
Zoonotic Dis 2011; 11: 1343-50. 
Kleinerman G, King R, Nachum-Biala Y, Baneth G. Borrelia persica infection in rock 
hyraxes. Ticks Tick Borne Dis 2018; 9: 382-8. 
Knauer J, Krupka I, Fueldner C, Lehmann J, Straubinger RK. Evaluation of the preventive 
capacities of a topically applied azithromycin formulation against Lyme borreliosis in a 
murine model. J Antimicrob Chemother 2011; 66: 2814-22. 
Bibliography  102 
 
Kornblatt AN, Steere AC, Brownstein DG. Experimental Lyme disease in rabbits: 
spirochetes found in erythema migrans and blood. Infect Immun 1984; 46: 220-3. 
Kraiczy P, Skerka C, Kirschfink M, Zipfel PF, Brade V. Mechanism of complement 
resistance of pathogenic Borrelia burgdorferi isolates. Int Immunopharmacol 2001; 1: 393-
401. 
Kraiczy P, Stevenson B. Complement regulator-acquiring surface proteins of 
Borrelia burgdorferi: Structure, function and regulation of gene expression. Ticks Tick 
Borne Dis 2013; 4: 26-34. 
Krause PJ, Hendrickson JE, Steeves TK, Fish D. Blood transfusion transmission of the tick-
borne relapsing fever spirochete Borrelia miyamotoi in mice. Transfusion 2015; 55: 593-7. 
Krupka I, Straubinger RK. Lyme Borreliosis in Dogs and Cats: Background, Diagnosis, 
Treatment and Prevention of Infections with Borrelia burgdorferi sensu stricto. Veterinary 
Clinics of North America: Small Animal Practice 2010; 40: 1103-19. 
Kugeler KJ, Farley GM, Forrester JD, Mead PS. Geographic Distribution and Expansion of 
Human Lyme Disease, United States. Emerg Infect Dis 2015; 21: 1455-7. 
Kurtenbach K, De Michelis S, Etti S, Schäfer SM, Sewell HS, Brade V, Kraiczy P. Host 
association of Borrelia burgdorferi sensu lato--the key role of host complement. Trends 
Microbiol 2002; 10: 74-9. 
Kutsuna S, Kawabata H, Kasahara K, Takano A, Mikasa K. The First Case of Imported 
Relapsing Fever in Japan. The American Journal of Tropical Medicine and Hygiene 2013; 
89: 460-1. 
Lane RS, Piesman J, Burgdorfer W. Lyme borreliosis: relation of its causative agent to its 
vectors and hosts in North America and Europe. Annu Rev Entomol 1991; 36: 587-609. 
Larsson C, Andersson M, Pelkonen J, Guo BP, Nordstrand A, Bergström S. Persistent brain 
infection and disease reactivation in relapsing fever borreliosis. Microbes and infection 2006; 
8: 2213-9. 
Leiby DA. Threats to blood safety posed by emerging protozoan pathogens. Vox Sang 2004; 
87: 120-2. 
Bibliography  103 
 
Lindgren E, Jaenson TG, Menne B, Organization. World Health Organization. Lyme 
borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and 
adaptation measures. Copenhagen: WHO Regional Office for Europe, 2006. 
Little SE, Heise SR, Blagburn BL, Callister SM, Mead PS. Lyme borreliosis in dogs and 
humans in the USA. Trends Parasitol 2010; 26: 213-8. 
Liu N, Montgomery RR, Barthold SW, Bockenstedt LK. Myeloid differentiation antigen 88 
deficiency impairs pathogen clearance but does not alter inflammation in 
Borrelia burgdorferi-infected mice. Infect Immun 2004; 72: 3195-203. 
Liveris D, Schwartz I, Bittker S, Cooper D, Iyer R, Cox ME, Wormser GP. Improving the 
yield of blood cultures from patients with early Lyme disease. Journal of Clinical 
Microbiology 2011; 49: 2166-8. 
Lohr B, Fingerle V, Norris DE, Hunfeld K-P. Laboratory diagnosis of Lyme borreliosis: 
Current state of the art and future perspectives. Critical Reviews in Clinical Laboratory 
Sciences 2018; 55: 219-45. 
Lopez JE, Vinet-Oliphant H, Wilder HK, Brooks CP, Grasperge BJ, Morgan TW, Stuckey 
KJ, Embers ME. Real-Time Monitoring of Disease Progression in Rhesus Macaques 
Infected With Borrelia turicatae by Tick Bite. J Infect Dis 2014; 210: 1639-48. 
Lopez JE, Krishnavahjala A, Garcia MN, Bermudez S. Tick-Borne Relapsing Fever 
Spirochetes in the Americas. Veterinary sciences 2016; 3: 16. 
Magnarelli LA, Meegan JM, Anderson JF, Chappell WA. Comparison of an indirect 
fluorescent-antibody test with an enzyme-linked immunosorbent assay for serological 
studies of Lyme disease. Journal of Clinical Microbiology 1984; 20: 181-4. 
Magnarelli LA, Anderson JF, Johnson RC. Cross-reactivity in serological tests for Lyme 
disease and other spirochetal infections. J Infect Dis 1987a; 156: 183-8. 
Magnarelli LA, Anderson JF, Fish D. Transovarial transmission of Borrelia burgdorferi in 
Ixodes dammini (Acari:Ixodidae). J Infect Dis 1987b; 156: 234-6. 
Manzano-Román R, Díaz-Martín V, de la Fuente J, Pérez-Sánchez R. Soft ticks as pathogen 
vectors: distribution, surveillance and control. Parasitology 2012; 7: 125-62. 
Bibliography  104 
 
Maraspin V, Ružić-Sabljić E, Cimperman J, Lotrič-Furlan S, Jurca T, Picken R, Strle F. 
Isolation of Borrelia burgdorferi sensu lato from blood of patients with erythema migrans. 
Infection 2001; 29: 65-70. 
Maraspin V, Ogrinc K, Ružić-Sabljić E, Lotrič-Furlan S, Strle F. Isolation of 
Borrelia burgdorferi sensu lato from blood of adult patients with borrelial lymphocytoma, 
Lyme neuroborreliosis, Lyme arthritis and acrodermatitis chronica atrophicans. Infection 
2011; 39: 35-40. 
Margos G, Vollmer SA, Ogden NH, Fish D. Population genetics, taxonomy, phylogeny and 
evolution of Borrelia burgdorferi sensu lato. Infect Genet Evol 2011; 11: 1545-63. 
Margos G, Wilske B, Sing A, Hizo-Teufel C, Cao WC, Chu C, Scholz H, Straubinger RK, 
Fingerle V. Borrelia bavariensis sp. nov. is widely distributed in Europe and Asia. Int J Syst 
Evol Microbiol 2013; 63: 4284-8. 
Margos G, Marosevic D, Cutler S, Derdakova M, Diuk-Wasser M, Emler S, Fish D, Gray J, 
Hunfeldt KP, Jaulhac B, Kahl O, Kovalev S, Kraiczy P, Lane RS, Lienhard R, Lindgren PE, 
Ogden N, Ornstein K, Rupprecht T, Schwartz I, Sing A, Straubinger RK, Strle F, Voordouw 
M, Rizzoli A, Stevenson B, Fingerle V. There is inadequate evidence to support the division 
of the genus Borrelia. Int J Syst Evol Microbiol 2017; 67: 1081-4. 
Masoumi Asl H, Goya MM, Vatandoost H, Zahraei SM, Mafi M, Asmar M, Piazak N, 
Aghighi Z. The epidemiology of tick-borne relapsing fever in Iran during 1997-2006. Travel 
Med Infect Dis 2009; 7: 160-4. 
Masters E, Granter S, Duray P, Cordes P. Physician-diagnosed erythema migrans and 
erythema migrans-like rashes following Lone Star tick bites. Arch Dermatol 1998; 134: 955-
60. 
Masters EJ, Grigery CN, Masters RW. STARI, or Masters disease: Lone Star tick-vectored 
Lyme-like illness. Infect Dis Clin North Am 2008; 22: 361-76. 
Matuschka F-R, Allgöwer R, Spielman A, Richter D. Characteristics of Garden Dormice 
That Contribute to Their Capacity as Reservoirs for Lyme Disease Spirochetes. Applied and 
Environmental Microbiology 1999; 65: 707-11. 
Bibliography  105 
 
Matuschka FR, Eiffert H, Ohlenbusch A, Spielman A. Amplifying role of edible dormice in 
Lyme disease transmission in central Europe. J Infect Dis 1994; 170: 122-7. 
McDowell JV, Sung SY, Hu LT, Marconi RT. Evidence that the variable regions of the central 
domain of VlsE are antigenic during infection with Lyme disease spirochetes. Infect Immun 
2002; 70: 4196-203. 
Mehra R, Londoño D, Sondey M, Lawson C, Cadavid D. Structure-Function Investigation 
of Vsp Serotypes of the Spirochete Borrelia hermsii. PLoS One 2009; 4: e7597. 
Meier JT, Simon MI, Barbour AG. Antigenic variation is associated with DNA 
rearrangements in a relapsing fever Borrelia. Cell 1985; 41: 403-9. 
Meri T, Cutler SJ, Blom AM, Meri S, Jokiranta TS. Relapsing Fever Spirochetes 
Borrelia recurrentis and B. duttonii Acquire Complement Regulators C4b-Binding Protein 
and Factor H. Infection and immunity 2006; 74: 4157-63. 
Milsom CC, Lee CR, Hackl C, Man S, Kerbel RS. Differential post-surgical metastasis and 
survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγnull mice with parental and subline 
variants of human breast cancer: implications for host defense mechanisms regulating 
metastasis. PLoS One 2013; 8: e71270. 
Moriarty TJ, Norman MU, Colarusso P, Bankhead T, Kubes P, Chaconas G. Real-time high 
resolution 3D imaging of the Lyme disease spirochete adhering to and escaping from the 
vasculature of a living host. PLoS Pathog 2008; 4: e1000090. 
Motameni AR, Bates TC, Juncadella IJ, Petty C, Hedrick MN, Anguita J. Distinct bacterial 
dissemination and disease outcome in mice subcutaneously infected with 
Borrelia burgdorferi in the midline of the back and the footpad. FEMS Immunol Med 
Microbiol 2005; 45: 279-84. 
Muller I, Freitag MH, Poggensee G, Scharnetzky E, Straube E, Schoerner C, Hlobil H, 
Hagedorn HJ, Stanek G, Schubert-Unkmeir A, Norris DE, Gensichen J, Hunfeld KP. 
Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: 
a retrospective model analysis. Clin Dev Immunol 2012; 2012: 595427. 
Murray TS, Shapiro ED. Lyme Disease. Clin Lab Med 2010; 30: 311-28. 
Bibliography  106 
 
Nadelman RB, Wormser GP, Sherer C. Blood transfusion-associated relapsing fever. 
Transfusion 1990; 30: 380-1. 
Nadelman RB, Nowakowski J, Forseter G, Goldberg NS, Bittker S, Cooper D, Aguero-
Rosenfeld M, Wormser GP. The clinical spectrum of early Lyme borreliosis in patients with 
culture-confirmed erythema migrans. The American journal of medicine 1996; 100: 502-8. 
Nelson CA, Saha S, Kugeler KJ, Delorey MJ, Shankar MB, Hinckley AF, Mead PS. 
Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005-2010. Emerg Infect 
Dis 2015; 21: 1625-31. 
Nordstrand A, Shamaei-Tousi A, Ny A, Bergström S. Delayed Invasion of the Kidney and 
Brain by Borrelia crocidurae in Plasminogen-Deficient Mice. Infection and immunity 2001; 
69: 5832-9. 
Norman MU, Moriarty TJ, Dresser AR, Millen B, Kubes P, Chaconas G. Molecular 
mechanisms involved in vascular interactions of the Lyme disease pathogen in a living host. 
PLoS Pathog 2008; 4: e1000169. 
Norris SJ. Antigenic variation with a twist--the Borrelia story. Mol Microbiol 2006; 60: 
1319-22. 
Ogden N, Koffi J, Pelcat Y, Lindsay L. Lyme disease: Environmental risk from Lyme disease 
in central and eastern Canada: a summary of recent surveillance information. Canada 
Communicable Disease Report 2014; 40: 74. 
Ogden NH, Nuttall PA, Randolph SE. Natural Lyme disease cycles maintained via sheep by 
co-feeding ticks. Parasitology 1997; 115 ( Pt 6): 591-9. 
Ojaimi C, Mulay V, Liveris D, Iyer R, Schwartz I. Comparative transcriptional profiling of 
Borrelia burgdorferi clinical isolates differing in capacities for hematogenous dissemination. 
Infection and immunity 2005; 73: 6791-802. 
Olsen B, Gylfe Å, Bergström S. Canary finches (Serinus canaria) as an avian infection 
model for Lyme borreliosis. Microbial pathogenesis 1996; 20: 319-24. 
Oren A, Garrity GM. Notification of changes in taxonomic opinion previously published 
outside the IJSEM. International Journal of Systematic and Evolutionary Microbiology 2016; 
66: 7-8. 
Bibliography  107 
 
Orloski KA, Hayes EB, Campbell GL, Dennis DT. Surveillance for Lyme disease--United 
States, 1992-1998. MMWR CDC Surveill Summ 2000; 49: 1-11. 
Oshaghi MA, Rafinejad J, Choubdar N, Piazak N, Vatandoost H, Telmadarraiy Z, Mohtarami 
F, Ravasan NM. Discrimination of relapsing fever Borrelia persica and Borrelia microtti by 
diagnostic species-specific primers and polymerase chain reaction-restriction fragment 
length polymorphism. Vector Borne Zoonotic Dis 2011; 11: 201-7. 
Pal U, Fikrig E. Adaptation of Borrelia burgdorferi in the vector and vertebrate host. 
Microbes and infection 2003; 5: 659-66. 
Pal U, Yang X, Chen M, Bockenstedt LK, Anderson JF, Flavell RA, Norgard MV, Fikrig E. 
OspC facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary glands. J Clin 
Invest 2004; 113: 220-30. 
Pappas CJ, Iyer R, Petzke MM, Caimano MJ, Radolf JD, Schwartz I. Borrelia burgdorferi 
requires glycerol for maximum fitness during the tick phase of the enzootic cycle. PLoS 
Pathog 2011; 7: e1002102. 
Parola P, Raoult D. Ticks and tickborne bacterial diseases in humans: an emerging infectious 
threat. Clin Infect Dis 2001; 32: 897-928. 
Peng Z, Li M, Wang W, Liu H, Fanning S, Hu Y, Zhang J, Li F. Genomic insights into the 
pathogenicity and environmental adaptability of Enterococcus hirae R17 isolated from pork 
offered for retail sale. Microbiologyopen 2017; 6 
Pettersson J, Schrumpf ME, Raffel SJ, Porcella SF, Guyard C, Lawrence K, Gherardini FC, 
Schwan TG. Purine salvage pathways among Borrelia species. Infect Immun 2007; 75: 
3877-84. 
Piesman J, Gern L. Lyme borreliosis in Europe and North America. Parasitology 2004; 129 
Suppl: S191-220. 
Plasterk RH, Simon MI, Barbour AG. Transposition of structural genes to an expression 
sequence on a linear plasmid causes antigenic variation in the bacterium Borrelia hermsii. 
Nature 1985; 318: 257-63. 
Policastro PF, Raffel SJ, Schwan TG. Borrelia hermsii Acquisition Order in Superinfected 
Ticks Determines Transmission Efficiency. Infection and immunity 2013; 81: 2899-908. 
Bibliography  108 
 
Pollack RJ, Telford SR, 3rd, Spielman A. Standardization of medium for culturing Lyme 
disease spirochetes. J Clin Microbiol 1993; 31: 1251-5. 
Popovic V, Popovic P. Permanent cannulation of aorta and vena cava in rats and ground 
squirrels. Journal of Applied Physiology 1960; 15: 727-8. 
Probert WS, Johnson BJ. Identification of a 47 kDa fibronectin-binding protein expressed 
by Borrelia burgdorferi isolate B31. Mol Microbiol 1998; 30: 1003-15. 
Råberg L. Infection intensity and infectivity of the tick-borne pathogen Borrelia afzelii. J 
Evol Biol 2012; 25: 1448-53. 
Radolf JD, Caimano MJ, Stevenson B, Hu LT. Of ticks, mice and men: understanding the 
dual-host lifestyle of Lyme disease spirochaetes. Nature Reviews. Microbiology 2012; 10: 
87-99. 
Raffel SJ, Battisti JM, Fischer RJ, Schwan TG. Inactivation of genes for antigenic variation 
in the relapsing fever spirochete Borrelia hermsii reduces infectivity in mice and 
transmission by ticks. PLoS Pathog 2014; 10: e1004056. 
Rafinejad J, Choubdar N, Oshaghi M, Piazak N, Satvat T, Mohtarami F, Barmaki A. 
Detection of Borrelia persica Infection in Ornithodoros tholozani Using PCR Targeting rrs 
Gene and Xenodiagnosis. Iran J Public Health 2011; 40: 138-45. 
Rafinejad J, Shemshad K, Omid B (2012) Epidemiological Study on Tick-Borne (Acari: 
Argasidae) Relapsing Fever in Kurdistan Province, Iran, 2000–2004. 758-63 
Randolph SE. Ecology of Non-nidicolous Ticks. In: Biology of ticks. Sonenshine DE, Roe. 
RM, eds. New York: Oxford University Press 1993: p. 3-38. 
Ras NM, Postic D, Ave P, Huerre M, Baranton G. Antigenic variation of Borrelia turicatae 
Vsp surface lipoproteins occurs in vitro and generates novel serotypes. Res Microbiol 2000; 
151: 5-12. 
Rebaudet S, Parola P. Epidemiology of relapsing fever borreliosis in Europe. FEMS 
Immunol Med Microbiol 2006; 48: 11-5. 
Rego RO, Bestor A, Štefka J, Rosa PA. Population bottlenecks during the infectious cycle 
of the Lyme disease spirochete Borrelia burgdorferi. PLoS One 2014; 9: e101009. 
Bibliography  109 
 
Richter D, Debski A, Hubalek Z, Matuschka FR. Absence of Lyme disease spirochetes in 
larval Ixodes ricinus ticks. Vector Borne Zoonotic Dis 2012; 12: 21-7. 
Ristow LC, Bonde M, Lin YP, Sato H, Curtis M, Wesley E, Hahn BL, Fang J, Wilcox DA, 
Leong JM. Integrin binding by Borrelia burgdorferi P66 facilitates dissemination but is not 
required for infectivity. Cellular microbiology 2015; 17: 1021-36. 
Rizzoli A, Hauffe HC, Carpi G, Vourc’h G, Neteler M, Rosa R. Lyme borreliosis in Europe. 
Eurosurveillance 2011; 16: 19906. 
Rogovskyy AS, Bankhead T. Variable VlsE is critical for host reinfection by the Lyme 
disease spirochete. PLoS One 2013; 8: e61226. 
Rollend L, Fish D, Childs JE. Transovarial transmission of Borrelia spirochetes by 
Ixodes scapularis: a summary of the literature and recent observations. Ticks Tick Borne Dis 
2013; 4: 46-51. 
Rosa PA, Tilly K, Stewart PE. The burgeoning molecular genetics of the Lyme disease 
spirochaete. Nature Reviews Microbiology 2005; 3: 129. 
Rossmann E, Kraiczy P, Herzberger P, Skerka C, Kirschfink M, Simon MM, Zipfel PF, 
Wallich R. Dual binding specificity of a Borrelia hermsii-associated complement regulator-
acquiring surface protein for factor H and plasminogen discloses a putative virulence factor 
of relapsing fever spirochetes. J Immunol 2007; 178: 7292-301. 
Röttgerding F, Wagemakers A, Koetsveld J, Fingerle V, Kirschfink M, Hovius JW, Zipfel PF, 
Wallich R, Kraiczy P. Immune evasion of Borrelia miyamotoi: CbiA, a novel outer surface 
protein exhibiting complement binding and inactivating properties. Sci Rep 2017; 7: 303. 
Rudenko N, Golovchenko M, Vancova M, Clark K, Grubhoffer L, Oliver Jr J. Isolation of 
live Borrelia burgdorferi sensu lato spirochaetes from patients with undefined disorders and 
symptoms not typical for Lyme borreliosis. Clinical Microbiology and Infection 2016; 22: 
267. e9 - 267. e15. 
Safdie G, Farrah IY, Yahia R, Marva E, Wilamowski A, Sawalha SS, Wald N, Schmiedel J, 
Moter A, Gobel UB, Bercovier H, Abdeen Z, Assous MV, Fishman Y. Molecular 
characterization of Borrelia persica, the agent of tick borne relapsing fever in Israel and the 
Palestinian Authority. PLoS One 2010; 5: e14105. 
Bibliography  110 
 
Sakata K, Endo Y, Kimura F, Yamamoto I. Effects of Bilateral Jugular Vein Ligation on Local 
Cerebral Blood Flow. Skull base surgery 1999; 9: 207-10. 
Schotthoefer AM, Frost HM. Ecology and Epidemiology of Lyme Borreliosis. Clin Lab Med 
2015; 35: 723-43. 
Schuhardt V, Wilkerson M. Relapse phenomena in rats infected with single spirochetes 
(Borrelia recurrentis var. turicatae). J Bacteriol 1951; 62: 215-9. 
Schuijt TJ, Hovius JW, van Burgel ND, Ramamoorthi N, Fikrig E, van Dam AP. The tick 
salivary protein Salp15 inhibits the killing of serum-sensitive Borrelia burgdorferi sensu lato 
isolates. Infection and immunity 2008; 76: 2888-94. 
Schwan TG, Burgdorfer W, Schrumpf ME, Karstens RH. The urinary bladder, a consistent 
source of Borrelia burgdorferi in experimentally infected white-footed mice 
(Peromyscus leucopus). J Clin Microbiol 1988; 26: 893-5. 
Schwan TG, Piesman J. Vector interactions and molecular adaptations of Lyme disease and 
relapsing fever spirochetes associated with transmission by ticks. Emerg Infect Dis 2002; 8: 
115-21. 
Schwan TG, Raffel SJ, Schrumpf ME, Policastro PF, Rawlings JA, Lane RS, Breitschwerdt 
EB, Porcella SF. Phylogenetic analysis of the spirochetes Borrelia parkeri and 
Borrelia turicatae and the potential for tick-borne relapsing fever in Florida. Journal of 
Clinical Microbiology 2005; 43: 3851-9. 
Schwarzer S, Margos G, Overzier E, Fingerle V, Baneth G, Straubinger RK. Borrelia persica: 
In vitro cultivation and characterization via conventional PCR and multilocus sequence 
analysis of two strains isolated from a cat and ticks from Israel. Ticks Tick Borne Dis 2015; 
6: 751-7. 
Schwarzer S, Overzier E, Hermanns W, Baneth G, Straubinger RK. Borrelia persica 
Infection in Immunocompetent Mice - A New Tool to Study the Infection Kinetics In Vivo. 
PLoS Neglected Tropical Diseases 2016; 10: e0004404. 
Shamaei-Tousi A, Martin P, Bergh A, Burman N, Brannstrom T, Bergstrom S. Erythrocyte-
aggregating relapsing fever spirochete Borrelia crocidurae induces formation of 
microemboli. J Infect Dis 1999; 180: 1929-38. 
Bibliography  111 
 
Shih CM, Pollack RJ, Telford SR, Spielman A. Delayed dissemination of Lyme disease 
spirochetes from the site of deposition in the skin of mice. J Infect Dis 1992; 166: 827-31. 
Shin JJ, Bryksin AV, Godfrey HP, Cabello FC. Localization of BmpA on the exposed outer 
membrane of Borrelia burgdorferi by monospecific anti-recombinant BmpA rabbit 
antibodies. Infection and immunity 2004; 72: 2280-7. 
Shirani D, Rakhshanpoor A, Cutler SJ, Ghazinezhad B, Naddaf SR. A case of canine 
borreliosis in Iran caused by Borrelia persica. Ticks Tick Borne Dis 2016; 7: 424-6. 
Sidi G, Davidovitch N, Balicer RD, Anis E, Grotto I, Schwartz E. Tickborne relapsing fever 
in Israel. Emerging Infectious Diseases 2005; 11: 1784. 
Simon MM, Schaible UE, Wallich R, Kramer MD. A mouse model for Borrelia burgdorferi 
infection: approach to a vaccine against Lyme disease. Immunol Today 1991; 12: 11-6. 
Singh SK, Girschick HJ. Lyme borreliosis: from infection to autoimmunity. Clin Microbiol 
Infect 2004; 10: 598-614. 
Skerman VBD, McGowan V, Sneath PHA. Approved lists of bacterial names. Int J Syst 
Bacteriol 1980; 30: 225-30. 
Southern PM, Sanford JP. Relapsing fever: A Clinical and Microbiological Review. 
Medicine (Baltimore) 1969; 48: 129-50. 
Speck S, Reiner B, Wittenbrink MM. Isolation of Borrelia afzelii from a dog. Vet Rec 2001; 
149: 19-20. 
Sprong H, Azagi T, Hoornstra D, Nijhof AM, Knorr S, Baarsma ME, Hovius JW. Control of 
Lyme borreliosis and other Ixodes ricinus-borne diseases. Parasit Vectors 2018; 11: 145. 
Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. The Lancet 2012; 379: 461-73. 
Stanek G, Strle F. Lyme borreliosis–from tick bite to diagnosis and treatment. FEMS 
Microbiol Rev 2018; 42: 233-58. 
Steel CD, Stephens AL, Hahto SM, Singletary SJ, Ciavarra RP. Comparison of the lateral 
tail vein and the retro-orbital venous sinus as routes of intravenous drug delivery in a 
transgenic mouse model. Lab Anim (NY) 2008; 37: 26-32. 
Bibliography  112 
 
Steere AC, Malawista SE, Snydman DR, Shope RE, Andiman WA, Ross MR, Steele FM. 
Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three 
connecticut communities. Arthritis Rheum 1977; 20: 7-17. 
Steere AC, Malawista SE. Cases of Lyme disease in the United States: locations correlated 
with distribution of Ixodes dammini. Ann Intern Med 1979; 91: 730-3. 
Steere AC, Grodzicki RL, Kornblatt AN, Craft JE, Barbour AG, Burgdorfer W, Schmid GP, 
Johnson E, Malawista SE. The spirochetal etiology of Lyme disease. N Engl J Med 1983; 
308: 733-40. 
Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 
1987; 107: 725-31. 
Steere AC. Lyme disease. N Engl J Med 1989; 321: 586-96. 
Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of 
treatment. N Engl J Med 2003; 348: 2472-4. 
Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, Mead PS. Lyme 
borreliosis. Nat Rev Dis Primers 2016; 2: 16090. 
Stoenner HG, Dodd T, Larsen C. Antigenic variation of Borrelia hermsii. J Exp Med 1982; 
156: 1297-311. 
Stone BL, Brissette CA. Host Immune Evasion by Lyme and Relapsing Fever Borreliae: 
Findings to Lead Future Studies for Borrelia miyamotoi. Front Immunol 2017; 8: 12. 
Straubinger RK, Straubinger AF, Harter L, Jacobson RH, Chang YF, Summers BA, Erb HN, 
Appel MJ. Borrelia burgdorferi migrates into joint capsules and causes an up-regulation of 
interleukin-8 in synovial membranes of dogs experimentally infected with ticks. Infect 
Immun 1997; 65: 1273-85. 
Straubinger RK. PCR-based quantification of Borrelia burgdorferi organisms in canine 
tissues over a 500-day postinfection period. Journal of Clinical Microbiology 2000; 38: 
2191-9. 
Strle F, Stanek G. Clinical manifestations and diagnosis of Lyme borreliosis. In: Lyme 
Borreliosis: Karger Publishers 2009: 51-110. 
Bibliography  113 
 
Stübs G, Fingerle V, Wilske B, Göbel UB, Zähringer U, Schumann RR, Schröder NW. 
Acylated cholesteryl galactosides are specific antigens of Borrelia causing Lyme disease and 
frequently induce antibodies in late stages of disease. J Biol Chem 2009; 284: 13326-34. 
Takano A, Toyomane K, Konnai S, Ohashi K, Nakao M, Ito T, Andoh M, Maeda K, Watarai 
M, Sato K, Kawabata H. Tick surveillance for relapsing fever spirochete Borrelia miyamotoi 
in Hokkaido, Japan. PLoS One 2014; 9: e104532. 
Talagrand-Reboul E, Boyer PH, Bergstrom S, Vial L, Boulanger N. Relapsing Fevers: 
Neglected Tick-Borne Diseases. Front Cell Infect Microbiol 2018; 8: 98. 
Teegler A, Herzberger P, Margos G, Fingerle V, Kraiczy P. The relapsing fever spirochete 
Borrelia miyamotoi resists complement-mediated killing by human serum. Ticks Tick Borne 
Dis 2014; 5: 898-901. 
Templeton TJ. Borrelia outer membrane surface proteins and transmission through the tick. 
Journal of Experimental Medicine 2004; 199: 603-6. 
Théodoridès J. [A great Franco-Mauritian epidemiologist: Joseph Desire Tholozan (1820-
18970]. Bull Soc Pathol Exot 1998; 91: 104-8. 
Thompson RS, Burgdorfer W, Russell R, Francis BJ. Outbreak of tick-borne relapsing fever 
in Spokane County, Washington. Jama 1969; 210: 1045-50. 
Thöne A. Ixodes ricinus und Erythema chronicum migrans (Afzelius). Dermatology 1968; 
136: 57-60. 
Tilly K, Krum JG, Bestor A, Jewett MW, Grimm D, Bueschel D, Byram R, Dorward D, 
VanRaden MJ, Stewart P. Borrelia burgdorferi OspC protein required exclusively in a crucial 
early stage of mammalian infection. Infection and immunity 2006; 74: 3554-64. 
Tilly K, Rosa PA, Stewart PE. Biology of infection with Borrelia burgdorferi. Infectious 
disease clinics of North America 2008; 22: 217-34. 
Töpfer K. Charakterisierung der humoralen Immunantwort im Hund nach Impfung mit 
verschiedenen Impfstoffen gegen den Erreger der Lyme-Borreliose, Borrelia burgdorferi, 
unter Berücksichtigung zweier verschiedener Impfstrategien. Universität Leipzig, 2005. 
Bibliography  114 
 
Töpfer KH, Straubinger RK. Characterization of the humoral immune response in dogs after 
vaccination against the Lyme borreliosis agent: a study with five commercial vaccines using 
two different vaccination schedules. Vaccine 2007; 25: 314-26. 
Tracy KE, Baumgarth N. Borrelia burgdorferi manipulates innate and adaptive immunity to 
establish persistence in rodent reservoir hosts. Front Immunol 2017; 8: 116. 
Trape JF, Diatta G, Arnathau C, Bitam I, Sarih M, Belghyti D, Bouattour A, Elguero E, Vial 
L, Mane Y, Balde C, Prugnolle F, Chauvancy G, Mahe G, Granjon L, Duplantier JM, Durand 
P, Renaud F. The epidemiology and geographic distribution of relapsing fever borreliosis in 
West and North Africa, with a review of the Ornithodoros erraticus complex (Acari: 
Ixodida). PLoS One 2013; 8: e78473. 
Tunev SS, Hastey CJ, Hodzic E, Feng S, Barthold SW, Baumgarth N. Lymphoadenopathy 
during Lyme borreliosis is caused by spirochete migration-induced specific B cell activation. 
PLoS Pathog 2011; 7: e1002066. 
Tyson KR, J. P. Lyme Disease Spirochete-Tick-Host Interactions. In: Advances in Insect 
Physiology: Physiology of Human and Animal Disease Vectors. Simpson S, Casas J, eds. 
London, UK: Academic Press 2009a: p. 267. 
Tyson KR, J. P. Lyme Disease Spirochete-Tick-Host Interactions. In: Advances in Insect 
Physiology: Physiology of Human and Animal Disease Vectors. Simpson S, Casas J, eds. 
London, UK: Academic Press 2009b: p. 245. 
Valenzuela JG, Charlab R, Mather TN, Ribeiro JM. Purification, cloning, and expression of 
a novel salivary anticomplement protein from the tick, Ixodes scapularis. J Biol Chem 2000; 
275: 18717-23. 
van den Wijngaard CC, Hofhuis A, Simões M, Rood E, van Pelt W, Zeller H, Van Bortel W. 
Surveillance perspective on Lyme borreliosis across the European Union and European 
Economic Area. Eurosurveillance 2017; 22: 30569. 
Vasil'eva I, Ershova A, Vilisov G, Khizhinskiĭ P, Shoismatulloev B, Ikbolov A, Nidoev S, 
Muminshoev M. The current status of foci of tick-borne relapsing fever in the western 
Pamirs. Med Parazitol (Mosk) 1990: 31-4. 
Bibliography  115 
 
Veinović G, Filipić B, Stanković J. Isolation, cultivation, and in vitro susceptibility testing 
of Borrelia burgdorferi sensu lato: a review. Archives of Biological Science Belgrade 2013; 
65: 533-47. 
Verhaegh D, Joosten LAB, Oosting M. The role of host immune cells and 
Borrelia burgdorferi antigens in the etiology of Lyme disease. Eur Cytokine Netw 2017; 28: 
70-84. 
Vial L, Diatta G, Tall A, Ba el H, Bouganali H, Durand P, Sokhna C, Rogier C, Renaud F, 
Trape JF. Incidence of tick-borne relapsing fever in west Africa: longitudinal study. Lancet 
2006; 368: 37-43. 
Wagemakers A, Oei A, Fikrig MM, Miellet WR, Hovius JW. The relapsing fever spirochete 
Borrelia miyamotoi is cultivable in a modified Kelly-Pettenkofer medium, and is resistant to 
human complement. Parasit Vectors 2014; 7: 418. 
Wagemakers A, Koetsveld J, Narasimhan S, Wickel M, Deponte K, Bleijlevens B, Jahfari S, 
Sprong H, Karan LS, Sarksyan DS, van der Poll T, Bockenstedt LK, Bins AD, Platonov AE, 
Fikrig E, Hovius JW. Variable Major Proteins as Targets for Specific Antibodies against 
Borrelia miyamotoi. J Immunol 2016; 196: 4185-95. 
Wang C, Lee C. Malaria and Relapsing Fever following Blood Transfusion including the 
Report of a Case of Congenital Transmission of Relapsing Fever. Chinese Medical Journal 
1936; 50(3). 
Wilske B, Preac-Mursic V, Göbel U, Graf B, Jauris S, Soutschek E, Schwab E, Zumstein G. 
An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal 
antibodies and OspA sequence analysis. Journal of Clinical Microbiology 1993; 31: 340-50. 
Wilske B, Zöller L, Brade V, Eiffert H, Göbel U, Stanek G, Pfister H. MiQ 12/2000 
Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik: Lyme-Borreliose. 
Urban & Fischer Verlag. München, Jena, 2000. 
Woodman ME, Cooley AE, Avdiushko R, Bowman A, Botto M, Wooten RM, van Rooijen 
N, Cohen DA, Stevenson B. Roles for phagocytic cells and complement in controlling 
relapsing fever infection. J Leukoc Biol 2009; 86: 727-36. 
Bibliography  116 
 
Wooten RM, Weis JJ. Host-pathogen interactions promoting inflammatory Lyme arthritis: 
use of mouse models for dissection of disease processes. Curr Opin Microbiol 2001; 4: 274-
9. 
Wormser GP, Nowakowski J, Nadelman RB, Bittker S, Cooper D, Pavia C. Improving the 
yield of blood cultures for patients with early Lyme disease. Journal of Clinical 
Microbiology 1998; 36: 296-8. 
Wormser GP, Liveris D, Nowakowski J, Nadelman RB, Cavaliere LF, McKenna D, 
Holmgren D, Schwartz I. Association of specific subtypes of Borrelia burgdorferi with 
hematogenous dissemination in early Lyme disease. J Infect Dis 1999; 180: 720-5. 
Wormser GP. Hematogenous dissemination in early Lyme disease. Wiener klinische 
Wochenschrift 2006; 118: 634-7. 
Xu Q. Anesthesia and Analgesia. In: A handbook of mouse models of cardiovascular disease. 
John Wiley & Sons 2006; p. 11. 
Yakhchali M, Bahramnejad K, Almasi O. Ticks (Acari: Ixodida: Ixodidae and Argasidae) 
abundance and associated risk factors for animals in the natural habitat of Sanandaj suburb, 
Iran. International journal of acarology 2012; 38: 353-61. 
Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S. Retro-orbital 
injections in mice. Lab Anim (NY) 2011; 40: 155-60. 
Zamani Z, Arjmand M, Oreiz F, Soleimani M, Hosseini SH, Assmar M, Javadian S, Saghiri 
R, Pourfallah F. Culture of Borrelia persica and its flagellar antigen in vitro. Pak J Biol Sci 
2014; 17: 190-7. 
Zeidner N, Mbow ML, Dolan M, Massung R, Baca E, Piesman J. Effects of Ixodes 
scapularis and Borrelia burgdorferi on modulation of the host immune response: induction 
of a TH2 cytokine response in Lyme disease-susceptible (C3H/HeJ) mice but not in disease-
resistant (BALB/c) mice. Infection and immunity 1997; 65: 3100-6. 
Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease 
borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997; 89: 
275-85. 
Bibliography  117 
 
Zöller L, Cremer J, Faulde M. Western blot as a tool in the diagnosis of Lyme borreliosis. 
Electrophoresis 1993; 14: 937-44. 
 
 
  
Acknowledgments  118 
 
 
X ACKNOWLEDGMENTS 
First of all, I would like to express my special gratitude to Prof. Dr. med. vet. Reinhard K 
Straubinger, my supervisor, who kindly provided me the opportunity to study in Munich and 
the scientifically interesting topic to attract me into research. I would like to thank him for 
his outstanding care about my living conditions, for his competent support and advice, for 
his patience, motivation, and immense knowledge not only on my graduate study and 
doctoral dissertation but also on my further career. 
My special thanks also go to Dr. Sandra Schwarzer, Dr. Shari Fell, and Dr. Jinyong Wang. 
They all, with rigorous attitude, introduced me at the beginning of my study here to the 
laboratory routines and mouse experiments. I am also very grateful to their valuable 
guidance and critical discussion and correction of both the paper and this doctoral 
dissertation.  
Many deepest thanks go to Dr. Evelyn Overzier, Dr. Georg Wolf and Dr. Frank Ebel in our 
team, for their helpfulness and great advice on the scientific and mouse model work. They 
are always there for helping me with all problem solutions and all answers to my questions. 
I would like to thank Dr. Korbinian Pieper and Dr. Andreas Raith from chirurgische und 
gynäkologische Kleintierklinik (Tierärztliche Fakultät, LMU), who provided me the 
anesthetics for the mouse experiment and professional experience on anaesthetizing, 
handling and caring the animals with experimental surgery. Especially, I am indebted to Dr. 
Christine Baumgartner and her colleagues from Klinikum Rechts der Isar (Fakultät für 
Medizin, TUM) for their extremely competent training on the tough surgery of the mouse 
jugular vein. 
In particular, I want to thank sincerely Lucas Schorter, Thu Phong Trong, and Christoph 
Kleinemeier, who dedicated with great enthusiasm to doing the scientific work in the lab and 
in the mouse house even at the weekends and holidays. Without their great ideas and 
cooperation, this work wound not have been possible to finish effectively. Additionally, I am 
very grateful to Elisabeth Aschinger-Kirch who did excellent technical assistance, to 
Stephanie Hiereth, Astrid Thomas, and Anke Schiller who diligently supported me 
practically as well as technically in the lab. 
Acknowledgments  119 
 
 
I would like to thank the animal care takers in the department of Infectious Medicine and 
Zoonosis (Tierärztliche Fakultät, LMU), in particular Ursula Klostermeier, Axel Gross, and 
Johannes Döring for the competent, responsible and reliable care of the mice. 
Last but not least, I would like to sincerely thank the entire working group at the department 
of Bacteriology and Mycology. Particularly worthy of mention are Polixeni Kyriakaki and 
Mareike Nadler. Their positive attitude and supportive help encouraged me on many issues 
at all times. The fantastic atmosphere among the colleagues is an unforgettable experience 
in my life. 
Of importance in the financial support, I would like to express my gratefulness to my 
scholarship sponsor, the China Scholarship Council (CSC). I wish to offer my sincere 
blessing to all of former supervisors in China, to all of the friends who supported me in any 
respect. 
I cannot thank my parents enough and I cannot say how grateful I am to them. Only with 
their lasting support and love, I would have the strength and willpower to do this Ph.D. study. 
In particular, I thank my sister and brother, who help me to take care of the whole family 
enabling me to study further without any worry. 
Lastly, many special and heartfelt thanks go to my boyfriend Stefan Gruhler and his family, 
extremely his lovely and kind parents Bruno Gruhler and Brigitte Gruhler. Their love and 
care, not only during the period of doing the scientific work in the lab, but also in the final 
phase of writing the paper and doctoral thesis in Augsburg, gave me continuous support in 
every possible way to complete my Ph.D. study. 
 
Appendix  120 
 
 
XI APPENDIX 
 
Figure A1: Antigenic variation mechanisms in Lyme and Relapsing fever Borrelia  
(A) VlsE: the expression locus (vlsE) is located near the telomere (open oval) of linear plasmid 
(lp) 28-1 (blue or green arrow, promoter is indicated by a black arrow). Silent vls cassettes are 
located upstream and in the opposite orientation of vlsE. Antigenic variation occurs through the 
random and sequential insertion of silent cassette fragments (labeled 1, 2, and 3). 
(B) vlp (pink arrows) and vsp (purple arrows) cassettes are located throughout the genome on lp28-
1, 28-2, 28-3, 28-4, and 32-1. The expression locus (blue or green arrow, promoter is indicated by 
a black arrow) is found on lp28-1 near the telomere (open oval). Changing the expressed Vmp 
cassette is achieved through deletion of the current cassette (blue arrow) followed by insertion of 
a copy of a new cassette (green arrow via recombination events) resulting in a change in the 
expressed Vmp on the surface of the bacterium (denoted by blue or green triangles, respectively). 
Gray arrows indicate non-Vmp ORFs; tan arrows indicate downstream homology sequences 
(DHS, sequences found throughout the genome and required for mapping recombination events at 
the Vmp expression locus). 
Data from Stone and Brissette (STONE & BRISSETTE, 2017) 
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Table A1: Clinical characteristics, common manifestations, and laboratory support in the diagnosis of LB 
Clinical 
characteristics  
(by state of infection) 
common manifestations essential laboratory 
evidence 
supporting laboratory evidence 
erythema migrans  
(early localizeda and  
disseminatedb 
infection) 
expanding red or bluish-red patch (≥ 5 cm  
in diameter) with or without central clearing; 
advancing edge is typically distinct, often 
intensely coloured, and not noticeably raised 
none if typical culture from skin biopsy;  
seroconversion of specific serum 
IgG antibodies or presence of 
specific IgMc 
borrelial 
lymphocytoma  
(a rare manifestation, 
localized infection) 
painless bluish-red nodule or plaque, usually 
on ear lobe, ear helix, nipple, or scrotum; 
more frequent in children (especially on ear) 
than in adults 
specific IgG antibodies histology;  
culture from skin biopsy 
Lyme 
neuroborreliosis  
(early disseminated 
infection) 
meningitis, cranial neuritis, radiculitis (motor 
or sensory), meningoradiculitis  
lymphocytic pleocytosis in 
CSF; intrathecally produced 
specific antibodiesd 
intrathecal total IgM and/or IgG 
synthesis;  
specific oligoclonal bands in CSF; 
seroconversion of specific serum 
IgG antibodiesc;  
culture from CSF 
Lyme 
neuroborreliosis 
(persistente infection) 
chronic encephalomyelitis, demyelinating-like 
syndrome, axonal polyneuropathy, cognitive 
and behavioral changes 
lymphocytic pleocytosis in 
CSF; intrathecally produced 
specific antibodiesd;  
specific serum IgG antibodies 
specific oligoclonal bands in CSF 
cardiac Lyme 
disease  
(a rare manifestation, 
early disseminated 
infection) 
acute onset of atrioventricular (I–III) 
conduction disturbances, rhythm 
disturbances, and sometimes myocarditis or 
pericarditis; 
alternative explanations should be excluded 
significant change in levels of 
specific IgG antibodiesc 
culture from endomyocardial 
biopsy 
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Lyme arthritis  
(early disseminated 
and persistent 
infection) 
recurrent attacks or persisting objective joint 
swelling in one or more large joints;  
alternative explanations should be excluded 
high level of specific serum 
IgG antibodies 
detection of borrelial DNA in 
synovial fluid and/or 
tissue (culture from synovial fluid 
and/or tissue) 
acrodermatitis 
chronica 
atrophicans  
(persistent infection) 
long-standing red or bluish-red lesions, 
usually on the extensor surfaces of 
extremities;  
initial doughy swelling; 
lesions eventually become atrophic; 
possible skin induration and fibroid nodules 
over bony prominences 
high level of specific serum 
IgG antibodies 
histology; 
culture from skin biopsy 
 
 
 
  
a Duration of infection is days to ~ 4 weeks. 
b Duration of infection is weeks to months (range, 1 - 14 months). 
c Specific antibody levels in serum may increase in response to progression of infection or treatment, or may decrease due to abrogation of the infection 
process. Samples collected a minimum of 3 months apart may be required in order to detect a decrease in IgG levels. 
d Intrathecally produced specific antibodies are determined by investigating simultaneously drawn samples of CSF and serum. 
e Duration of infection is months to years. 
Data modified from references (PAROLA & RAOULT, 2001; STANEK et al., 2012; STANEK & STRLE, 2018) 
 
 
Appendix  123 
 
Table A2: Treatment regimens for tick-borne relapsing fever 
medication druga dose for 
adults 
interval 
(times daily) 
treatment 
duration 
oral Chloramphenicol 500 mg 4 7 - 10 days 
 Doxycycline 100 mg 2 
 Erythromycin 500 mg 4 
 Tetracycline 500 mg 4 
parenteralb Chloramphenicol 500 mg 4 
 Doxycycline 100 mg 2 
 Erythromycin 500 mg 4 
 Penicillin G (procaine) 600,000 IU 1 
 Tetracycline 250 mg 4 
 
 
 
 
a Most commonly used antibiotics are in bold. 
b Parenteral medication should be continued until oral medication is tolerated. If oral medication 
is tolerated at the time of diagnosis, parenteral medication may not be necessary. 
Data modified from references (DWORKIN et al., 2008; KUTSUNA et al., 2013) 
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Table A3: Antibiotic treatment regimens available for Lyme borreliosis 
route druga dose for 
adults 
dose for children treatment 
durationb 
oral therapy 
 
Doxycycline 
(patients 
≥ 8yrs) 
100 mg 
2× day 
 
4 mg/kg 
(up to 100 mg) 
2× day 
14 - 28 days 
 Amoxicillin 500 mg 
3× day 
50 mg/kg 
(up to 500 mg) 
3× day 
 Cefuroxime 
axetil 
500 mg 
2× day 
30 mg/kg 
(up to 500 mg) 
2× day 
intravenous 
therapy 
Ceftriaxone 2 g 
1× day 
50 - 75 mg/kg 
(up to 2 g) 
1× day 
 Cefotaxime 2 g 
every 8 hrs 
150 - 200 mg/kg 
(up to 2 g) 
every 8 hrs 
    Penicillin G 18 - 24 million 
U/day divided 
every 4 hrs 
200,000 - 400,000 
U/kg daily 
divided every 4 hrs 
(up to 18 - 24 
million U/day) 
 
a Most commonly used antibiotics are in bold. 
b Duration of treatment is based mainly on the clinical manifestations of LB. 
Data modified from references (MURRAY & SHAPIRO, 2010; STANEK et al., 2012) 
